Skip Navigation
Skip to contents

Endocrinol Metab : Endocrinology and Metabolism

clarivate
OPEN ACCESS
SEARCH
Search

Search

Page Path
HOME > Search
101 "Won Bae Kim"
Filter
Filter
Article type
Keywords
Publication year
Authors
Funded articles
Original Articles
Thyroid
Prognostic Impact of Primary Tumor Size in Papillary Thyroid Carcinoma without Lymph Node Metastasis
Chae A Kim, Hye In Kim, Na Hyun Kim, Tae Yong Kim, Won Bae Kim, Jae Hoon Chung, Min Ji Jeon, Tae Hyuk Kim, Sun Wook Kim, Won Gu Kim
Endocrinol Metab. 2025;40(3):405-413.   Published online February 25, 2025
DOI: https://doi.org/10.3803/EnM.2024.2199
  • 4,557 View
  • 110 Download
AbstractAbstract PDFPubReader   ePub   
Background
We aimed to investigate the prognostic significance of primary tumor size in patients with pT1–T3a N0 M0 papillary thyroid carcinoma (PTC), minimizing the impact of confounding factors.
Methods
A multicenter retrospective study included 5,759 patients with PTC. Those with lymph node metastasis, gross extrathyroidal extension (ETE), and aggressive variants were excluded. Patients were categorized by primary tumor size (≤1, 1.1–2, 2.1–4, and >4 cm) and subdivided based on the presence of microscopic ETE (mETE).
Results
The median age was 48.0 years, and 87.5% were female. The median primary tumor size was 0.7 cm, with mETE identified in 43.7%. The median follow-up was 8.0 years, with an overall recurrent/persistent disease rate of 2.8%. Multivariate analysis identified male sex, larger tumor size, and the presence of mETE as significant prognostic risk factors. The 10-year recurrent/persistent disease rates for tumors ≤1, 1.1–2, 2.1–4, and >4 cm were 2.5%, 4.7%, 11.1%, and 6.0%, respectively. The 2.1–4 cm group had a significantly higher hazard ratio (HR), with the >4 cm group had the highest HR than the ≤1 cm group. Patients with mETE had a higher recurrent/persistent disease rate (4.5%) than those without, with rates by tumor size being 2.6%, 5.6%, 16.7%, and 8.2%.
Conclusion
Larger tumor size and the presence of mETE significantly increased the risk of recurrent/persistent disease in PTC. Patients with pT2–T3a N0 M0 PTC (>2 cm) had a recurrent/persistent disease risk exceeding 5%, warranting vigilant management.
Close layer
Thyroid
Dynamic Risk Model for the Medical Treatment of Graves’ Hyperthyroidism according to Treatment Duration
Meihua Jin, Chae A Kim, Min Ji Jeon, Won Bae Kim, Tae Yong Kim, Won Gu Kim
Endocrinol Metab. 2024;39(4):579-589.   Published online May 23, 2024
DOI: https://doi.org/10.3803/EnM.2024.1918
  • 5,801 View
  • 190 Download
  • 3 Web of Science
  • 3 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Changes in thyrotropin receptor antibody (TRAb) levels are associated with the clinical outcomes of Graves’ hyperthyroidism. However, the effects of the patterns of TRAb changes on patient prognosis according to the treatment duration of antithyroid drugs (ATDs) are not well established.
Methods
In this retrospective cohort study, 1,235 patients with Graves’ hyperthyroidism who were treated with ATDs for more than 12 months were included. Patients were divided into two groups according to treatment duration: group 1 (12–24 months) and group 2 (>24 months). Risk prediction models comprising age, sex, and either TRAb levels at ATD withdrawal (model A) or patterns of TRAb changes (model B) were compared.
Results
The median treatment duration in groups 1 (n=667, 54%) and 2 (n=568, 46%) was 17.3 and 37.1 months, respectively. The recurrence rate was significantly higher in group 2 (47.9%) than in group 1 (41.4%, P=0.025). Group 2 had significantly more goiter, thyroid eye disease, and fluctuating and smoldering type of TRAb pattern compared with group 1 (all P<0.001). The patterns of TRAb changes were an independent risk factor for recurrence after adjusting for other confounding factors in all patients, except in group 1. Integrated discrimination improvement and net reclassification improvement analyses showed that model B performed better than model A in all patients, except in group 1.
Conclusion
The dynamic risk model, including the patterns of TRAb changes, was more suitable for predicting prognosis in patients with Graves’ hyperthyroidism who underwent longer ATD treatment duration.

Citations

Citations to this article as recorded by  
  • Integrating shear wave elastography into clinical prediction of Graves’ disease recurrence: a novel risk scoring system
    Xiao-Yun Zha, Ze-Hong Xu, Jia-Jia Dong, Liang-Xiao Xie, Peng-Bin Lai, Chang-Shun Wei, Hua-Qiang Zheng, Duo-Bin Huang, Jin-Zhi Wu
    Frontiers in Endocrinology.2025;[Epub]     CrossRef
  • Risk factors and outcomes of Graves’ orbitopathy after radioactive iodine therapy
    Hwa Young Ahn, Jooyoung Lee, Mina Kim, Jeong Kyu Lee
    Endocrine.2025; 90(1): 248.     CrossRef
  • High TRAb Titer at Diagnosis Predicts Persistent Positivity and Relapse in Graves’ Disease after Prolonged Antithyroid Therapy
    Zimiao Chen, Jinglu Xu, Wenrui Kang, Yang Zhang, Rujun Chen, Xiaohua Gong
    Endocrinology and Metabolism.2025; 40(6): 950.     CrossRef
Close layer
Thyroid
Prognostic Roles of Inflammatory Biomarkers in Radioiodine-Refractory Thyroid Cancer Treated with Lenvatinib
Chae A Kim, Mijin Kim, Meihua Jin, Hee Kyung Kim, Min Ji Jeon, Dong Jun Lim, Bo Hyun Kim, Ho-Cheol Kang, Won Bae Kim, Dong Yeob Shin, Won Gu Kim
Endocrinol Metab. 2024;39(2):334-343.   Published online April 4, 2024
DOI: https://doi.org/10.3803/EnM.2023.1854
  • 4,941 View
  • 106 Download
  • 4 Web of Science
  • 4 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Inflammatory biomarkers, such as the neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR), and platelet-to-lymphocyte ratio (PLR), serve as valuable prognostic indicators in various cancers. This multicenter, retrospective cohort study assessed the treatment outcomes of lenvatinib in 71 patients with radioactive iodine (RAI)-refractory thyroid cancer, considering the baseline inflammatory biomarkers.
Methods
This study retrospectively included patients from five tertiary hospitals in Korea whose complete blood counts were available before lenvatinib treatment. Progression-free survival (PFS) and overall survival (OS) were evaluated based on the median value of inflammatory biomarkers.
Results
No significant differences in baseline characteristics were observed among patients grouped according to the inflammatory biomarkers, except for older patients with a higher-than-median NLR (≥2) compared to their counterparts with a lower NLR (P= 0.01). Patients with a higher-than-median NLR had significantly shorter PFS (P=0.02) and OS (P=0.017) than those with a lower NLR. In multivariate analysis, a higher-than-median NLR was significantly associated with poor OS (hazard ratio, 3.0; 95% confidence interval, 1.24 to 7.29; P=0.015). However, neither the LMR nor the PLR was associated with PFS. A higher-than-median LMR (≥3.9) was significantly associated with prolonged OS compared to a lower LMR (P=0.036). In contrast, a higher-than-median PLR (≥142.1) was associated with shorter OS compared to a lower PLR (P=0.039).
Conclusion
Baseline inflammatory biomarkers can serve as predictive indicators of PFS and OS in patients with RAI-refractory thyroid cancer treated with lenvatinib.

Citations

Citations to this article as recorded by  
  • Development and validation of a prognostic model for first-line immunotherapy for metastatic esophageal squamous cell carcinoma
    Loulu Gao, Jieqiong Peng, Zixuan Hu, Xiangxue Li, Siyi Zhang, Xiaoxuan Li, Ziheng Zhang, Jing Lv, Jialin Song, Wensheng Qiu
    International Immunopharmacology.2026; 168: 115813.     CrossRef
  • Nomogram Model for Prognosis of Distant Metastatic DTC Based on Inflammatory and Clinicopathological Factors
    Chenghui Lu, Guoqiang Wang, Zengmei Si, Fengqi Li, Xinfeng Liu, Na Han, Congcong Wang, Jiao Li, Xufu Wang
    Journal of the Endocrine Society.2025;[Epub]     CrossRef
  • Turning tumor microenvironmental foes to friends: A new opportunity for thyroid cancer therapy and redifferentiation
    Liya Zhu, Xiuli Jing, Byeong-Cheol Ahn
    Oral Oncology.2025; 168: 107513.     CrossRef
  • Predictive and prognostic role of Neutrophil-to-Lymphocyte ratio in patients with advanced thyroid cancer treated with targeted therapy
    Tuerhong Diliyaer, Yueyan Ren, Xuejiao Chen, Xixi Zhu, Tuerxun Yilidana, Jiaye Liu, Gang Chen, Zhihui Li
    Endocrine.2025; 90(3): 1380.     CrossRef
Close layer
Thyroid
Long-Term Changes in the Mortality Rates of Thyroid Cancer in Korea: Analysis of Korean National Data from 1985 to 2020
Yun Mi Choi, Min-Ju Kim, Jiwoo Lee, Mi Kyung Kwak, Min Ji Jeon, Tae Yong Kim, Eun-Gyoung Hong, Won Bae Kim, Won Gu Kim
Endocrinol Metab. 2023;38(5):588-595.   Published online September 8, 2023
DOI: https://doi.org/10.3803/EnM.2023.1723
  • 6,390 View
  • 150 Download
  • 5 Web of Science
  • 5 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Thyroid cancer mortality has been largely overlooked as relatively stable given the large gap between thyroid cancer incidence and mortality. This study evaluated long-term trends in age-standardized mortality rates (ASMRs) throughout Korea and compared them with mortality data reported by the Surveillance, Epidemiology, and End Results (SEER).
Methods
Cancer-specific mortality data from 1985 to 2020 were obtained from Statistics Korea. ASMRs from thyroid cancer were calculated based on the Korean mid-year resident registration population of 2005. We assessed SEER*Explorer and downloaded the mortality data.
Results
The ASMR increased from 0.19 to 0.77/100,000 between 1985 and 2002 but decreased continuously to 0.36/100,000 in 2020. The annual percent change (APC) in the ASMR between 1985 and 2003 and between 2003 and 2020 was 6.204 and −4.218, respectively, with similar patterns observed in both men and women. The ASMR of the SEER showed a modest increase from 1988 to 2016 and then stabilized. In subgroup analysis, the ASMR of the old age group (≥55 years) increased significantly from 0.82 in 1985 to 3.92/100,000 in 2002 (APC 6.917) but then decreased again to 1.86/100,000 in 2020 (APC −4.136). ASMRs according to the age group in the SEER showed a relatively stable trend even in the elderly group.
Conclusion
The ASMR of thyroid cancer in Korea had increased from 1985 to 2002 but has since been steadily decreasing. This trend was mainly attributed to elderly people aged 55 or over. The absolute APC value of Korea was much higher than that of the SEER.

Citations

Citations to this article as recorded by  
  • Association Between Metabolic Dysfunction-Associated Steatotic Liver Disease and Thyroid Cancer
    Sang Yi Moon, Minkook Son, Jung-Hwan Cho, Hye In Kim, Ji Min Han, Ji Cheol Bae, Sunghwan Suh
    Thyroid®.2025; 35(1): 79.     CrossRef
  • It Is Time to Understand the Additional Benefits of Active Surveillance for Low-Risk Papillary Thyroid Carcinoma
    Kyeong Jin Kim
    Endocrinology and Metabolism.2024; 39(1): 95.     CrossRef
  • Thyroid cancer-specific mortality during 2005–2018 in Korea, aftermath of the overdiagnosis issue: a nationwide population-based cohort study
    Kyeong Jin Kim, Jimi Choi, Sue K. Park, Young Joo Park, Sin Gon Kim
    International Journal of Surgery.2024; 110(9): 5489.     CrossRef
  • Trends in Thyroid Cancer Mortality Rates in Korea: Insights from National Health Database
    Won Gu Kim
    Endocrinology and Metabolism.2024; 39(6): 853.     CrossRef
  • A Clinical Audit of Thyroid Hormonal Replacement After Total Thyroidectomy
    Islam Mansy, Abdelfatah M Elsenosy, Eslam M Hassan, Mujtaba Zakria
    Cureus.2023;[Epub]     CrossRef
Close layer
Corrigendum
Thyroid
Corrigendum: Abstract and Text Correction. Thyroid Stimulating Hormone Reference Range and Prevalence of Thyroid Dysfunction in the Korean Population: Korea National Health and Nutrition Examination Survey 2013 to 2015
Won Gu Kim, Won Bae Kim, Gyeongji Woo, Hyejin Kim, Yumi Cho, Tae Yong Kim, Sun Wook Kim, Myung-Hee Shin, Jin Woo Park, Hai-Lin Park, Kyungwon Oh, Jae Hoon Chung
Endocrinol Metab. 2023;38(3):357.   Published online May 16, 2023
DOI: https://doi.org/10.3803/EnM.2023.301
Corrects: Endocrinol Metab 2017;32(1):106
  • 3,106 View
  • 78 Download
  • 1 Web of Science
  • 1 Crossref
PDFPubReader   ePub   

Citations

Citations to this article as recorded by  
  • The Establishment of Reference Intervals for Thyroid Hormone Tests in the Korean Population: Using a Direct Selection Technique
    Jong Do Seo, Eun-Jung Cho, Changhee Ha, Hyung-Doo Park, Shinae Yu, Woochang Lee, Sollip Kim, Yeo-Min Yun
    Diagnostics.2025; 15(19): 2510.     CrossRef
Close layer
Original Article
Thyroid
Big Data Articles (National Health Insurance Service Database)
Recent Changes in the Incidence of Thyroid Cancer in Korea between 2005 and 2018: Analysis of Korean National Data
Yun Mi Choi, Jiwoo Lee, Mi Kyung Kwak, Min Ji Jeon, Tae Yong Kim, Eun-Gyoung Hong, Won Bae Kim, Won Gu Kim
Endocrinol Metab. 2022;37(5):791-799.   Published online October 11, 2022
DOI: https://doi.org/10.3803/EnM.2022.1533
  • 8,283 View
  • 243 Download
  • 19 Web of Science
  • 18 Crossref
AbstractAbstract PDFPubReader   ePub   
Background
In this study, we evaluated the recent changes in the standardized, age-specific, stage-specific incidence rates (IRs) of thyroid cancer in Korea and compared them with the incidence data reported by the Surveillance, Epidemiology, and End Results Program.
Methods
The analysis was conducted using the incidence data (2005 to 2018) from the Statistics Korea and Korea Central Cancer Registry.
Results
The age-standardized IR (SIR) of thyroid cancer increased from 24.09 per 100,000 in 2005 to 74.83 in 2012 (annual percent change [APC], 14.5). From 2012 to 2015, the SIR decreased to 42.52 (APC, –17.9) and then remained stable until 2018 (APC, 2.1). This trend was similar in both men and women. Regarding age-specific IRs, the IRs for ages of 30 years and older showed a trend similar to that of the SIR; however, for ages below 30 years, no significant reduction was observed from the vertex of IR in 2015. Regarding stage-specific IRs, the increase was more prominent in those with regional disease (APC, 17.4) than in those with localized disease until 2012; then, the IR decreased until 2015 (APC, –16.1). The average APC from 2005 to 2018 increased in men, those under the age of 30 years, and those with regional disease.
Conclusion
The SIR in Korea peaked in 2012 and decreased until 2015 and then remained stable until 2018. However, in young individuals under the age of 30 years, the IR did not significantly decrease but tended to increase again. In terms of stage-specific IRs, the sharpest increase was seen among those with regional disease.

Citations

Citations to this article as recorded by  
  • Deep Learning Technology for Classification of Thyroid Nodules Using Multi-View Ultrasound Images: Potential Benefits and Challenges in Clinical Application
    Jinyoung Kim, Min-Hee Kim, Dong-Jun Lim, Hankyeol Lee, Jae Jun Lee, Hyuk-Sang Kwon, Mee Kyoung Kim, Ki-Ho Song, Tae-Jung Kim, So Lyung Jung, Yong Oh Lee, Ki-Hyun Baek
    Endocrinology and Metabolism.2025; 40(2): 216.     CrossRef
  • 2025 Korean Thyroid Association Clinical Management Guideline on Active Surveillance for Low-Risk Papillary Thyroid Carcinoma
    Eun Kyung Lee, Min Joo Kim, Seung Heon Kang, Bon Seok Koo, Kyungsik Kim, Mijin Kim, Bo Hyun Kim, Ji-hoon Kim, Shin Je Moon, Kyorim Back, Young Shin Song, Jong-hyuk Ahn, Hwa Young Ahn, Ho-Ryun Won, Won Sang Yoo, Min Kyoung Lee, Jeongmin Lee, Ji Ye Lee, Kyo
    International Journal of Thyroidology.2025; 18(1): 30.     CrossRef
  • 2025 Korean Thyroid Association Clinical Management Guideline on Active Surveillance for Low-Risk Papillary Thyroid Carcinoma
    Eun Kyung Lee, Min Joo Kim, Seung Heon Kang, Bon Seok Koo, Kyungsik Kim, Mijin Kim, Bo Hyun Kim, Ji-hoon Kim, Shinje Moon, Kyorim Back, Young Shin Song, Jong-hyuk Ahn, Hwa Young Ahn, Ho-Ryun Won, Won Sang Yoo, Min Kyoung Lee, Jeongmin Lee, Ji Ye Lee, Kyon
    Endocrinology and Metabolism.2025; 40(3): 307.     CrossRef
  • Hybrid Transoral Endoscopic Thyroidectomy Submental Access (H-TOETSA) Versus Conventional and Bilateral-Axillo Breast Approach (BABA) Thyroidectomy: A Comparative Study of Feasibility and Safety
    Myungyup Hyun, Junwon Min, Euitae Kim
    Journal of Endocrine Surgery.2025; 25(4): 139.     CrossRef
  • Comparison of postoperative pain between transoral and conventional thyroidectomy: a propensity score-matched analysis
    Min Kyu Park, Van Cuong Nguyen, Eugene Kim, Chang Myeon Song, Yong Bae Ji, Jin Hyeok Jeong, Kyung Tae
    Surgical Endoscopy.2024; 38(3): 1512.     CrossRef
  • Contents analysis of thyroid cancer-related information uploaded to YouTube by physicians in Korea: endorsing thyroid cancer screening, potentially leading to overdiagnosis
    EunKyo Kang, HyoRim Ju, Soojeong Kim, Juyoung Choi
    BMC Public Health.2024;[Epub]     CrossRef
  • Bilateral axillo-breast approach robotic total thyroidectomy without isthmectomy: a case report
    Hyeji Kim, Hyeonuk Hwang, Hyungju Kwon
    The Ewha Medical Journal.2024;[Epub]     CrossRef
  • Association between Consumption of Iodine-Rich Foods and Thyroid Cancer Prevalence: Findings from a Large Population-Based Study
    Yu-Jin Kwon, Hye-Sun Lee, Sang-Wook Kang, Ji-Won Lee
    Nutrients.2024; 16(7): 1041.     CrossRef
  • Cost-Utility Analysis of Early Detection with Ultrasonography of Differentiated Thyroid Cancer: A Retrospective Study on a Korean Population
    Han-Sang Baek, Jeonghoon Ha, Kwangsoon Kim, Ja Seong Bae, Jeong Soo Kim, Sungju Kim, Dong-Jun Lim, Chul-Min Kim
    Endocrinology and Metabolism.2024; 39(2): 310.     CrossRef
  • Thyroid Cancer Incidence Among Korean Individuals: A Comparison of South Korea and the United States
    Dohun Kim, Guan Li, Peter K. Moon, Yifei Ma, Soohyun Sim, Sung Y. Park, Minkyung Oh, Uchechukwu C. Megwalu
    The Laryngoscope.2024; 134(9): 4156.     CrossRef
  • Thyroid cancer-specific mortality during 2005–2018 in Korea, aftermath of the overdiagnosis issue: a nationwide population-based cohort study
    Kyeong Jin Kim, Jimi Choi, Sue K. Park, Young Joo Park, Sin Gon Kim
    International Journal of Surgery.2024; 110(9): 5489.     CrossRef
  • Trends in Thyroid Cancer Mortality Rates in Korea: Insights from National Health Database
    Won Gu Kim
    Endocrinology and Metabolism.2024; 39(6): 853.     CrossRef
  • Cancer and Mortality Risks of Graves’ Disease in South Korea Based on National Data from 2010 to 2019
    Young Ju Choi, Kyungdo Han, Won Kyoung Cho, Min Ho Jung, Byung-Kyu Suh
    Clinical Epidemiology.2023; Volume 15: 535.     CrossRef
  • Survival Comparison of Incidentally Found versus Clinically Detected Thyroid Cancers: An Analysis of a Nationwide Cohort Study
    Shinje Moon, Eun Kyung Lee, Hoonsung Choi, Sue K. Park, Young Joo Park
    Endocrinology and Metabolism.2023; 38(1): 81.     CrossRef
  • Cumulative exposure to metabolic syndrome increases thyroid cancer risk in young adults: a population-based cohort study
    Jinyoung Kim, Kyungdo Han, Mee Kyoung Kim, Ki-Hyun Baek, Ki-Ho Song, Hyuk-Sang Kwon
    The Korean Journal of Internal Medicine.2023; 38(4): 526.     CrossRef
  • Cost-Effectiveness of Active Surveillance Compared to Early Surgery of Small Papillary Thyroid Cancer: A Retrospective Study on a Korean Population
    Han-Sang Baek, Jeonghoon Ha, Kwangsoon Kim, Jaseong Bae, Jeong Soo Kim, Sungju Kim, Dong-Jun Lim, Chulmin Kim
    Journal of Korean Medical Science.2023;[Epub]     CrossRef
  • Long-Term Changes in the Mortality Rates of Thyroid Cancer in Korea: Analysis of Korean National Data from 1985 to 2020
    Yun Mi Choi, Min-Ju Kim, Jiwoo Lee, Mi Kyung Kwak, Min Ji Jeon, Tae Yong Kim, Eun-Gyoung Hong, Won Bae Kim, Won Gu Kim
    Endocrinology and Metabolism.2023; 38(5): 588.     CrossRef
  • Age and Post-Lobectomy Recurrence after Endoscopic or Robotic Thyroid Surgery: A Retrospective Cohort Study of 2348 Papillary Thyroid Carcinoma Patients
    Jin-Seong Cho, Yong-Min Na, Hee Kyung Kim
    Cancers.2023; 15(23): 5506.     CrossRef
Close layer
Corrigenda
Miscellaneous
Corrigendum: Correction of Acknowledgments. Protocol for a Korean Multicenter Prospective Cohort Study of Active Surveillance or Surgery (KoMPASS) in Papillary Thyroid Microcarcinoma
Min Ji Jeon, Yea Eun Kang, Jae Hoon Moon, Dong Jun Lim, Chang Yoon Lee, Yong Sang Lee, Sun Wook Kim, Min-Hee Kim, Bo Hyun Kim, Ho-Cheol Kang, Minho Shong, Sun Wook Cho, Won Bae Kim
Endocrinol Metab. 2022;37(1):181-182.   Published online February 28, 2022
DOI: https://doi.org/10.3803/EnM.2022.104
Corrects: Endocrinol Metab 2021;36(2):359
  • 5,226 View
  • 125 Download
  • 1 Web of Science
  • 1 Crossref
PDFPubReader   ePub   

Citations

Citations to this article as recorded by  
  • Risk of thyroid cancer associated with glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes: A population‐based cohort study
    Sungho Bea, Heejun Son, Jae Hyun Bae, Sun Wook Cho, Ju‐Young Shin, Young Min Cho
    Diabetes, Obesity and Metabolism.2024; 26(1): 108.     CrossRef
Close layer
Miscellaneous
Corrigendum: Correction of Acknowledgments. Active Surveillance as an Effective Management Option for Low-Risk Papillary Thyroid Microcarcinoma
Min Ji Jeon, Won Gu Kim, Tae Yong Kim, Young Kee Shong, Won Bae Kim
Endocrinol Metab. 2022;37(1):180.   Published online February 28, 2022
DOI: https://doi.org/10.3803/EnM.2022.103
Corrects: Endocrinol Metab 2021;36(4):717
  • 4,675 View
  • 116 Download
  • 1 Web of Science
  • 1 Crossref
PDFPubReader   ePub   

Citations

Citations to this article as recorded by  
  • Lateral Involvement in Different Sized Papillary Thyroid Carcinomas Patients with Central Lymph Node Metastasis: A Multi-Center Analysis
    Yu Heng, Zheyu Yang, Pengyu Cao, Xi Cheng, Lei Tao
    Journal of Clinical Medicine.2022; 11(17): 4975.     CrossRef
Close layer
Original Articles
Thyroid
Clinical Characteristics and Prognosis of Coexisting Thyroid Cancer in Patients with Graves’ Disease: A Retrospective Multicenter Study
Jee Hee Yoon, Meihua Jin, Mijin Kim, A Ram Hong, Hee Kyung Kim, Bo Hyun Kim, Won Bae Kim, Young Kee Shong, Min Ji Jeon, Ho-Cheol Kang
Endocrinol Metab. 2021;36(6):1268-1276.   Published online November 26, 2021
DOI: https://doi.org/10.3803/EnM.2021.1227
  • 9,331 View
  • 228 Download
  • 17 Web of Science
  • 18 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
The association between Graves’ disease (GD) and co-existing thyroid cancer is still controversial and most of the previously reported data have been based on surgically treated GD patients. This study investigated the clinicopathological findings and prognosis of concomitant thyroid cancer in GD patients in the era of widespread application of ultrasonography.
Methods
Data of GD patients who underwent thyroidectomy for thyroid cancer between 2010 and 2019 in three tertiary hospitals in South Korea (Asan Medical Center, Chonnam National University Hwasun Hospital, and Pusan National University Hospital) were collected and analyzed retrospectively. In the subgroup analysis, aggressiveness and clinical outcomes of thyroid cancer were compared nodular GD and non-nodular GD groups according to the presence or absence of the thyroid nodules other than thyroid cancer (index nodules).
Results
Of the 15,159 GD patients treated at the hospitals during the study period, 262 (1.7%) underwent thyroidectomy for coexisting thyroid cancer. Eleven patients (4.2%) were diagnosed with occult thyroid cancer and 182 patients (69.5%) had microcarcinomas. No differences in thyroid cancer aggressiveness, ultrasonographic findings, or prognosis were observed between the nodular GD and non-nodular GD groups except the cancer subtype. In the multivariate analysis, only lymph node (LN) metastasis was an independent prognostic factor for recurrent/persistent disease of thyroid cancer arising in GD (P=0.020).
Conclusion
The prevalence of concomitant thyroid cancer in GD patients was considerably lower than in previous reports. The clinical outcomes of thyroid cancer in GD patients were also excellent but, more cautious follow-up is necessary for patients with LN metastasis in the same way as for thyroid cancer in non-GD patients.

Citations

Citations to this article as recorded by  
  • Coexisting Graves' Disease and Papillary Thyroid Carcinoma: The Importance of Nodule Surveillance in Autoimmune Hyperthyroidism
    Eliany Leon Figueredo, Ana B Cuni Hernandez, Annia Vega Fuentes, Juan T Vargas Rivera, Eduardo Oropesa, Ricardo Silvera
    Cureus.2026;[Epub]     CrossRef
  • Incidental Thyroid Cancer in Patients With Graves’ Disease: Not as Rare as We Previously Believed
    Shaidy Moronta, Lauren Slattery, Rongzhi Wang, Fiemu Nwariaku, Jessica Liu McMullin
    Journal of Surgical Research.2025; 308: 122.     CrossRef
  • Preoperative serum lipids as novel predictors for concomitant thyroid carcinoma in Graves’ disease
    Xingxing Gao, Mi Liu, Yijun Wu
    PeerJ.2025; 13: e19915.     CrossRef
  • Clinicopathologic predictors of incidental thyroid cancer in Graves’ disease: a single-center retrospective cohort study
    Wei Huang, Wei-Hsin Chen
    Updates in Surgery.2025;[Epub]     CrossRef
  • Comparison of Surgical Outcomes of Transoral Versus Open Thyroidectomy for Graves Disease
    Suo-Hsien Wang, Wu-Po Chao, Ta-You Lo, Soh-Ching Ng, Yu-Hsien Chen
    Surgical Laparoscopy, Endoscopy & Percutaneous Techniques.2024; 34(2): 150.     CrossRef
  • Characterization of Immune Infiltrate Along the Leading Edge of Differentiated Thyroid Cancer
    Anupam Kotwal, Krysten Vance, Kemal Hajric, Ana Yuil-Valdes, Benjamin Swanson, Ernesto Martinez Duarte, Oleg Shats, Michael Hollingsworth, Hamid Band, Whitney Goldner
    Thyroid®.2024; 34(8): 999.     CrossRef
  • The Role of Risk Factors for the Progression of Patients with T1b-T2 Papillary Thyroid Carcinoma (PC) during Long-Term Follow-Up
    Andrea Marongiu, Susanna Nuvoli, Andrea De Vito, Antonio Mura, Sonia Vargiu, Angela Spanu, Giuseppe Madeddu
    Journal of Clinical Medicine.2024; 13(18): 5373.     CrossRef
  • Outcomes of Surgical Treatment for Graves’ Disease: A Single-Center Experience of 216 Cases
    Hanxing Sun, Hui Tong, Xiaohui Shen, Haoji Gao, Jie Kuang, Xi Chen, Qinyu Li, Weihua Qiu, Zhuoran Liu, Jiqi Yan
    Journal of Clinical Medicine.2023; 12(4): 1308.     CrossRef
  • Cancer and Mortality Risks of Graves’ Disease in South Korea Based on National Data from 2010 to 2019
    Young Ju Choi, Kyungdo Han, Won Kyoung Cho, Min Ho Jung, Byung-Kyu Suh
    Clinical Epidemiology.2023; Volume 15: 535.     CrossRef
  • Risk and Prognosis of Thyroid Cancer in Patients with Graves’ Disease: An Umbrella Review
    Marco Palella, Francesca Maria Giustolisi, Adriana Modica Fiascaro, Martina Fichera, Antonella Palmieri, Rossella Cannarella, Aldo E. Calogero, Margherita Ferrante, Maria Fiore
    Cancers.2023; 15(10): 2724.     CrossRef
  • Characteristics, staging and outcomes of differentiated thyroid cancer in patients with and without Graves’ disease
    Chaitra Gopinath, Hanna Crow, Sujata Panthi, Leonidas Bantis, Kenneth D. Burman, Chitra Choudhary
    Journal of Clinical & Translational Endocrinology.2023; 33: 100321.     CrossRef
  • Prevalence, Treatment Status, and Comorbidities of Hyperthyroidism in Korea from 2003 to 2018: A Nationwide Population Study
    Hwa Young Ahn, Sun Wook Cho, Mi Young Lee, Young Joo Park, Bon Seok Koo, Hang-Seok Chang, Ka Hee Yi
    Endocrinology and Metabolism.2023; 38(4): 436.     CrossRef
  • Hashimoto’s Thyroiditis and Papillary Thyroid Carcinoma: A Follow-Up Study in Patients with Absence of Aggressive Risk Factors at the Surgery of the Primary Tumor
    Andrea Marongiu, Susanna Nuvoli, Andrea De Vito, Sonia Vargiu, Angela Spanu, Giuseppe Madeddu
    Diagnostics.2023; 13(19): 3068.     CrossRef
  • Table of Contents

    Clinical Thyroidology.2022; 34(2): 48.     CrossRef
  • Predisposition to and Prognosis of Thyroid Cancer May Not Be Affected by Graves’ Disease, But Some Questions Still Remain
    Yanrui Huang, Haixia Guan
    Clinical Thyroidology.2022; 34(2): 59.     CrossRef
  • A Comparative Follow-Up Study of Patients with Papillary Thyroid Carcinoma Associated or Not with Graves’ Disease
    Andrea Marongiu, Susanna Nuvoli, Andrea De Vito, Maria Rondini, Angela Spanu, Giuseppe Madeddu
    Diagnostics.2022; 12(11): 2801.     CrossRef
  • An unusual case of papillary thyroid carcinoma presenting as Graves’ disease
    Pooja Tiwari, Uma Kaimal Saikia, Abhamoni Baro, Ashok Krishna Bhuyan
    Thyroid Research and Practice.2022; 19(1): 47.     CrossRef
  • An unusual case of papillary thyroid carcinoma presenting as Graves’ disease
    Pooja Tiwari, Uma Kaimal Saikia, Abhamoni Baro, Ashok Krishna Bhuyan
    Thyroid Research and Practice.2021; 18(3): 129.     CrossRef
Close layer
Thyroid
Clinicopathological Characteristics and Disease-Free Survival in Patients with Hürthle Cell Carcinoma: A Multicenter Cohort Study in South Korea
Meihua Jin, Eun Sook Kim, Bo Hyun Kim, Hee Kyung Kim, Yea Eun Kang, Min Ji Jeon, Tae Yong Kim, Ho-Cheol Kang, Won Bae Kim, Young Kee Shong, Mijin Kim, Won Gu Kim
Endocrinol Metab. 2021;36(5):1078-1085.   Published online October 28, 2021
DOI: https://doi.org/10.3803/EnM.2021.1151
  • 7,706 View
  • 131 Download
  • 9 Web of Science
  • 11 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Hürthle cell carcinoma (HCC), a type of thyroid carcinoma, is rare in South Korea, and few studies have investigated its prognosis.
Methods
This long-term multicenter retrospective cohort study evaluated the clinicopathological features and clinical outcomes in patients with HCC who underwent thyroid surgery between 1996 and 2009.
Results
The mean age of the 97 patients included in the study was 50.3 years, and 26.8% were male. The mean size of the primary tumor was 3.2±1.8 cm, and three (3.1%) patients had distant metastasis at initial diagnosis. Ultrasonographic findings were available for 73 patients; the number of nodules with low-, intermediate-, and high suspicion was 28 (38.4%), 27 (37.0%), and 18 (24.7%), respectively, based on the Korean-Thyroid Imaging Reporting and Data System. Preoperatively, follicular neoplasm (FN) or suspicion for FN accounted for 65.2% of the cases according to the Bethesda category, and 13% had malignancy or suspicious for malignancy. During a median follow-up of 8.5 years, eight (8.2%) patients had persistent/recurrent disease, and none died of HCC. Older age, gross extrathyroidal extension (ETE), and widely invasive types of tumors were significantly associated with distant metastasis (all P<0.01). Gross ETE (hazard ratio [HR], 27.7; 95% confidence interval [CI], 2.2 to 346.4; P=0.01) and widely invasive classification (HR, 6.5; 95% CI, 1.1 to 39.4; P=0.04) were independent risk factors for poor disease-free survival (DFS).
Conclusion
The long-term prognosis of HCC is relatively favorable in South Korea from this study, although this is not a nation-wide data, and gross ETE and widely invasive cancer are significant prognostic factors for DFS. The diagnosis of HCC by ultrasonography and cytopathology remains challenging.

Citations

Citations to this article as recorded by  
  • Epidemiology and prognostic factors of Hürthle-oncocytic cell carcinoma of the thyroid
    Omar Hamdy, Hedaa Atwa, Ekbal Elkhouli, Ahmed H. Ata, Radwa M. Abdelsattar, Maryam Dawood, Shadi Awny, Mohamed Ezat
    Discover Oncology.2026;[Epub]     CrossRef
  • Prognostic impact of fibrosclerotic changes in non-papillary, non-anaplastic, follicular cell-derived thyroid carcinomas
    Giulia Orlando, Giulia Capella, Giulia Vocino Trucco, Elena Vissio, Jasna Metovic, Francesca Maletta, Marco Volante, Mauro Papotti
    Virchows Archiv.2025; 487(3): 701.     CrossRef
  • Differentiating oncocytic carcinoma from oncocytic adenoma: a comprehensive evaluation of preoperative characteristics and diagnostic approaches in a retrospective cohort study
    Eunji Kim, Jun Hyun Park, Ji-Young Park, Sang-Woo Lee, Jin Hyang Jung
    Annals of Surgical Treatment and Research.2025; 109(2): 105.     CrossRef
  • 2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer
    Matthew D. Ringel, Julie Ann Sosa, Zubair Baloch, Lindsay Bischoff, Gary Bloom, Gregory A. Brent, Pamela L. Brock, Roger Chou, Robert R. Flavell, Whitney Goldner, Elizabeth G. Grubbs, Megan Haymart, Steven M. Larson, Angela M. Leung, Joseph Osborne, John
    Thyroid®.2025; 35(8): 841.     CrossRef
  • Molecular Alterations and Comprehensive Clinical Management of Oncocytic Thyroid Carcinoma
    Lindsay A. Bischoff, Ian Ganly, Laura Fugazzola, Erin Buczek, William C. Faquin, Bryan R. Haugen, Bryan McIver, Caitlin P. McMullen, Kate Newbold, Daniel J. Rocke, Marika D. Russell, Mabel Ryder, Peter M. Sadow, Eric Sherman, Maisie Shindo, David C. Shonk
    JAMA Otolaryngology–Head & Neck Surgery.2024; 150(3): 265.     CrossRef
  • Oncocytic carcinoma of the thyroid: Conclusions from a 20‐year patient cohort
    Nelson R. Gruszczynski, Shahzeb S. Hasan, Ana G. Brennan, Julian De La Chapa, Adithya S. Reddy, David N. Martin, Prem P. Batchala, Edward B. Stelow, Eric M. Dowling, Katherine L. Fedder, Jonathan C. Garneau, David C. Shonka
    Head & Neck.2024; 46(8): 2042.     CrossRef
  • Oncocytic cell carcinoma of the thyroid with TERT promoter mutation presenting as asphyxia in an elderly: a case report
    Xiqian Wang, Yingao Liu, Lijie Chen, Jie Zhang, Ruoyu Jiang, Lei Zhang, Han Yan, Jie Zhang
    Frontiers in Endocrinology.2024;[Epub]     CrossRef
  • Clinical Considerations of Oncocytic Thyroid Cancer: A Review
    Soo Young Kim
    Journal of Endocrine Surgery.2024; 24(3): 49.     CrossRef
  • Mitochondrial Proteome Defined Molecular Pathological Characteristics of Oncocytic Thyroid Tumors
    Lu Li, Likun Zhang, Wenhao Jiang, Zhiqiang Gui, Zhihong Wang, Hao Zhang, Yi He, Yi Zhu, Tiannan Guo, Haixia Guan, Zhiyan Liu, Yaoting Sun, Jianqing Gao
    Endocrine Pathology.2024; 35(4): 442.     CrossRef
  • Hurthle cell carcinoma: a rare variant of thyroid malignancy – a case report
    Yuvraj Adhikari, Anupama Marasini, Nawaraj Adhikari, Laxman D. Paneru, Binit Upadhaya Regmi, Manita Raut
    Annals of Medicine & Surgery.2023; 85(5): 1940.     CrossRef
  • Hürthle Cell Carcinoma: Single Center Analysis and Considerations for Surgical Management Based on the Recent Literature
    Costanza Chiapponi, Milan J.M. Hartmann, Matthias Schmidt, Michael Faust, Christiane J. Bruns, Anne M. Schultheis, Hakan Alakus
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
Close layer
Review Article
Thyroid
Active Surveillance as an Effective Management Option for Low-Risk Papillary Thyroid Microcarcinoma
Min Ji Jeon, Won Gu Kim, Tae Yong Kim, Young Kee Shong, Won Bae Kim
Endocrinol Metab. 2021;36(4):717-724.   Published online August 11, 2021
DOI: https://doi.org/10.3803/EnM.2021.1042
Correction in: Endocrinol Metab 2022;37(1):180
  • 8,332 View
  • 205 Download
  • 9 Web of Science
  • 6 Crossref
AbstractAbstract PDFPubReader   ePub   
Active surveillance (AS) for low-risk papillary thyroid microcarcinoma (PTMC) has been accepted worldwide as safe and effective. Despite the growing acceptance of AS in the management of low-risk PTMCs, there are barriers to AS in real clinical settings, and it is important to understand and establish appropriate AS protocol from initial evaluation to follow-up. PTMC management strategies should be decided upon after careful consideration of patient and tumor characteristics by a multidisciplinary team of thyroid cancer specialists. Patients should understand the risks and benefits of AS, participate in decision-making and follow structured monitoring strategies. In this review, we discuss clinical outcomes of AS from previous studies, optimal indications and follow-up strategies for AS, and unresolved questions about AS.

Citations

Citations to this article as recorded by  
  • Towards an Integrated Framework for Health Surveillance Systems: A Systematic Literature Review of Design Components and Implementation Challenges
    Maryam Mollabagher, Alireza Hassanzadeh, Mohammad Mahdi Sepehri, Abbas Habibelahi, Abolghasem Sarabadani
    Health Science Reports.2026;[Epub]     CrossRef
  • Risk factors for lateral neck lymph node metastasis in papillary thyroid ultra micro carcinoma with implications for active surveillance
    Hyeung Kyoo Kim, Ho Jung Jeong, Jin Seok Lee, Soo Young Kim, Yong Sang Lee, Hang-Seok Chang
    Scientific Reports.2025;[Epub]     CrossRef
  • Diagnostic Accuracy of Preoperative Radiologic Findings in Papillary Thyroid Microcarcinoma: Discrepancies with the Postoperative Pathologic Diagnosis and Implications for Clinical Outcomes
    Ying Li, Seul Ki Kwon, Hoonsung Choi, Yoo Hyung Kim, Sunyoung Kang, Kyeong Cheon Jung, Jae-Kyung Won, Do Joon Park, Young Joo Park, Sun Wook Cho
    Endocrinology and Metabolism.2024; 39(3): 450.     CrossRef
  • Serum thyroglobulin testing after thyroid lobectomy in patients with 1–4 cm papillary thyroid carcinoma
    Ahreum Jang, Meihua Jin, Chae A Kim, Min Ji Jeon, Yu-Mi Lee, Tae-Yon Sung, Tae Yong Kim, Won Bae Kim, Young Kee Shong, Won Gu Kim
    Endocrine.2023; 81(2): 290.     CrossRef
  • Papillary Thyroid Microcarcinoma: Active Surveillance Against Surgery. Considerations of an Italian Working Group From a Systematic Review
    Giuseppina Orlando, Gregorio Scerrino, Alessandro Corigliano, Irene Vitale, Roberta Tutino, Stefano Radellini, Francesco Cupido, Giuseppa Graceffa, Gianfranco Cocorullo, Giuseppe Salamone, Giuseppina Melfa
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Prognosis of Patients with 1–4 cm Papillary Thyroid Cancer Who Underwent Lobectomy: Focus on Gross Extrathyroidal Extension Invading Only the Strap Muscles
    Ahreum Jang, Meihua Jin, Won Woong Kim, Min Ji Jeon, Tae-Yon Sung, Dong Eun Song, Tae Yong Kim, Ki-Wook Chung, Won Bae Kim, Young Kee Shong, Yu-Mi Lee, Won Gu Kim
    Annals of Surgical Oncology.2022; 29(12): 7835.     CrossRef
Close layer
Original Articles
Clinical Study
Gender-Dependent Reference Range of Serum Calcitonin Levels in Healthy Korean Adults
Eyun Song, Min Ji Jeon, Hye Jin Yoo, Sung Jin Bae, Tae Yong Kim, Won Bae Kim, Young Kee Shong, Hong-Kyu Kim, Won Gu Kim
Endocrinol Metab. 2021;36(2):365-373.   Published online April 7, 2021
DOI: https://doi.org/10.3803/EnM.2020.939
  • 9,329 View
  • 175 Download
  • 6 Web of Science
  • 7 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Serum calcitonin measurement contains various clinical and methodological aspects. Its reference level is wide and unclear despite sensitive calcitonin kits are available. This study aimed to identify the specific reference range in the healthy Korean adults.
Methods
Subjects were ≥20 years with available calcitonin (measured by a two-site immunoradiometric assay) data by a routine health checkup. Three groups were defined as all eligible subjects (group 1, n=10,566); subjects without self or family history of thyroid disease (group 2, n=5,152); and subjects without chronic kidney disease, autoimmune thyroid disease, medication of proton pump inhibitor/H2 blocker/steroid, or other malignancies (group 3, n=4,638).
Results
This study included 6,341 male and 4,225 female subjects. Males had higher mean calcitonin than females (2.3 pg/mL vs. 1.9 pg/mL, P<0.001) in group 1. This gender difference remained similar in groups 2 and 3. Calcitonin according to age or body mass index was not significant in both genders. Higher calcitonin in smoking than nonsmoking men was observed but not in women. Sixty-nine subjects had calcitonin higher than the upper reference limit (10 pg/mL) and 64 of them had factors associated with hypercalcitoninemia besides medullary thyroid cancer. Our study suggests the reference intervals for men who were non, ex-, current smokers, and women (irrespective of smoking status) as <5.7, <7.1, <7.9, and <3.6 pg/mL, respectively.
Conclusion
Specific calcitonin reference range should be provided considering for sex and smoking status. Taking account for several factors known to induce hypercalcitoninemia can help interpret the gray zone of moderately elevated calcitonin.

Citations

Citations to this article as recorded by  
  • Circulating Biomarkers in Medullary Thyroid Carcinoma: Bridging Laboratory Complexities and Clinical Application Through Algorithm Design
    Luca Giovanella, Federica D’Aurizio, Petra Petranović Ovčariček
    Journal of Clinical Medicine.2025; 14(16): 5645.     CrossRef
  • Determinants of circulating calcitonin value: analysis of thyroid features, demographic data, anthropometric characteristics, comorbidities, medications, and smoking habits in a population with histological full exclusion of medullary thyroid carcinoma
    Pierpaolo Trimboli, Giuseppe Peloni, Dorotea Confalonieri, Elena Gamarra, Tommaso Piticchio, Francesco Frasca, Petra Makovac, Arnoldo Piccardo, Lorenzo Ruinelli
    Frontiers in Oncology.2024;[Epub]     CrossRef
  • Surgical treatment of solid variant of papillary thyroid carcinoma: Fifteen-year experience of a tertiary center
    Katarina Tausanović, Marina Stojanović, Milan Jovanović, Boban Stepanović, Jovan Ilić, Sara Ivaniš, Vladan Živaljević
    Medicinska istrazivanja.2024; 57(1): 121.     CrossRef
  • Impact of dietary, lifestyle and sociodemographic factors on calcitonin levels in a healthy population
    Ivana Gunjača, Mirjana Babić Leko, Nikolina Pleić, Ante Jurić, Dubravka Brdar, Vesela Torlak, Marko Vuletić, Ante Punda, Ozren Polašek, Caroline Hayward, Tatijana Zemunik
    Bone.2024; 187: 117214.     CrossRef
  • Some genetic differences in patients with rheumatoid arthritis
    Hosam M. Ahmad, Zaki M. Zaki, Asmaa S. Mohamed, Amr E. Ahmed
    BMC Research Notes.2023;[Epub]     CrossRef
  • Presence or severity of Hashimoto’s thyroiditis does not influence basal calcitonin levels: observations from CROHT biobank
    M. Cvek, A. Punda, M. Brekalo, M. Plosnić, A. Barić, D. Kaličanin, L. Brčić, M. Vuletić, I. Gunjača, V. Torlak Lovrić, V. Škrabić, V. Boraska Perica
    Journal of Endocrinological Investigation.2022; 45(3): 597.     CrossRef
  • Environmental Factors That Affect Parathyroid Hormone and Calcitonin Levels
    Mirjana Babić Leko, Nikolina Pleić, Ivana Gunjača, Tatijana Zemunik
    International Journal of Molecular Sciences.2021; 23(1): 44.     CrossRef
Close layer
Clinical Study
Protocol for a Korean Multicenter Prospective Cohort Study of Active Surveillance or Surgery (KoMPASS) in Papillary Thyroid Microcarcinoma
Min Ji Jeon, Yea Eun Kang, Jae Hoon Moon, Dong Jun Lim, Chang Yoon Lee, Yong Sang Lee, Sun Wook Kim, Min-Hee Kim, Bo Hyun Kim, Ho-Cheol Kang, Minho Shong, Sun Wook Cho, Won Bae Kim
Endocrinol Metab. 2021;36(2):359-364.   Published online March 23, 2021
DOI: https://doi.org/10.3803/EnM.2020.890
Correction in: Endocrinol Metab 2022;37(1):181
  • 9,550 View
  • 241 Download
  • 22 Web of Science
  • 24 Crossref
AbstractAbstract PDFPubReader   ePub   
Background
A Korean Multicenter Prospective cohort study of Active Surveillance or Surgery (KoMPASS) for papillary thyroid microcarcinomas (PTMCs) has been initiated. The aim is to compare clinical outcomes between active surveillance (AS) and an immediate lobectomy for low-risk PTMCs. We here outline the detailed protocol for this study.
Methods
Adult patients with a cytopathologically confirmed PTMC sized 6.0 to 10.0 mm by ultrasound (US) will be included. Patients will be excluded if they have a suspicious extra-thyroidal extension or metastasis of a PTMC or multiple thyroid nodules or other thyroid diseases which require a total thyroidectomy. Printed material describing the prognosis of PTMCs, and the pros and cons of each management option, will be provided to eligible patients to select their preferred intervention. For the AS group, thyroid US, thyroid function, and quality of life (QoL) parameters will be monitored every 6 months during the first year, and then annually thereafter. Disease progression will be defined as a ≥3 mm increase in maximal diameter of a PTMC, or the development of new thyroid cancers or metastases. If progression is detected, patients should undergo appropriate surgery. For the lobectomy group, a lobectomy with prophylactic central neck dissection will be done within 6 months. After initial surgery, thyroid US, thyroid function, serum thyroglobulin (Tg), anti-Tg antibody, and QoL parameters will be monitored every 6 months during the first year and annually thereafter. Disease progression will be defined in these cases as the development of new thyroid cancers or metastases.
Conclusion
KoMPASS findings will help to confirm the role of AS, and develop individualized management strategies, for low-risk PTMCs.

Citations

Citations to this article as recorded by  
  • Shared Decision-Making for Determining Treatment Strategies in Low-Risk Thyroid Cancer: Protocol of a Multicenter Cluster-Randomized Trial (MAeSTro-SDM)
    Eun Kyung Lee, Min Joo Kim, Yul Hwangbo, Jae Hoon Moon, Sun Wook Cho, Young Jun Chai, June Young Choi, Yuh-Seog Jung, Kyu Eun Lee, Eun-Jae Chung, Kyungsik Kim, Su-jin Kim, Woochul Kim, Yoo Hyung Kim, Young Ki Lee, Jinsun Jang, Young Shin Song, Ka Hee Yi,
    Journal of Korean Medical Science.2026;[Epub]     CrossRef
  • 2025 Korean Thyroid Association Clinical Management Guideline on Active Surveillance for Low-Risk Papillary Thyroid Carcinoma
    Eun Kyung Lee, Min Joo Kim, Seung Heon Kang, Bon Seok Koo, Kyungsik Kim, Mijin Kim, Bo Hyun Kim, Ji-hoon Kim, Shin Je Moon, Kyorim Back, Young Shin Song, Jong-hyuk Ahn, Hwa Young Ahn, Ho-Ryun Won, Won Sang Yoo, Min Kyoung Lee, Jeongmin Lee, Ji Ye Lee, Kyo
    International Journal of Thyroidology.2025; 18(1): 30.     CrossRef
  • 2025 Korean Thyroid Association Clinical Management Guideline on Active Surveillance for Low-Risk Papillary Thyroid Carcinoma
    Eun Kyung Lee, Min Joo Kim, Seung Heon Kang, Bon Seok Koo, Kyungsik Kim, Mijin Kim, Bo Hyun Kim, Ji-hoon Kim, Shinje Moon, Kyorim Back, Young Shin Song, Jong-hyuk Ahn, Hwa Young Ahn, Ho-Ryun Won, Won Sang Yoo, Min Kyoung Lee, Jeongmin Lee, Ji Ye Lee, Kyon
    Endocrinology and Metabolism.2025; 40(3): 307.     CrossRef
  • Ultrasound for Active Surveillance of Low-Risk Thyroid Carcinoma
    Sang Yull Kang, Hyeong Eun Jeong, Ha Rim Ahn, Hyun Jo Youn
    Journal of Surgical Ultrasound.2025; 12(2): 23.     CrossRef
  • Active Surveillance for Low-Risk Thyroid Cancers: A Review of Current Practice Guidelines
    Min Joo Kim, Jae Hoon Moon, Eun Kyung Lee, Young Shin Song, Kyong Yeun Jung, Ji Ye Lee, Ji-hoon Kim, Kyungsik Kim, Sue K. Park, Young Joo Park
    Endocrinology and Metabolism.2024; 39(1): 47.     CrossRef
  • It Is Time to Understand the Additional Benefits of Active Surveillance for Low-Risk Papillary Thyroid Carcinoma
    Kyeong Jin Kim
    Endocrinology and Metabolism.2024; 39(1): 95.     CrossRef
  • Active Surveillance for Low-Risk Papillary Thyroid Carcinoma as an Acceptable Management Option with Additional Benefits: A Comprehensive Systematic Review
    Jee Hee Yoon, Wonsuk Choi, Ji Yong Park, A Ram Hong, Hee Kyung Kim, Ho-Cheol Kang
    Endocrinology and Metabolism.2024; 39(1): 152.     CrossRef
  • Active Surveillance for Low-Risk Papillary Thyroid Carcinoma as an Acceptable Management Option with Additional Benefits: A Comprehensive Systematic Review
    Jee Hee Yoon, Wonsuk Choi, Ji Yong Park, A Ram Hong, Hee Kyung Kim, Ho-Cheol Kang
    Endocrinology and Metabolism.2024; 39(1): 152.     CrossRef
  • Comparison of Patient-Reported Outcomes Between Active Surveillance and Immediate Lobectomy in Patients with Low-Risk Papillary Thyroid Microcarcinoma: Initial Findings from the KoMPASS Cohort
    Min Joo Kim, Hojeong Won, Won Bae Kim, Eun Kyung Lee, Chang Yoon Lee, Sun Wook Cho, Han-Sang Baek, Yong Sang Lee, Yea Eun Kang, Sun Wook Kim, Ho-Cheol Kang, Jeongmin Lee, Mijin Kim, Min Ji Jeon, Jae Hoon Moon
    Thyroid®.2024; 34(11): 1371.     CrossRef
  • Standardized Ultrasound Evaluation for Active Surveillance of Low-Risk Thyroid Microcarcinoma in Adults: 2024 Korean Society of Thyroid Radiology Consensus Statement
    Ji Ye Lee, Min Kyoung Lee, Hyun Kyung Lim, Chang Yoon Lee, Jin Yong Sung, Jung Hyun Yoon, Soo Yeon Han, Jung Hee Shin, Ji-hoon Kim, So Lyung Jung, Sae Rom Chung, Jung Hwan Baek, Dong Gyu Na
    Korean Journal of Radiology.2024; 25(11): 942.     CrossRef
  • Standardized Ultrasound Evaluation for Active Surveillance of Low-Risk Thyroid Microcarcinoma in Adults: 2024 Korean Society of Thyroid Radiology Consensus Statement
    Ji Ye Lee, Min Kyoung Lee, Hyun Kyung Lim, Chang Yoon Lee, Jin Yong Sung, Jung Hyun Yoon, Soo Yeon Hahn, Jung Hee Shin, Ji-hoon Kim, So Lyung Jung, Sae Rom Chung, Jung Hwan Baek, Dong Gyu Na
    Journal of the Korean Society of Radiology.2024; 85(6): 1060.     CrossRef
  • Thyroid‐Stimulating Hormone, Age, and Tumor Size are Risk Factors for Progression During Active Surveillance of Low‐Risk Papillary Thyroid Microcarcinoma in Adults
    Yasuhiro Ito, Akira Miyauchi, Makoto Fujishima, Takuya Noda, Tsutomu Sano, Takahiro Sasaki, Taketoshi Kishi, Tomohiko Nakamura
    World Journal of Surgery.2023; 47(2): 392.     CrossRef
  • Thyroid FNA cytology: The Eastern versus Western perspectives
    Mitsuyoshi Hirokawa, Manon Auger, Chan Kwon Jung, Fabiano Mesquita Callegari
    Cancer Cytopathology.2023; 131(7): 415.     CrossRef
  • To Screen or Not to Screen?
    Do Joon Park
    Endocrinology and Metabolism.2023; 38(1): 69.     CrossRef
  • Lower Thyroid Cancer Mortality in Patients Detected by Screening: A Meta-Analysis
    Shinje Moon, Young Shin Song, Kyong Yeun Jung, Eun Kyung Lee, Young Joo Park
    Endocrinology and Metabolism.2023; 38(1): 93.     CrossRef
  • Long-Term Outcomes of Active Surveillance and Immediate Surgery for Adult Patients with Low-Risk Papillary Thyroid Microcarcinoma: 30-Year Experience
    Akira Miyauchi, Yasuhiro Ito, Makoto Fujishima, Akihiro Miya, Naoyoshi Onoda, Minoru Kihara, Takuya Higashiyama, Hiroo Masuoka, Shiori Kawano, Takahiro Sasaki, Mitsushige Nishikawa, Shuji Fukata, Takashi Akamizu, Mitsuru Ito, Eijun Nishihara, Mako Hisakad
    Thyroid®.2023; 33(7): 817.     CrossRef
  • Active Surveillance Outcomes of Patients with Low-Risk Papillary Thyroid Microcarcinoma According to Levothyroxine Treatment Status
    Masashi Yamamoto, Akira Miyauchi, Yasuhiro Ito, Makoto Fujishima, Takahiro Sasaki, Takumi Kudo
    Thyroid®.2023; 33(10): 1182.     CrossRef
  • Cost-Effectiveness of Active Surveillance Compared to Early Surgery of Small Papillary Thyroid Cancer: A Retrospective Study on a Korean Population
    Han-Sang Baek, Jeonghoon Ha, Kwangsoon Kim, Jaseong Bae, Jeong Soo Kim, Sungju Kim, Dong-Jun Lim, Chulmin Kim
    Journal of Korean Medical Science.2023;[Epub]     CrossRef
  • Optimal Cutoff Values of the Contact Angle of Tumor on Sonography System for Predicting Extrathyroidal Extension of Papillary Thyroid Carcinoma by Tumor Location
    Ik Beom Shin, Do Hoon Koo, Dong Sik Bae
    Clinical Medicine Insights: Oncology.2023;[Epub]     CrossRef
  • Thermal Ablation for Papillary Thyroid Microcarcinoma Located in The Isthmus: a Study With 3 Years Of Follow-Up
    Lin Zheng, Fang-yi Liu, Jie Yu, Zhi-gang Cheng, Xiao-ling Yu, Xiao-cong Dong, Zhi-yu Han, Ping Liang
    Future Oncology.2022; 18(4): 471.     CrossRef
  • Trends in the Management of Localized Papillary Thyroid Carcinoma in the United States (2000–2018)
    Elisa Pasqual, Julie Ann Sosa, Yingxi Chen, Sara J. Schonfeld, Amy Berrington de González, Cari M. Kitahara
    Thyroid.2022; 32(4): 397.     CrossRef
  • Management of Low-Risk Thyroid Cancers: Is Active Surveillance a Valid Option? A Systematic Review of the Literature
    Renato Patrone, Nunzio Velotti, Stefania Masone, Alessandra Conzo, Luigi Flagiello, Chiara Cacciatore, Marco Filardo, Vincenza Granata, Francesco Izzo, Domenico Testa, Stefano Avenia, Alessandro Sanguinetti, Andrea Polistena, Giovanni Conzo
    Journal of Clinical Medicine.2021; 10(16): 3569.     CrossRef
  • Cost-Effectiveness Analysis of Active Surveillance Compared to Early Surgery in Small Papillary Thyroid Cancer: A Systemic Review
    Han-sang Baek, Chai-ho Jeong, Jeonghoon Ha, Ja-Seong Bae, Jeong-soo Kim, Dong-Jun Lim, Chul-Min Kim
    Cancer Management and Research.2021; Volume 13: 6721.     CrossRef
  • Active Surveillance as an Effective Management Option for Low-Risk Papillary Thyroid Microcarcinoma
    Min Ji Jeon, Won Gu Kim, Tae Yong Kim, Young Kee Shong, Won Bae Kim
    Endocrinology and Metabolism.2021; 36(4): 717.     CrossRef
Close layer
Clinical Study
Clinical Outcomes after Early and Delayed Radioiodine Remnant Ablation in Patients with Low-Risk Papillary Thyroid Carcinoma: Propensity Score Matching Analysis
Jonghwa Ahn, Meihua Jin, Eyun Song, Min Ji Jeon, Tae Yong Kim, Jin-Sook Ryu, Won Bae Kim, Young Kee Shong, Ji Min Han, Won Gu Kim
Endocrinol Metab. 2020;35(4):830-837.   Published online November 18, 2020
DOI: https://doi.org/10.3803/EnM.2020.747
  • 7,605 View
  • 149 Download
  • 8 Web of Science
  • 9 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
The clinical outcomes of delayed radioiodine remnant ablation (RRA) therapy in patients with low-risk papillary thyroid carcinoma (PTC) are unclear. We aimed to evaluate the clinical impact of the interval between total thyroidectomy (TT) and RRA therapy in patients with low-risk PTC.
Methods
We included 526 patients who underwent TT and RRA for low-risk PTC with a primary tumor size of >1 cm between 2000 and 2012. Patients were divided into the early (<90 days) and the delayed (≥90 days) RRA groups based on the interval between TT and RRA. The results of diagnostic whole-body scan (DxWBS), ongoing risk stratification (ORS; response to therapy), and disease-free survival (DFS) were evaluated before and after propensity score matching (PSM).
Results
Among the 526 patients, 75 (14.3%) patients underwent delayed RRA; they had more cervical lymph node metastasis and received a higher RRA dose than those who underwent early RRA. The median follow-up period was 9.1 years after initial therapy, and the structural recurrence rate was 1.9%. In DxWBS, 60 patients had focal iodine uptake limited in operative bed, with no significant difference between groups. According to ORS, 78%, 20%, 1%, and 1% patients were classified into excellent, indeterminate, biochemical incomplete, and structural incomplete response groups, respectively. There was no significant difference in ORS or DFS between groups before and after PSM.
Conclusion
The timing of the first RRA had no clinical impact in patients with low-risk PTC. Thus, the clinical decision for RRA can be determined >3 months after TT considering other prognostic factors.

Citations

Citations to this article as recorded by  
  • Dynamic risk assessment in patients with differentiated thyroid cancer
    Erika Abelleira, Fernando Jerkovich
    Reviews in Endocrine and Metabolic Disorders.2024; 25(1): 79.     CrossRef
  • Ablation Rates and Long-Term Outcome Following Low-Dose Radioiodine for Differentiated Thyroid Cancer in the West of Scotland: A Retrospective Analysis
    Kathryn Graham, Fay Tough, Helena Belikova, Irene Wotherspoon, David Colville, Nicholas Reed
    Endocrine Practice.2024; 30(4): 327.     CrossRef
  • Radioiodine ablation after thyroidectomy could be safely abandoned or postponed in selected stage I papillary thyroid carcinoma patients of low-risk group: an observational prospective study
    S.M. Cherenko, A.Yu. Glagolieva, D.E. Makhmudov
    INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine).2024; 20(1): 7.     CrossRef
  • Analysis of delayed initial radioactive iodine therapy and clinical outcomes in papillary thyroid cancer: a two-center retrospective study
    Tao He, Ming Li, Zheng-lian Gao, Xiang-yu Li, Hai-rong Zhong, Cui-shuang Ding, Hua-wei Cai
    Nuclear Medicine Communications.2024; 45(9): 779.     CrossRef
  • Advances in the selection and timing of postoperative radioiodine treatment in patients with differentiated thyroid carcinoma
    Xin Dai, Xinyi Ren, Jinyu Zhang, Yuxin Zheng, Zhengjie Wang, Gang Cheng
    Annals of Nuclear Medicine.2024; 38(9): 688.     CrossRef
  • Comparative evaluation of low and high radioiodine doses in differentiated thyroid carcinoma management: A multicenter study
    M.B. Al-Osaimi, E.M. Abdelrazek, Ehab M. Attalla, Hosam Salaheldin
    Journal of Radiation Research and Applied Sciences.2024; 17(4): 101206.     CrossRef
  • Patient Preparation and Radiation Protection Guidance for Adult Patients Undergoing Radioiodine Treatment for Thyroid Cancer in the UK
    J. Wadsley, N. Armstrong, V. Bassett-Smith, M. Beasley, R. Chandler, L. Cluny, A.J. Craig, K. Farnell, K. Garcez, N. Garnham, K. Graham, A. Hallam, S. Hill, H. Hobrough, F. McKiddie, M.W.J. Strachan
    Clinical Oncology.2023; 35(1): 42.     CrossRef
  • Delay of initial radioactive iodine therapy beyond 3 months has no effect on clinical responses and overall survival in patients with thyroid carcinoma: A cohort study and a meta‐analysis
    Fang Cheng, Juan Xiao, Fengyan Huang, Chunchun Shao, Shouluan Ding, Canhua Yun, Hongying Jia
    Cancer Medicine.2022; 11(12): 2386.     CrossRef
  • Delayed (>3 Months) Postoperative Radioactive Iodine Ablation Does Not Impact Clinical Response or Survival in Differentiated Thyroid Cancers
    Tatiana Fedorova, Lilah F. Morris-Wiseman
    Clinical Thyroidology.2022; 34(10): 456.     CrossRef
Close layer
Clinical Study
Clinical Implication of World Health Organization Classification in Patients with Follicular Thyroid Carcinoma in South Korea: A Multicenter Cohort Study
Meihua Jin, Eun Sook Kim, Bo Hyun Kim, Hee Kyung Kim, Hyon-Seung Yi, Min Ji Jeon, Tae Yong Kim, Ho-Cheol Kang, Won Bae Kim, Young Kee Shong, Mijin Kim, Won Gu Kim
Endocrinol Metab. 2020;35(3):618-627.   Published online September 22, 2020
DOI: https://doi.org/10.3803/EnM.2020.742
  • 8,958 View
  • 134 Download
  • 10 Web of Science
  • 11 Crossref
AbstractAbstract PDFPubReader   ePub   
Background
The study aimed to compare the prognostic value of the 4th edition of World Health Organization classification (WHO-2017) with the previous WHO classification (WHO-2004) for follicular thyroid carcinoma (FTC).
Methods
This multicenter retrospective cohort study included 318 patients with FTC from five tertiary centers who underwent thyroid surgery between 1996 and 2009. We evaluated the prognosis of patients with minimally invasive (MI), encapsulated angioinvasive (EA), and widely invasive (WI) FTC according to WHO-2017. Further, we evaluated the proportion of variation explained (PVE) and Harrell’s C-index to compare the predictability of disease-free survival (DFS) and disease-specific survival (DSS).
Results
In total, 227, 58, and 33 patients had MI-, EA-, and WI-FTC, respectively. During a median follow-up of 10.6 years, 46 (14.5%) patients had disease recurrence and 20 (6.3%) patients died from FTC. The 10-year DFS rates of patients with MI-, EA-, and WI-FTC were 91.1%, 78.2%, and 54.9%, respectively (P<0.001, PVE=7.1%, C-index=0.649). The corresponding 10-year DSS rates were 95.9%, 93.5%, and 73.5%, respectively (P<0.001, PVE=2.6%, C-index=0.624). The PVE and C-index values were higher using WHO-2017 than using WHO-2004 for the prediction of DFS, but not for DSS. In multivariate analysis, older age (P=0.02), gross extrathyroidal extension (ETE) (P=0.003), and distant metastasis (P<0.001) were independent risk factors for DSS.
Conclusion
WHO-2017 improves the predictability of DFS, but not DSS, in patients with FTC. Distant metastasis, gross ETE and older age (≥55 years) were independent risk factors for DSS.

Citations

Citations to this article as recorded by  
  • The Initial Risk Stratification System for Differentiated Thyroid Cancer: Key Updates in the 2024 Korean Thyroid Association Guideline
    Shinje Moon, Young Shin Song, Kyong Yeun Jung, Eun Kyung Lee, Jeongmin Lee, Dong-Jun Lim, Chan Kwon Jung, Young Joo Park
    Endocrinology and Metabolism.2025; 40(3): 357.     CrossRef
  • Association of Ultrasonography Features of Follicular Thyroid Carcinoma With Tumor Invasiveness and Prognosis Based on WHO Classification and TERT Promoter Mutation
    Myoung Kyoung Kim, Hyunju Park, Young Lyun Oh, Jung Hee Shin, Tae Hyuk Kim, Soo Yeon Hahn
    Korean Journal of Radiology.2024; 25(1): 103.     CrossRef
  • Clinical Outcomes and Implications of Radioactive Iodine Therapy on Cancer-specific Survival in WHO Classification of FTC
    Genpeng Li, Ziyang Ye, Tao Wei, Jingqiang Zhu, Zhihui Li, Jianyong Lei
    The Journal of Clinical Endocrinology & Metabolism.2024; 109(9): 2294.     CrossRef
  • Radioiodine whole body scan pitfalls in differentiated thyroid cancer
    Cristina Basso, Alessandra Colapinto, Valentina Vicennati, Alessandra Gambineri, Carla Pelusi, Guido Di Dalmazi, Elisa Lodi Rizzini, Elena Tabacchi, Arber Golemi, Letizia Calderoni, Stefano Fanti, Uberto Pagotto, Andrea Repaci
    Endocrine.2024; 85(2): 493.     CrossRef
  • Korean Thyroid Association Guidelines on the Management of Differentiated Thyroid Cancers; Part I. Initial Management of Differentiated Thyroid Cancers - Chapter 5. Evaluation of Recurrence Risk Postoperatively and Initial Risk Stratification in Different
    Eun Kyung Lee, Young Shin Song, Ho-Cheol Kang, Sun Wook Kim, Dong Gyu Na, Shin Je Moon, Dong-Jun Lim, Kyong Yeun Jung, Yun Jae Chung, Chan Kwon Jung, Young Joo Park
    International Journal of Thyroidology.2024; 17(1): 68.     CrossRef
  • The Prognostic Impact of Extent of Vascular Invasion in Follicular Thyroid Carcinoma
    David Leong, Anthony J. Gill, John Turchini, Michael Waller, Roderick Clifton‐Bligh, Anthony Glover, Mark Sywak, Stan Sidhu
    World Journal of Surgery.2023; 47(2): 412.     CrossRef
  • TERT Promoter Mutation as a Prognostic Marker in Encapsulated Angioinvasive and Widely Invasive Follicular Thyroid Carcinomas
    Yasuhiro Ito, Takashi Akamizu
    Clinical Thyroidology.2023; 35(5): 202.     CrossRef
  • Risk factors for death of follicular thyroid carcinoma: a systematic review and meta-analysis
    Ting Zhang, Liang He, Zhihong Wang, Wenwu Dong, Wei Sun, Ping Zhang, Hao Zhang
    Endocrine.2023; 82(3): 457.     CrossRef
  • Molecular classification of follicular thyroid carcinoma based on TERT promoter mutations
    Hyunju Park, Hyeong Chan Shin, Heera Yang, Jung Heo, Chang-Seok Ki, Hye Seung Kim, Jung-Han Kim, Soo Yeon Hahn, Yun Jae Chung, Sun Wook Kim, Jae Hoon Chung, Young Lyun Oh, Tae Hyuk Kim
    Modern Pathology.2022; 35(2): 186.     CrossRef
  • Whole-genome Sequencing of Follicular Thyroid Carcinomas Reveal Recurrent Mutations in MicroRNA Processing Subunit DGCR8
    Johan O Paulsson, Nima Rafati, Sebastian DiLorenzo, Yi Chen, Felix Haglund, Jan Zedenius, C Christofer Juhlin
    The Journal of Clinical Endocrinology & Metabolism.2021; 106(11): 3265.     CrossRef
  • Clinicopathological Characteristics and Disease-Free Survival in Patients with Hürthle Cell Carcinoma: A Multicenter Cohort Study in South Korea
    Meihua Jin, Eun Sook Kim, Bo Hyun Kim, Hee Kyung Kim, Yea Eun Kang, Min Ji Jeon, Tae Yong Kim, Ho-Cheol Kang, Won Bae Kim, Young Kee Shong, Mijin Kim, Won Gu Kim
    Endocrinology and Metabolism.2021; 36(5): 1078.     CrossRef
Close layer
Clinical Study
Clinical Outcomes of N1b Papillary Thyroid Cancer Patients Treated with Two Different Doses of Radioiodine Ablation Therapy
Meihua Jin, Jonghwa Ahn, Yu-Mi Lee, Tae-Yon Sung, Won Gu Kim, Tae Yong Kim, Jin-Sook Ryu, Won Bae Kim, Young Kee Shong, Min Ji Jeon
Endocrinol Metab. 2020;35(3):602-609.   Published online September 22, 2020
DOI: https://doi.org/10.3803/EnM.2020.741
  • 9,000 View
  • 136 Download
  • 7 Web of Science
  • 6 Crossref
AbstractAbstract PDFPubReader   ePub   
Background
The optimal dose of radioactive iodine (RAI) therapy for N1b papillary thyroid carcinoma (PTC) is controversial. We evaluated the clinical outcome of N1b PTC patients treated with either 100 or 150 mCi of RAI.
Methods
We retrospectively analyzed N1b PTC patients who underwent total thyroidectomy and postoperative RAI therapy at a tertiary referral center between 2012 and 2017. As the baseline characteristics differed between treatment groups, we performed exact matching for various pathological factors according to RAI dose. We evaluated the response to therapy and recurrence-free survival (RFS) in the matched patients. Structural recurrent/persistent disease was defined as new structural disease detected after initial therapy, which was confirmed by cytology or pathology.
Results
Of the total 436 patients, 37 (8.5%) received 100 mCi of RAI and 399 (91.5%) received 150 mCi of RAI. After an exact 1:3 matching, 34 patients in the 100 mCi group and 100 patients in the 150 mCi group remained. There was no significant difference in response to therapy between the groups in the matched population (P=0.63). An excellent response was achieved in 70.6% (n=24) of patients in the 100 mCi group and 76.0% (n=76) in the 150 mCi group. Two (5.9%) patients in the 100 mCi group and four (4.0%) in the 150 mCi group had recurrence and there was no significant difference in RFS between the groups in the matched population (P=0.351).
Conclusion
There were no differences in response to therapy and RFS in N1b PTC patients according to RAI dose.

Citations

Citations to this article as recorded by  
  • Radioactive iodine therapy dose impact on recurrence and survival in N1 papillary thyroid cancer
    Elizabeth E. Odil, Katelyn R. Ward, Ryan T. Davis, Jordan M. Reilly, Fionna Sun, Heba Elassar, Morta Lapkus, Jacquelyn Pastewski, Diane M. Studzinski, Rose E. Callahan, Peter F. Czako, Sapna Nagar
    Nuclear Medicine Communications.2025; 46(2): 113.     CrossRef
  • Efficacy of Adjuvant Radioactive Iodine Therapy in Histological Variants of DTC: A Scoping Review
    Brian A. Keith, Evan S. Chernov, Shaun A. Nguyen, Jyotika K. Fernandes, William G. Albergotti
    Head & Neck.2025; 47(8): 2324.     CrossRef
  • Comparison of total thyroidectomy and lobectomy for intermediate-risk papillary thyroid carcinoma with lateral lymph node metastasis: a systematic review and meta-analysis
    Xinhua Li, Zhiqiang Gui, Chun Xu, Jingzhe Xiang, Jie Ming, Tao Huang, Mingming Jiang, Hao Zhang, Zhihong Wang
    International Journal of Surgery.2025; 111(9): 6343.     CrossRef
  • Multicenter analysis of radioactive iodine therapy outcomes after total thyroidectomy for T1-T2 stage papillary thyroid carcinoma with cervical lymph node metastasis in China
    Xinhua Li, Qingshu Wu, Jie Zhao, Zhiqiang Gui, Jingzhe Xiang, Jie Ming, Tao Huang, Mingming Jiang, Hao Zhang, Zhihong Wang
    International Journal of Surgery.2025; 111(10): 6931.     CrossRef
  • Controversies in the Management of Intermediate-Risk Differentiated Thyroid Cancer
    David Toro-Tobon, Juan P. Brito
    Endocrine Practice.2024; 30(9): 879.     CrossRef
  • The Definition of Recurrence of Differentiated Thyroid Cancer: A Systematic Review of the Literature
    Daniël J. van de Berg, Pedro M. Rodriguez Schaap, Faridi S. Jamaludin, Hanneke M. van Santen, Sarah C. Clement, Menno R. Vriens, A. S Paul van Trotsenburg, Christiaan F. Mooij, Eveline Bruinstroop, Schelto Kruijff, Robin P. Peeters, Frederik A. Verburg, R
    Thyroid®.2024; 34(11): 1324.     CrossRef
Close layer
Clinical Study
Modification of the Tumor-Node-Metastasis Staging System for Differentiated Thyroid Carcinoma by Considering Extra-Thyroidal Extension and Lateral Cervical Lymph Node Metastasis
Mijin Kim, Won Gu Kim, Min Ji Jeon, Hee Kyung Kim, Hyon-Seung Yi, Eun Sook Kim, Bo Hyun Kim, Won Bae Kim, Young Kee Shong, Ho-Cheol Kang, Tae Yong Kim
Endocrinol Metab. 2020;35(1):149-156.   Published online March 19, 2020
DOI: https://doi.org/10.3803/EnM.2020.35.1.149
  • 9,359 View
  • 96 Download
  • 8 Web of Science
  • 6 Crossref
AbstractAbstract PDFPubReader   ePub   
Background

Concerns have arisen about the classification of extra-thyroidal extension (ETE) and lateral cervical lymph node metastasis (N1b) in the 8th edition of the tumor-node-metastasis staging system (TNM-8). This study evaluated the prognostic validity of a modified-TNM staging system, focusing on ETE and N1b, in differentiated thyroid carcinoma (DTC) patients.

Methods

This multicenter retrospective cohort study included 4,878 DTC patients from five tertiary hospitals. In the modified-TNM, T3b in TNM-8 was down-staged to T2, and stage II was subdivided into stages IIA and IIB. Older patients with N1b were reclassified as stage IIB.

Results

The modified-TNM resulted in staging migration in 540 patients (11%) classified as stage II according to the TNM-8, with 75 (14%), 381 (71%), and 84 patients (16%) classified as stages I, IIA, and IIB, respectively. The 10-year disease-specific survival (DSS) rates in patients classified as stages I, II, III, and IV by TNM-8 were 99.8%, 95.9%, 81.0%, and 41.6%, respectively. The DSS rates of patients classified as stages I, IIA, IIB, III, and IV according to the modified-TNM were 99.8%, 96.4%, 93.3%, 81.0%, and 41.6%, respectively. DSS curves between stages on TNM-8 (P<0.001) and modified-TNM (P<0.001) differed significantly, but the modified-TNM discriminated better than TNM-8. The proportions of variation explained values of TNM-8 and modified-TNM were 6.3% and 6.5%, respectively.

Conclusion

Modification of the TNM staging system focusing on ETE and N1b could improve the prediction of DSS in patients with DTC. Further researches are needed to validate the prognostic accuracy of this modified-TNM staging system.

Citations

Citations to this article as recorded by  
  • Clinicopathological features of differentiated thyroid carcinoma as predictors of the effects of radioactive iodine therapy
    Wen Liu, Beibei Jiang, Jingli Xue, Ruijing Liu, Yuqing Wei, Peifeng Li
    Annals of Diagnostic Pathology.2024; 69: 152243.     CrossRef
  • Prognostic significance of T3b in papillary thyroid carcinoma: Appropriateness of classifying T3bN0M0 in patients aged 55 years or older into stage II
    Yasuhiro Ito, Akira Miyauchi, Makoto Kawakami, Minoru Kihara, Akihiro Miya
    World Journal of Surgery.2024; 48(9): 2132.     CrossRef
  • Thyroid Collision Tumors: The Presence of the Medullary Thyroid Carcinoma Component Negatively Influences the Prognosis
    Ion Negura, Victor Ianole, Mihai Danciu, Cristina Preda, Diana Gabriela Iosep, Radu Dănilă, Alexandru Grigorovici, Delia Gabriela Ciobanu Apostol
    Diagnostics.2023; 13(2): 285.     CrossRef
  • Serum thyroglobulin testing after thyroid lobectomy in patients with 1–4 cm papillary thyroid carcinoma
    Ahreum Jang, Meihua Jin, Chae A Kim, Min Ji Jeon, Yu-Mi Lee, Tae-Yon Sung, Tae Yong Kim, Won Bae Kim, Young Kee Shong, Won Gu Kim
    Endocrine.2023; 81(2): 290.     CrossRef
  • Prognostic Impact of Microscopic Extra-Thyroidal Extension (mETE) on Disease Free Survival in Patients with Papillary Thyroid Carcinoma (PTC)
    Nadia Bouzehouane, Pascal Roy, Myriam Decaussin-Petrucci, Mireille Bertholon-Grégoire, Chantal Bully, Agnès Perrin, Helene Lasolle, Jean-Christophe Lifante, Françoise Borson-Chazot, Claire Bournaud
    Cancers.2022; 14(11): 2591.     CrossRef
  • Impacts of the American Joint Committee on Cancer (AJCC) 8th edition tumor, node, metastasis (TNM) staging system on outcomes of differentiated thyroid cancer in Thai patients
    Yotsapon Thewjitcharoen, Waralee Chatchomchuan, Krittadhee Karndumri, Sriurai Porramatikul, Sirinate Krittiyawong, Ekgaluck Wanothayaroj, Siriwan Butadej, Soontaree Nakasatien, Veekij Veerasomboonsin, Auchai Kanchanapituk, Rajata Rajatanavin, Thep Himatho
    Heliyon.2021; 7(3): e06624.     CrossRef
Close layer
Review Article
Thyroid
Unmet Clinical Needs in the Treatment of Patients with Thyroid Cancer
Won Bae Kim, Min Ji Jeon, Won Gu Kim, Tae Yong Kim, Young Kee Shong
Endocrinol Metab. 2020;35(1):14-25.   Published online March 19, 2020
DOI: https://doi.org/10.3803/EnM.2020.35.1.14
  • 10,984 View
  • 163 Download
  • 16 Web of Science
  • 13 Crossref
AbstractAbstract PDFPubReader   ePub   

The increased incidence of thyroid cancer is a worldwide phenomenon; however, the issue of overdiagnosis has been most prominent in South Korea. The age-standardized mortality rate of thyroid cancer in Korea steeply increased from 1985 to 2004 (from 0.17 per 100,000 to 0.85 per 100,000), and then decreased until 2015 to 0.42 per 100,000, suggesting that early detection reduced mortality. However, early detection of thyroid cancer may be cost-ineffective, considering its very high prevalence and indolent course. Therefore, risk stratification and tailored management are vitally important, but many prognostic markers can only be evaluated postoperatively. Discovery of preoperative marker(s), especially for small cancers, is the most important unmet clinical need for thyroid cancer. Herein, we discuss some such factors that we recently discovered. Another unmet clinical need is better treatment of radioiodine-refractory (RAIR) differentiated thyroid cancer (DTC) and undifferentiated cancers. Although sorafenib and lenvatinib are available, better drugs are needed. We found that phosphoglycerate dehydrogenase, a critical enzyme for serine biosynthesis, could be a novel therapeutic target, and that the lymphocyte-to-monocyte ratio is a prognostic marker of survival in patients with anaplastic thyroid carcinoma or RAIR DTC. Deeper insights are needed into tumor-host interactions in thyroid cancer to improve treatment.

Citations

Citations to this article as recorded by  
  • EpCAM activates the ERK-EGR1 signaling axis and promotes TNF-α-induced the progression of anaplastic thyroid cancer
    Chi-Chiu Lee, Yi-Jen Su, Sushree Shankar Panda, Chiung-Yi Chiu, Chung-Hsuan Wu, Tsai-Ming Lu, Pi-Chun Li, Yen-Lin Huang, Ruey-Long Hong, Shao-Hsi Hung, Cassian Yee, Stephen Y. Lai, Han-Chung Wu
    Journal of Translational Medicine.2025;[Epub]     CrossRef
  • Macrophage-Induced Carboxypeptidase A4 Promotes the Progression of Anaplastic Thyroid Cancer
    Yeon-Sook Choi, Min Ji Jeon, Woo Kyung Lee Doolittle, Dong Eun Song, Kyunggon Kim, Won Bae Kim, Won Gu Kim
    Thyroid®.2024; 34(9): 1150.     CrossRef
  • Lenvatinib Compared with Sorafenib as a First-Line Treatment for Radioactive Iodine-Refractory, Progressive, Differentiated Thyroid Carcinoma: Real-World Outcomes in a Multicenter Retrospective Cohort Study
    Mijin Kim, Meihua Jin, Min Ji Jeon, Eui Young Kim, Dong Yeob Shin, Dong Jun Lim, Bo Hyun Kim, Ho-Cheol Kang, Won Bae Kim, Young Kee Shong, Hee Kyung Kim, Won Gu Kim
    Thyroid.2023; 33(1): 91.     CrossRef
  • Serum thyroglobulin testing after thyroid lobectomy in patients with 1–4 cm papillary thyroid carcinoma
    Ahreum Jang, Meihua Jin, Chae A Kim, Min Ji Jeon, Yu-Mi Lee, Tae-Yon Sung, Tae Yong Kim, Won Bae Kim, Young Kee Shong, Won Gu Kim
    Endocrine.2023; 81(2): 290.     CrossRef
  • Integration of ultrasound-based radiomics with clinical features for predicting cervical lymph node metastasis in postoperative patients with differentiated thyroid carcinoma
    Fengjing Fan, Fei Li, Yixuan Wang, Zhengjun Dai, Yuyang Lin, Lin Liao, Bei Wang, Hongjun Sun
    Endocrine.2023; 84(3): 999.     CrossRef
  • Transcriptomic Analysis of Papillary Thyroid Cancer: A Focus on Immune-Subtyping, Oncogenic Fusion, and Recurrence
    Seung-Jin Park, Yea Eun Kang, Jeong-Hwan Kim, Jong-Lyul Park, Seon-Kyu Kim, Seung-Woo Baek, In Sun Chu, Shinae Yi, Seong Eun Lee, Young Joo Park, Eun-Jae Chung, Jin Man Kim, Hye Mi Ko, Je-Ryong Kim, Seung-Nam Jung, Ho-Ryun Won, Jae Won Chang, Bon Seok Koo
    Clinical and Experimental Otorhinolaryngology.2022; 15(2): 183.     CrossRef
  • Prognosis of Patients with 1–4 cm Papillary Thyroid Cancer Who Underwent Lobectomy: Focus on Gross Extrathyroidal Extension Invading Only the Strap Muscles
    Ahreum Jang, Meihua Jin, Won Woong Kim, Min Ji Jeon, Tae-Yon Sung, Dong Eun Song, Tae Yong Kim, Ki-Wook Chung, Won Bae Kim, Young Kee Shong, Yu-Mi Lee, Won Gu Kim
    Annals of Surgical Oncology.2022; 29(12): 7835.     CrossRef
  • Carboxy terminus of HSP70‐interacting protein (CHIP) attenuates the stemness of thyroid cancer cells through decreasing OCT4 protein stability
    Ying Xu, Gang Xu, Huimin Dang, Wei Qu, Dan Chang, Xin He, Minmin Li, Qian Wang
    Environmental Toxicology.2021; 36(4): 686.     CrossRef
  • Lactate Dehydrogenase A as a Potential New Biomarker for Thyroid Cancer
    Eun Jeong Ban, Daham Kim, Jin Kyong Kim, Sang-Wook Kang, Jandee Lee, Jong Ju Jeong, Kee-Hyun Nam, Woong Youn Chung, Kunhong Kim
    Endocrinology and Metabolism.2021; 36(1): 96.     CrossRef
  • Clinical implications of age and excellent response to therapy in patients with high‐risk differentiated thyroid carcinoma
    Meihua Jin, Jonghwa Ahn, Yu‐Mi Lee, Tae‐Yon Sung, Dong Eun Song, Tae Yong Kim, Ki‐Wook Chung, Jin‐Sook Ryu, Won Bae Kim, Young Kee Shong, Min Ji Jeon, Won Gu Kim
    Clinical Endocrinology.2021; 95(6): 882.     CrossRef
  • 80MAP17 promotes the tumorigenesis of papillary thyroid carcinoma by reducing the stability of p53
    Kun Yu, Hongjiang Lu, Yanhong Chen, Ying Xin, Zhuo Tan, Qiong Yang
    Frontiers in Bioscience-Landmark.2021;[Epub]     CrossRef
  • CD73 Overexpression Promotes Progression and Recurrence of Papillary Thyroid Carcinoma
    Young Mun Jeong, Haejin Cho, Tae-Min Kim, Yourha Kim, Sora Jeon, Andrey Bychkov, Chan Kwon Jung
    Cancers.2020; 12(10): 3042.     CrossRef
  • The Role of Exosomes in Thyroid Cancer and Their Potential Clinical Application
    Kaixiang Feng, Runsheng Ma, Lele Zhang, Hongqiang Li, Yifeng Tang, Gongbo Du, Dongpeng Niu, Detao Yin
    Frontiers in Oncology.2020;[Epub]     CrossRef
Close layer
Original Articles
Clinical Study
Quality of Life in Patients with Papillary Thyroid Microcarcinoma According to Treatment: Total Thyroidectomy with or without Radioactive Iodine Ablation
Jonghwa Ahn, Min Ji Jeon, Eyun Song, Tae Yong Kim, Won Bae Kim, Young Kee Shong, Won Gu Kim
Endocrinol Metab. 2020;35(1):115-121.   Published online March 19, 2020
DOI: https://doi.org/10.3803/EnM.2020.35.1.115
  • 8,765 View
  • 128 Download
  • 17 Web of Science
  • 19 Crossref
AbstractAbstract PDFPubReader   ePub   
Background

Recently, there has been some controversy regarding the role of radioactive iodine (RAI) ablation in the treatment of low-risk differentiated thyroid carcinoma (DTC), especially papillary thyroid microcarcinoma (PTMC). This study aimed to compare quality of life (QoL) parameters between patients with PTMC who underwent total thyroidectomy (TT) alone and those who underwent TT with RAI ablation.

Methods

In this cross-sectional study, patients with PTMC who underwent TT with/without RAI remnant ablation were prospectively enrolled between June 2016 and October 2017. All patients completed three questionnaires: the 12-item short-form health survey (SF-12), thyroid cancer-specific quality of life (THYCA-QoL) questionnaire, and fear of progression (FoP) questionnaire.

Results

The TT and TT with RAI groups comprised 107 and 182 patients, respectively. The TT with RAI group had significantly lower serum thyrotropin (TSH) levels than the TT group. However, after matching for TSH levels between the groups (n=100 in both groups), there were no significant differences in baseline characteristics. According to the SF-12, the score for general health was significantly lower in the TT with RAI group than in the TT group (P=0.047). The THYCA-QoL also showed a significant difference in the “felt chilly” score between groups (P=0.023). No significant differences in FoP scores were observed between the groups.

Conclusion

Patients with PTMC who underwent TT with RAI ablation experienced more health-related problems than those managed with TT alone. These findings support the idea that RAI ablation should be carefully considered in patients with low-risk DTCs.

Citations

Citations to this article as recorded by  
  • Patient‑reported outcome measures for assessing health‑related quality of life in patients with differentiated thyroid cancer: a systematic review
    Lujing Xiong, Lei Liu, Yuqing Xiang, Chao Li, Wei Dai, Jinchuan Hu, Chunyan Shui, Yuqiu Zhou, Xu Wang, Yongcong Cai
    International Journal of Surgery.2025; 111(1): 1311.     CrossRef
  • A comprehensive analysis of health-related quality of life in thyroid cancer patients using the THYCA-24 questionnaire
    Thi Huyen Dinh, Hoang-Bac Nguyen, Thi Bang-Suong Nguyen, Hong Tuan-Nam Pham, Lam Doan-Van, Trung-Thong Luu-Nguyen, Thi Hoe Nguyen, Hoang-Quan Pham, Thi Xuan-Thao Le, Kim-Hai Nguyen
    Scientific Reports.2025;[Epub]     CrossRef
  • Impact of Scar on Quality of Life in Well‐Differentiated Thyroid Carcinoma: A Systematic Review
    Aníbal Ariza, Alvaro Sanabria
    OTO Open.2025;[Epub]     CrossRef
  • From screening to follow-up: a review of quality of life and psychological status across the clinical care continuum in patients with differentiated thyroid cancer
    Zifeng Kuang, Hao Zhao, Chenjia Zhang, Xiaoyi Li
    Frontiers in Psychology.2025;[Epub]     CrossRef
  • Thyroid Lobectomy and Neck Dissection for N1b Papillary Thyroid Carcinoma
    Daniel W. Scholfield, Lillian A. Boe, Alana Eagan, Helena Levyn, Fergal Kavanagh, R. Michael Tuttle, Ashok R. Shaha, Jennifer R. Cracchiolo, Jatin P. Shah, Richard J. Wong, Snehal G. Patel, Ian Ganly
    JAMA Otolaryngology–Head & Neck Surgery.2025;[Epub]     CrossRef
  • Quality of life of patients with thyroid cancer in Colombia
    Oscar Gómez, Alvaro Sanabria
    Endocrinología, Diabetes y Nutrición.2024; 71(2): 61.     CrossRef
  • Quality of life of patients with thyroid cancer in Colombia
    Oscar Gómez, Alvaro Sanabria
    Endocrinología, Diabetes y Nutrición (English ed.).2024; 71(2): 61.     CrossRef
  • Fear of Cancer Recurrence in Differentiated Thyroid Cancer Survivors: A Systematic Review
    Jacob Hampton, Ahmad Alam, Nicholas Zdenkowski, Christopher Rowe, Elizabeth Fradgley, Christine J. O'Neill
    Thyroid®.2024; 34(5): 541.     CrossRef
  • Short‐Term Postoperative Depression and Anxiety in Patients with Differentiated Thyroid Carcinoma: Assessment of Potential Oncologic‐Psycho Relevance
    Lin Chen, Ningning Ren, Qing Yang, Xingsong Tian, Henrik Falhammar
    International Journal of Endocrinology.2024;[Epub]     CrossRef
  • Perception of health and illness and quality of life after total thyroidectomy for differentiated thyroid carcinoma: the PERSAM study
    Elena Groff, Beatrice Soccal, Fabiola Carrossa, Federica Vianello, Sara Talomo, Alessandra Feltrin, Giovanni Scarzello, Honoria Ocagli, Dario Gregori, Matteo Martinato
    Frontiers in Endocrinology.2024;[Epub]     CrossRef
  • Review: Improving quality of life in patients with differentiated thyroid cancer
    Pia Pace-Asciak, Jonathon O. Russell, Ralph P. Tufano
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Health-Related Quality of Life and Thyroid Cancer-Specific Symptoms in Patients Treated for Differentiated Thyroid Cancer: A Single-Center Cross-Sectional Survey from Mainland China
    Changlian Chen, Jiayan Cao, Yueyang Wang, Xuya Han, Yaju Zhang, Shumei Zhuang
    Thyroid.2023; 33(4): 474.     CrossRef
  • The "not so good" thyroid cancer: a scoping review on risk factors associated with anxiety, depression and quality of life
    Kyle Alexander, Sum-Yu Christina Lee, Stelios Georgiades, Constantina Constantinou
    Journal of Medicine and Life.2023; 16(3): 348.     CrossRef
  • Comparison of health‐related quality of life and cosmetic outcome between traditional gasless trans‐axillary endoscopic thyroidectomy and modified gasless trans‐axillary endoscopic thyroidectomy for patients with papillary thyroid microcarcinoma
    Deenraj Kush Dhoomun, HuiLan Cai, Ning Li, YanHuan Qiu, XingRui Li, XiaoPeng Hu, WenZhuang Shen
    Cancer Medicine.2023; 12(15): 16604.     CrossRef
  • Risk of Adverse Pregnancy Outcomes in Young Women with Thyroid Cancer: A Systematic Review and Meta-Analysis
    Shinje Moon, Ka Hee Yi, Young Joo Park
    Cancers.2022; 14(10): 2382.     CrossRef
  • Health-related quality of life following FDG-PET/CT for cytological indeterminate thyroid nodules
    Elizabeth J de Koster, Olga Husson, Eveline W C M van Dam, G Sophie Mijnhout, Romana T Netea-Maier, Wim J G Oyen, Marieke Snel, Lioe-Fee de Geus-Oei, Dennis Vriens, _ _
    Endocrine Connections.2022;[Epub]     CrossRef
  • Is a four-week hormone suspension necessary for thyroid remnant ablation in low and intermediate risk patients? A pilot study with quality-of-life assessment
    Poliane A.L. Santos, Maria E.D.M. Flamini, Felipe A. Mourato, Fernando R.A. Lima, Joelan A.L. Santos, Fabiana F. Lima, Estelita T.B. Albuquerque, Alexandra C. De Freitas, Simone C.S. Brandão
    Brazilian Journal of Radiation Sciences.2022; 10(4): 1.     CrossRef
  • Health-related quality of life after transoral robotic thyroidectomy in papillary thyroid carcinoma
    Chang Myeon Song, Hyang Sook Bang, Hyung Gu Kim, Hae Jin Park, Kyung Tae
    Surgery.2021; 170(1): 99.     CrossRef
  • Protocol for a Korean Multicenter Prospective Cohort Study of Active Surveillance or Surgery (KoMPASS) in Papillary Thyroid Microcarcinoma
    Min Ji Jeon, Yea Eun Kang, Jae Hoon Moon, Dong Jun Lim, Chang Yoon Lee, Yong Sang Lee, Sun Wook Kim, Min-Hee Kim, Bo Hyun Kim, Ho-Cheol Kang, Minho Shong, Sun Wook Cho, Won Bae Kim
    Endocrinology and Metabolism.2021; 36(2): 359.     CrossRef
Close layer
The Incidence of Thyroid Autoantibody in Subacute Thyroiditis and the Clinical Characteristics of Greeping Thyroiditis.
Jae Seok Jeon, Won Bae Kim, Hae Young Park, Young Joo Park, Hyun Kyung Chung, Sang Jeon Choi, Chan Soo Shin, Kyoung Soo Park, Seong Yeon Kim, Bo Youn Cho, Hong Kyu Lee, Chang Soon Koh
J Korean Endocr Soc. 1996;11(4):438-446.   Published online November 7, 2019
  • 1,853 View
  • 32 Download
AbstractAbstract PDF
Background
Subacute thyroiditis is a spontaneously resolving inflammatory disorder of thyroid gland, usually associated with painful goiter and short-lived thyrotoxicosis. Although its etiology is yet to be established, much evidence suggests viral infections and genetic factors play important roles. Usually, both lobes of thyroid gland are involved simultaneously, but in some patients one lobe is involved first and the other later(creeping thyroiditis), Thyroid autoantibodies which might appear probably due to inflammatory release of thyroid antigens, are found in a variable number of patients with subacute thyroiditis. However there have been few detailed reports on their incidence in Korean patients with subacute thyroiditis. So, we were to see the elinical characteristics of patients with subacute thyroiditis with special regards to the incidence of thyroid autoantibodies and to the incidence and characteristics of creeping thyroiditis, Methods: We reviewed the clinical records of 85 patients with subacute thyroiditis(7 men and 78 wornen, meam age of 43+9 years) who had visited the thyroid clinic in Seoul National University Hospital between 1986 and 1994. Results: At initial visit, the incidenees of thyroid autoantibodies were as follows: anti- microsomal antibody 7.8%, anti-thyroglobulin antibody 22.1%, and thyratropin binding inhibitor inununglobulin 6.3%. During the follow-up period, thyroid autoantibodies appeared most frequently between the first and the second month after initial visit. Compared to those with non-creeping thyroiditis, the patients with creeping thyroiditis(21.4%) had nonspecific systemic sy~rnptoms more frequently(89% vs. 42%, p<0.05). They required steroid therapy more ftequently(89% vs. 52%, p <0.05), and needed longer duration of treatment(9.3+6.2weeks vs, 4.7+3.7weeks, p<0.05). The incidence of abnormalities in liver function and the incidence of thyroid autoantibodies were higher in non-creeping thyroiditis group. Conclusion: In accordance with previous reports, thyroid autoantibodies were detected in only a small portion of Korean patients with subacute thyroiditis. Rather different clinical manifestations and different incidences of thyroid autoantibodies between ereeping group and non-creeping group suggest differences in the pathogenetic mechanisms between those two groups. However, there is need for further study to validate such observation and to elucidate the mechanisms.
Close layer
Case Report
A Case of Symptomatic Severe Hypercalcemia as Initial Manifestation of Hyperthyroidism.
Hye Young Park, Won Bae Kim, Hyeon Kyu Kim, Chan Soo Shin, Seong Yeon Kim, Bo Youn Cho, Hong Gyu Lee, Chang Soon Koh
J Korean Endocr Soc. 1996;11(1):124-126.   Published online November 7, 2019
  • 1,512 View
  • 21 Download
AbstractAbstract PDF
No abstract available.
Close layer
Original Articles
Clinical Characteristics of Graves' Disease Patients with Undetectable Thyrotropin Binding Inhibitor Immunoglubulin (TB2).
Bo Youn Cho, Won Bae Kim, Hong Gyu Lee, Chang Soon Koh, Seong Yeon Kim, Seok In Lee, Jae Seok Chun, Kyung Soo Park
J Korean Endocr Soc. 1996;11(1):68-74.   Published online November 7, 2019
  • 2,245 View
  • 22 Download
AbstractAbstract PDF
Background
Graves disease is an autoimmune disease caused by TSH receptor antibodies. Thyrotropin binding inhibitor immunoglobulins(TBII) are detected in most Graves patients, but some patients have no TBII activities in their sera. It is unknown whether the clinical features of TBII-positive patients are different from those of TBII-negative patients. Methods: To evaluate the prevalence of TBII-negative Graves' patients and its clinical differences from TBII-positive patients, we examined TBII by radioreceptor assay in 686 consecutive untreated Graves patients. We found 84 TBII-negative patients(15 men and 69 women, mean age ±EM: 40.9±.4 years) and compared their clinical characteristics with 87 TBII-positive patients (22 men and 65 women, mean age±EM: 39.9±.5 years) who were selected randomly from the same patients group. Results: In this study, TBII was undetectable in 12.2% of patients with Graves' disease(84 of 686). TBII-negative group had a less weight loss than TBII-positive group. However, there was no significant differences in age, sex ratio, prevalence of ophthalmopathy, duration of illness and positive rate of family history for thyroid diseases between TBII-negative and -positive groups. Serum total T or T levels were not different from each other, but T3-uptake was significantly higher in TBII-positive group than that in TBII-negative group, suggesting that the free hormone levels in TBII-negative group might be lower. The thyroid uptake of 99mTcO4 was significantly higher in TBII positive group than that in TBII-negative group. Thyroid autoantibodies, including antimicrosomal and antithyroglobulin antibodies were detected in almost all patients but there were no differences in titers and positive rate between TBII-negative and -positive groups. Conclusion: Although TBII-negative Graves patients showed less weight loss and low 99mTc04 thyroidal uptake compare to TBII-positive patients, the clinical and immunological characteristics of TBII-negative patients are not different from TBII-positive one.
Close layer
Changes in Serum Lipids and Apolipoproteins Levels According to the Thyroxine Treatment in The Patients with Subclinical Hypothyroidism.
Hye Young Park, Bo Youn Cho, Won Bae Kim, Hong Gyu Lee, Chang Soon Koh, Geon Sang Park, Hyung Kyu Park, Sook Kyung Kim, Chan Soo Shin, Seong Yeon Kim
J Korean Endocr Soc. 1996;11(1):41-51.   Published online November 7, 2019
  • 1,760 View
  • 21 Download
AbstractAbstract PDF
Background
Subclinical hypothyroidism(SCH) is a common biochemical abnormality which can be found in routine screening tests of thyroid function. We are increasingly faced with the question of whether its an indication for thyroxine replacement therapy. The effect of thyroxine replacement on lipid profile in SCH has aroused a great interest because of an association of overt hypothyroidism(OVH) with hyperlipidemia and increased risk of coronary artery disease. Method: We prospectively evaluated the changes in lipids and apoproteins before and after thyroxine replacement therapy in 23 patients with SCH and in 37 patients with OVH. We measured serum total cholesterol and triglyceride using autoanalyzer, high density lipoprotein(HDL) chole-sterol by dextran sulfate method, Apo A1 and Apo B by immunonephelometric assay. Results: Thyroxine replacement therapy significantly decreased total cholesterol, low density lipoprotein(LDL) cholesterol and apo B levels, but did not affect the level of triglyceride, HDL cholesterol or apo AI in patients with OVH. In SCH, thyroxine replacement therapy with the doses to normalize serum TSH concentrations also decreased significantly the level of cholesterol and LDL cholesterol albeit apo B levels did not change. Moreover, in most of patients with OVH (11 of 12) and in all of patients with SCH(5 of 5) who had had hyperchlesterolemia before treatment, thyroxine replament normalized their cholesterol and LDL cholesterol levels. Conclusion: In regard to the beneficial changes in blood lipid levels, patients with SCH should be treated, especially in cases who have other risk factors for the development of atherosclerosis. If thyroxine replacement only will reduce the incidence of coronary artery disease in SCH remains to be elucidated by long-term prospective studies.
Close layer
Difference of Thyroid Stimulating Antidody Activities Measured in Chinese Hamster Ovary Cells Stably Transfected with Human TSH Receptor and in FRTL-5 Cells in Graves Disease and Its Clinical Correlations.
Young Kee Shong Young Kee Shong, Hye Young Park, Bo Youn Cho, Won Bae Kim, Hong Gyu Lee, Chang Soon Koh, Yeon Sang Oh
J Korean Endocr Soc. 1996;11(1):18-29.   Published online November 7, 2019
  • 1,632 View
  • 22 Download
AbstractAbstract PDF
Background
: Thyroid stimulating antibodies result in the development of hyperthyroidism and goiter in Graves disease. However, thyroid stimulating antibody activities do not correlate with the clinical features in many patients with Graves disease. The purpose of this study is to address this discrepancy between thyroid stimulating antibody activities and clinical features of Graves patients. Methods: We measured thyroid stimulating antibody activities simultaneously using human TSH receptor transfected Chinese hamster(hTSHR-CHO) cells and rat thyroid(FRTL-5) cells in 57 untreated patients with Graves disease, and compared their activities with clinical features including thyroid hormone levels. Results : The detection rate of thyroid stimulating antibody measured by hTSHR-CHO cells was 90% in 57 untreated Graves patients and it was higher than that measured by FRTL-5 cells. Thyroid stimulating antibody activity by hTSHR-CHO cells was significantly correlated with that by FRTL-5 cells(r=0.5, p<0.001), however, 18 of 57(32%) patients showed marked discrepancy of thyroid stimulating antibody activity between in hTSHR-CHO and FRTL-5 systems. Thyroid stimulating antibody activity measured by hTSHR-CHO cells was significantly correlated with serum total T3, free T4 levels, and goiter size but not 99mTc-thyroid uptake. On the other hand, thyroid stimulating antibody activity measured by FRTL-5 cells was significantly correlated with goiter size and 99mTc-thyroid uptake but not thyroid hormone levels. The difference between function and goiter size with respect to thyroid stimulating antibody measurement in two cells system is, nevertheless, particularly evident in the free T4/goiter ratio in patients with high hTSHR-CHO and low FRTL-5 cell assay values. Conclusion: These findings suggest that thyroid stimulating antibodies in Graves disease are heterogeneous population in terms of responses to different origin of cells. Further, thyroid stimulating antibody activities measured by FRTL-5 cells tend to correlate better with goiter size and Tc-thyroid uptake, whereas thyroid stimulating antibody activities measured by hTSH-CHO cells correlate better with thyroid hormone levels.
Close layer
Assay of Thyrotropin Receptor Antibodies with Recombinant Human Thyrotropin Receptor Expressed on Chinese Hamster Ovary Cells.
Bo Youn Cho, Hong Kyu Lee, Chang Soon Koh, Jae Hoon Chung, Ka Hee Yi, Kyung Soo Ko, Won Bae Kim
J Korean Endocr Soc. 1995;10(4):347-361.   Published online November 7, 2019
  • 1,721 View
  • 21 Download
AbstractAbstract PDF
Thyroid stimulating antibody which results in the development of hyperthyroidism and goiter in Graves' patients used to be measured by using rat thyroid cells, FRTL-5. However, this assay has disadvantages: decreased sensitivity due to differences in species, and fastidious culture conditions for FRTL-5 cells. Thus, we recently created stably transfected Chinese hamster ovary(CHO) cells containing the human TSH receptor(hTSHR-CHO) and developed optimal conditions for the measurement of thyroid stimulating antibody using hTSHR-CHO cells. In this study, to evaluate the clinical relevance of thyroid stimulating antibody measurement using hTSHR-CHO cells, we measured thyroid stimulating antibody activities of IgGs from Graves' disease and other thyroid disease using hTSHR-CHO cells, and compared to those of thyroid stimulating antibody assays using FRTL-5 cells. 1) The cut off value of positive thyroid stimulating antibody activity measured in hTSHR-CHO cells was 145%(above the mean +2SD) which was lower than 165% in FRTL-5 cells. The intra-assay and inter-assay variances were 3.9% to 9.0% and 12.7% to 1.6%, respectively. 2) Thyroid stimulating antibody activity was detected in 90% of patients with untreated Graves' disease when patients initially presented. Further, in patients seen initially but already under therapy, 75% had positive values if they were hyperthyroid but only 43% had IgGs with activity if they were euthyroid. Patients in clinical remission after therapy showed positive values in 23% of cases. Only 2 of 25 patients with Hashimoto's thyroiditis showed weak thyroid stimulating antibody activity, none of 18 patients with nodular nontoxie goiter, 1 of 15 patients with primary myxedema, and 2 of 33 control patients with no thyroid disease. Thus, the detection frequency and specificity of the assay with hTSHR-CHO cells was excellent for this type bioassay.3) The detection frequency of thyroid stimulating antibody activity by hTSHR-CHO cells assay system(90%) was higher than that by FRTL-5 cells assay system(66%) in untreated Graves' patients. Those two activities were positively correlated with each other(r=0.52, p<0.001). However, some IgGs showed discrepancy of the thyroid stimulating antibody activity measured in hTSHR-CHO cells and in FRTL-5 cells; 56 of 87 patients were positive in both cells system, 8 of 87 were negative in both cells system, 1 of 87 was only positive in FRTL-5 cells and 22 of 87 were only positive in hTSHR-CHO cell system. Thus, 73%(22/30) of IgGs showing negative values of thyroid stimulating antibody activities in FRTL-5 cells were detected its activities in hTSHR-CHO cells system.In summary, thyroid stimulating antibody assay with hTSHR-CHO cells exhibited so excellent sensitivity and specificity that this technique should be used for clinical practice as well as basic research.
Close layer
Thyroid Stimulating Antibody Assay with Chinese Hamster Ovary Cells Expressing Human Thyroid Stimulating Hormone (TSH) Receptor; Optimization of Assay Condition.
Bo Youn Cho, Hong Kyu Lee, Young Kee Shong, Chang Soon Koh, Ka Hee Yi, Yeon Sahng Oh, Won Bae Kim
J Korean Endocr Soc. 1995;10(4):333-346.   Published online November 7, 2019
  • 1,573 View
  • 20 Download
AbstractAbstract PDF
We investigated the optimal condition of thyroid stimulating antibody(TSAb) assay using Chinese hamster ovary cells transfected with cDNA of human TSH receptor(TSHr-CHO) stably expressing functional TSH receptors. The extracellular cAMP responses of TSHr-CHO cells to the stimulation of bTSH or Graves' IgG were observed in three different incubation media. Stimulation indices of extracellular cAMP were higher when sucrose containing NaCl-free isotonic Hank's balanced salt solution(HBSS)(media A)was used as incubation media than those of NaCl-free hypotonic HBSS(media B) or those of NaCl containing isotonic HBSS(media C). The incubation of TSHr-CHO cells in media B caused marked increase in the basal cAMP level without concomittant fold-increase in the stimulated cAMP level at various doses of bTSH and Graves' IgG. Decreasing the stimulation indices of extracellular cAMP, use of media B failed to detect TSAb activities in two TSAb-positive Graves' IgG tested. In case of media C, extracellular cAMP responses are poor at 0.001 and 0.1U/L of bTSH and at all doses of Graves' IgG tested(0.5, 1, 5g/L). The incubation of TSHr-CHO cells in media B caused significant increase in the number of trypan blue-stained, nonviable cells(5.7+-1.5, 7.6+-1.9 and 8.5+-1.6% at 1, 2 and 3h of incubation, respectively; p<0.01) comparing to those incubated in media A or media C(about 2-3% in both media). Those decrease in the viability of TSHr-CHO cells when incubated in hypotonic incubation media may explain the decrease in the stimulation index of extracellular cAMP with the use of media B in contrast to the case of FRTL-5 cells. TSAb assay of 87 consecutive fresh Graves' patients with TSHr-CHO cells using media A detected TSAb activities in 90%(78 patients) of them, and moreover TSAb activities showed significant positive correlation with the pre-treatment serum T_3 and free T_4 levels of those patients. We conclude that TSAb assay with TSHr-CHO cells is a sensitive and physiologically relevant assay system to measure TSAb activities merely through measurements of extracellular cAMP provided that the cells are incubated in NaCl-free isotonic incubation media.
Close layer
Evaluation of the Usefulness of Free T4 Measured by 2 - Step Iimmunoextraction in the Patients with Thyroid and Non - Thyroid Diseases.
Bo Youn Cho, Hong Kyu Lee, Jae Hoon Chung, Seok In Lee, Won Bae Kim, Chang Soon Koh
J Korean Endocr Soc. 1994;10(2):98-104.   Published online November 6, 2019
  • 1,729 View
  • 18 Download
AbstractAbstract PDF
Many methods and commercial kits have become available for directly measuring free thyroxine(free T_4). However, most of them are inadequate for routine laboratory use because of their complexity and inaccuracy. Recently, 2-step RIA methods by immunoextraction(2-step immunoextraction) for free T_4 have been developed to improve its accuracy and convenience. We evaluated the usefulness of free T_4 measured by 2-step immunoextraction compared to free T_4 index(FT_4I), free T_4 measured by 1-step RIA, and TSH in 204 patients with thyroid and non-thyroid disease. There were no differences in sensitivities and specificities of free T_4(1-step, 2-step), FT_4I and TSH in the patients with hyperthyroidism and euthyroid nodule. However, the sensitivity of TSH in hypothyroidism was remarkablely higher than the others(100.0% vs. 61.5-81.5%). The sensitivity of free T_4(2-step) was also higher than those of free T_4(1-step), FT_4I and TSH in the patients with non-thyroid disease(94.3% vs. 74.3-83.8%). The values of free T_4 measured by 1-step RIA were significantly lower than those by 2-step immunoextraction, especially in the patients with non-thyroid disease(1.10+-0.04 vs. 1.55+-0.03ng/dL, p<0.05).In conclusion, no significant differences were found in sensitivity and specificity of free T_4(1-step, 2-step), FT_4I, and TSH in the patients with thyroid diseases except in hypothyroidism. However, the sensitivity of free T_4 measured by 2-step immunoextraction was significantly higher than the other tests, especially in the patients with non-thyroid disease. Therefore, free T_4 assay using 2-step immunoextraction is useful to differentiate the non-thyroid disease from thyroid diseases.
Close layer
Case Report
A Case of Thyroid Anaplastic Cancer with Intestinal Metastasis.
Seong Yeon Kim, Kyung Soo Park, Bo Youn Cho, Hong Kyu Lee, Chang Soon Koh, Jae Seok Jeon, Min Seon Kim, Won Bae Kim
J Korean Endocr Soc. 1994;9(4):375-379.   Published online November 6, 2019
  • 1,601 View
  • 23 Download
AbstractAbstract PDF
Thyroid anaplastic cancer is one of the most malignant neoplasms encountered in human. These tumors usually present as rapidly enlarging neck mass in old patients who may or may not have had a previously recognized goiter. The distant metastases of anaplastic cancer eventually occur in about 50% patients, mostly in the lung and bone and are an important prognostic factor, substantially reducing survival time.A 66-year old man visited out hospital because of rapidly growing anterior neck mass and hoarseness. He was diagnosed as thyroid anaplastic cancer with lymph node and lung metastasis and received combined chemotherapy and radiation therapy. On the 8th hospital day, severe abdominal pain developed and exploratory laparotomy was conducted. During operation, two intestinal mass were discovered, one of which was perforated. The microscopic examinations showed that undifferentiated malignant cells were infiltrated in the wall of small bowel. We report this case because we first experienced thyroid anaplastic cancer with intestinal metastasis.
Close layer
Original Articles
Changes in Thyrotropin Receptor Blocking Antibody after Antithyroid drug Administration to Patients with Atrophic Autoimmune Thyroiditis (Primary Myxedema).
Seong Yeon Kim, Bo Youn Cho, Hong Kyu Lee, Jae Hoon Chung, Chang Soon Koh, Chan Soo Shin, Won Bae Kim
J Korean Endocr Soc. 1994;10(3):229-241.   Published online November 6, 2019
  • 1,560 View
  • 18 Download
AbstractAbstract PDF
It is well Known that antithyroid drug treatment of Graves' disease suppresses excessive thyroid hormone synthesis and causes a parallel decrease in serum thyroid autoantibody levels including thyroid stimulating antibodies(TSAb) in most patients suggesting the immunosuppressive or immunomodulating effects of antithyroid drugs. In the context of view that thyrotropin receptor blocking antibody may play an important pathogenetic role at least in some patients with primary myxedema(chronic atrophic autoimmune thyroiditis), antithyroid drug treatment in these patients might be beneficial to disease course. To evaluate the effect of antithyroid drug on the thyrotropin receptor blocking antibody levels, we serially measured thyrotropin-binding inhibitor immunoglobulins(TBII) and thyroid stimulation blocking antibodies(TSBAb) using FRTL-5 cells, antimicrosomal- and antithyroglobulin antibody activities in 7 patients with primary myedema who have blocking TSH receptor antibodies during 6 months of methimazole(MMI, 40mg/day) administration. TBII and TSBAb activities did not change after MMI, but one of them showed stepwise decrease and disappearance of TBII and TSBAb activities. Antimicrosomal- and antithyroglobulin antibody activities decreased significantly after 3 months of MMI administration in those patients. These results suggest a minimal effect of antithyroid drug treatment on the level of thyrotropin receptor blocking antibodies. Persistence of thyrotropin receptor blocking antibodies despite of the decrease in antimicrosomal and antithyroglobulin antibodies might suggest that blocking TSH receptor antibodies of primary myxedema is produced mainly in extrathyroidal tissue in contrast to the thyroid stimulating antibodies of Graves' disease. One patient, whose blocking antibody have disappeared after MMI treatment, is under observation to see if she will remain in remission of hypothyroidism.
Close layer
Endocrine Research
Expression of NF2 Modulates the Progression of BRAFV600E Mutated Thyroid Cancer Cells
Mi-Hyeon You, Min Ji Jeon, Tae Yong Kim, Won Bae Kim, Young Kee Shong, Won Gu Kim
Endocrinol Metab. 2019;34(2):203-212.   Published online June 24, 2019
DOI: https://doi.org/10.3803/EnM.2019.34.2.203
  • 7,831 View
  • 75 Download
  • 8 Web of Science
  • 6 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background

We previously reported the frequent neurofibromatosis 2 (NF2) gene mutations in anaplastic thyroid cancers in association with the BRAFV600E mutation. We aimed to investigate the role of NF2 in thyroid cancer with BRAF mutation.

Methods

To identify the function of NF2 in thyroid cancers, we investigated the changes in cell proliferation, colon formation, migration and invasion of thyroid cancer cells (8505C, BHT101, and KTC-1) with BRAFV600E mutation after overexpression and knock-down of NF2. We also examined how cell proliferation changed when NF2 was mutagenized. Human NF2 expression in papillary thyroid carcinoma (PTC) was analyzed using the The Cancer Genome Atlas (TCGA) data.

Results

First, NF2 was overexpressed in 8505C and KTC-1 cells. Compared to control, NF2 overexpressed group of both thyroid cancer cells showed significant inhibition in cell proliferation and colony formation. These results were also confirmed by cell migration and invasion assay. After knock-down of NF2 in 8505C cells, there were no significant changes in cell proliferation and colony formation, compared with the control group. However, after mutagenized S288* and Q470* sites of NF2 gene, the cell proliferation increased compared to NF2 overexpression group. In the analysis of TCGA data, the mRNA expression of NF2 was significantly decreased in PTCs with lateral cervical lymph node (LN) metastasis compared with PTCs without LN metastasis.

Conclusion

Our study suggests that NF2 might play a role as a tumor suppressor in thyroid cancer with BRAF mutation. More studies are needed to elucidate the mechanism how NF2 acts in thyroid cancer with BRAF mutation.

Citations

Citations to this article as recorded by  
  • Decoding the Mutational Hierarchy of Thyroid Cancer and Associated Signaling Pathways
    Disha Nashier, Gowrang Kasaba Manjunath, Alisha Parveen, Sumira Malik, Tamoghna Mitra, Chandan Goswami, Muniasamy Neerathilingam, Ankit Watts, Abhishek Kumar
    Archives of Medical Research.2026; 57(4): 103366.     CrossRef
  • Mechanistic Insights of Thyroid Cancer Progression
    Luis Javier Leandro-García, Iñigo Landa
    Endocrinology.2023;[Epub]     CrossRef
  • Gene Editing with CRISPR/Cas Methodology and Thyroid Cancer: Where Are We?
    Cesar Seigi Fuziwara, Diego Claro de Mello, Edna Teruko Kimura
    Cancers.2022; 14(3): 844.     CrossRef
  • Extracellular Vesicles as Signal Carriers in Malignant Thyroid Tumors?
    Małgorzata Grzanka, Anna Stachurska-Skrodzka, Anna Adamiok-Ostrowska, Ewa Gajda, Barbara Czarnocka
    International Journal of Molecular Sciences.2022; 23(6): 3262.     CrossRef
  • Mitofusin-2 modulates the epithelial to mesenchymal transition in thyroid cancer progression
    Mi-Hyeon You, Min Ji Jeon, Seong ryeong Kim, Woo Kyung Lee, Sheue-yann Cheng, Goo Jang, Tae Yong Kim, Won Bae Kim, Young Kee Shong, Won Gu Kim
    Scientific Reports.2021;[Epub]     CrossRef
  • High Phosphoglycerate Dehydrogenase Expression Induces Stemness and Aggressiveness in Thyroid Cancer
    Min Ji Jeon, Mi-Hyeon You, Ji Min Han, Soyoung Sim, Hyun Ju Yoo, Woo Kyung Lee, Tae Yong Kim, Dong Eun Song, Young Kee Shong, Won Gu Kim, Won Bae Kim
    Thyroid.2020; 30(11): 1625.     CrossRef
Close layer
Thyroid
Clinical Outcomes of Differentiated Thyroid Cancer Patients with Local Recurrence or Distant Metastasis Detected in Old Age
Ji Min Han, Ji Cheol Bae, Hye In Kim, Sam Kwon, Min Ji Jeon, Won Gu Kim, Tae Yong Kim, Young Kee Shong, Won Bae Kim
Endocrinol Metab. 2018;33(4):459-465.   Published online November 30, 2018
DOI: https://doi.org/10.3803/EnM.2018.33.4.459
  • 8,771 View
  • 73 Download
  • 9 Web of Science
  • 7 Crossref
AbstractAbstract PDFPubReader   ePub   
Background

Differentiated thyroid carcinoma (DTC) shows a very good prognosis, but older patients have a higher recurrence rate and those show poor prognosis than younger patients. The aim of this study was to determine the clinical outcomes of thyroid cancer patients who experienced recurrence in old age according to the treatment strategy used.

Methods

This retrospective observational cohort study was conducted at Asan Medical Center, Seoul, Korea. Among DTC patients with no evidence of disease after initial treatment, we enrolled 86 patients who experienced recurrence at an age >65 years from 1994 to 2012. Sixty-nine patients had local recurrence and 17 patients showed distant metastasis.

Results

The mean age of patients at recurrence was 72 years. Patients were followed up for a median of 4.1 years after recurrence. Sixty-three of the 69 patients with local recurrence received additional treatment, while the other six received conservative care. The cancer-specific mortality rate was 15.5% in the local recurrence group. Airway problems were the main cause of death in patients who did not receive further treatment for local recurrence. Among the 17 patients with distant metastasis, 10 underwent specific treatment for metastasis and seven received only supportive management. Seven of those 17 patients died, and the cancer-specific mortality rate was 35% in the distant metastasis group.

Conclusion

The overall cancer-specific mortality rate was 20% in DTC patients in whom recurrence was first detected at an age >65 years. Mortality due to uncontrolled local disease occurred frequently in patients who did not receive definitive management for recurrence.

Citations

Citations to this article as recorded by  
  • Diagnostic performance of fluorine-18-fluorodeoxyglucose PET/MRI for detection of disease recurrence in differentiated thyroid cancer: a compartment-based analysis
    Elgin Özkan, Sena Ünal, Pinar Akkuş, Elif Peker, Mine Araz, Ecenur Dursun, Cigdem Soydal, Nil Sezer Yilmazer Zorlu, Mustafa Kursat Gökcan, Murat Faik Erdoğan, Yasemin Yavuz, Nuriye Ozlem Küçük
    Nuclear Medicine Communications.2025; 46(3): 230.     CrossRef
  • Radiofrequency Ablation for Recurrent Thyroid Cancers: 2025 Korean Society of Thyroid Radiology Guideline
    Eun Ju Ha, Min Kyoung Lee, Jung Hwan Baek, Hyun Kyung Lim, Hye Shin Ahn, Seon Mi Baek, Yoon Jung Choi, Sae Rom Chung, Ji-hoon Kim, Jae Ho Shin, Ji Ye Lee, Min Ji Hong, Hyun Jin Kim, Leehi Joo, Soo Yeon Hahn, So Lyung Jung, Chang Yoon Lee, Jeong Hyun Lee,
    Korean Journal of Radiology.2025; 26(1): 10.     CrossRef
  • 125I seed implantation for lymph node metastasis from radioactive iodine-refractory differentiated thyroid carcinoma: a study on short-term efficacy and dosimetry
    Wenwen Zhang, Shanhu Hao, Zhiguo Wang, Tingting Ding, Guoxu Zhang
    Frontiers in Oncology.2024;[Epub]     CrossRef
  • Identification of Circulating Tumor Cell Phenotype in Differentiated Thyroid Carcinoma
    Huiling Wang, Mian Lv, Yonghong Huang, Xiaoming Pan, Changyuan Wei
    Journal of Biomaterials and Tissue Engineering.2022; 12(4): 813.     CrossRef
  • Long-Term Outcomes and Prognoses of Elderly Patients (≥65-Years-Old) With Distant Metastases From Well-Differentiated Thyroid Cancer During Radioiodine Therapy and Follow-Up
    Zhong-Ling Qiu, Chen-Tian Shen, Zhen-Kui Sun, Hong-Jun Song, Chuang Xi, Guo-Qiang Zhang, Yang Wang, Quan-Yong Luo
    Frontiers in Endocrinology.2021;[Epub]     CrossRef
  • Head-to-Head Comparison of Neck 18F-FDG PET/MR and PET/CT in the Diagnosis of Differentiated Thyroid Carcinoma Patients after Comprehensive Treatment
    Yangmeihui Song, Fang Liu, Weiwei Ruan, Fan Hu, Muhsin H. Younis, Zairong Gao, Jie Ming, Tao Huang, Weibo Cai, Xiaoli Lan
    Cancers.2021; 13(14): 3436.     CrossRef
  • Highly sensitive electrochemical immunosensor using a protein-polyvinylidene fluoride nanocomposite for human thyroglobulin
    Maria Oneide Silva de Moraes, João de Deus Pereira de Moraes Segundo, Marcos Marques da Silva Paula, Maria Goreti Ferreira Sales, Walter Ricardo Brito
    Bioelectrochemistry.2021; 142: 107888.     CrossRef
Close layer
Thyroid
Comparison of Immunohistochemistry and Direct Sanger Sequencing for Detection of the BRAFV600E Mutation in Thyroid Neoplasm
Hye-Seon Oh, Hyemi Kwon, Suyeon Park, Mijin Kim, Min Ji Jeon, Tae Yong Kim, Young Kee Shong, Won Bae Kim, Jene Choi, Won Gu Kim, Dong Eun Song
Endocrinol Metab. 2018;33(1):62-69.   Published online January 30, 2018
DOI: https://doi.org/10.3803/EnM.2018.33.1.62
  • 9,388 View
  • 82 Download
  • 20 Web of Science
  • 22 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background

The BRAFV600E mutation is the most common genetic alteration identified in papillary thyroid carcinoma (PTC). Because of its costs effectiveness and sensitivity, direct Sanger sequencing has several limitations. The aim of this study was to evaluate the efficiency of immunohistochemistry (IHC) as an alternative method to detect the BRAFV600E mutation in preoperative and postoperative tissue samples.

Methods

We evaluated 71 patients who underwent thyroid surgery with the result of direct sequencing of the BRAFV600E mutation. IHC staining of the BRAFV600E mutation was performed in 49 preoperative and 23 postoperative thyroid specimens.

Results

Sixty-two patients (87.3%) had PTC, and of these, BRAFV600E was confirmed by direct sequencing in 57 patients (91.9%). In 23 postoperative tissue samples, the BRAFV600E mutation was detected in 16 samples (70%) by direct sequencing and 18 samples (78%) by IHC. In 24 fine needle aspiration (FNA) samples, BRAFV600E was detected in 18 samples (75%) by direct sequencing and 16 samples (67%) by IHC. In 25 core needle biopsy (CNB) samples, the BRAFV600E mutation was detected in 15 samples (60%) by direct sequencing and 16 samples (64%) by IHC. The sensitivity and specificity of IHC for detecting the BRAFV600E mutation were 77.8% and 66.7% in FNA samples and 99.3% and 80.0% in CNB samples.

Conclusion

IHC could be an alternative method to direct Sanger sequencing for BRAFV600E mutation detection both in postoperative and preoperative samples. However, application of IHC to detect the BRAFV600E mutation in FNA samples is of limited value compared with direct sequencing.

Citations

Citations to this article as recorded by  
  • 2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer
    Matthew D. Ringel, Julie Ann Sosa, Zubair Baloch, Lindsay Bischoff, Gary Bloom, Gregory A. Brent, Pamela L. Brock, Roger Chou, Robert R. Flavell, Whitney Goldner, Elizabeth G. Grubbs, Megan Haymart, Steven M. Larson, Angela M. Leung, Joseph Osborne, John
    Thyroid®.2025; 35(8): 841.     CrossRef
  • Circulating Nucleic Acids in Colorectal Cancer: Diagnostic and Prognostic Value
    Somayeh Igder, Mozhdeh Zamani, Shima Fakher, Morvarid Siri, Hassan Ashktorab, Negar Azarpira, Pooneh Mokarram, Sowjanya Thatikonda
    Disease Markers.2024; 2024: 1.     CrossRef
  • Fluorescent primers amplification refractory mutation system qPCR (FP ARMS-qPCR) for MTHFR C677T SNP genotyping
    Yongjun Han, Hong Wu
    Molecular Biology Reports.2024;[Epub]     CrossRef
  • Inter- and Intra-observer Reproducibility of Thyroid Fine Needle Aspiration Cytology: An investigation of Bethesda 2023 Using Immunohistochemical BRAFV600E Antibody
    Erdogan Bahattin, Dündar Emine, Çetin Kısmet Çivi, Yılmaz Fatih
    Journal of Cytology.2024; 41(4): 221.     CrossRef
  • The Accurate Interpretation and Clinical Significance of Morphological Features of Fine Needle Aspiration Cells in Papillary Thyroid Carcinoma
    Xue-Jiao Xiong, Ming-Ming Xiao, Yi-Xia Zhang, Dong-Ge Liu, Mu-Lan Jin, Jian Wang, Hong-Tao Xu, Qing-Chang Li, Guang-Ping Wu, Giovanni Tuccari
    Analytical Cellular Pathology.2023;[Epub]     CrossRef
  • An effective approach for BRAF V600E mutation analysis of routine thyroid fine needle aspirates
    Tanupriya Agrawal, Liqiang Xi, Winnifred Navarro, Mark Raffeld, Snehal B. Patel, Mark J. Roth, Joanna Klubo‐Gwiezdzinska, Armando C. Filie
    Cytopathology.2022; 33(3): 344.     CrossRef
  • A dual identification strategy based on padlock ligation and CRISPR/Cas14a for highly specific detection of BRAF V600E mutation in clinical samples
    Weicheng Shi, Yao Gong, Decai Zhang, Tiantian Yang, Ming Yi, Jingyi Tan, Shijia Ding, Wei Cheng
    Analytical Methods.2022; 14(19): 1913.     CrossRef
  • Research Progress of BRAF V600E Gene Mutation in Papillary Thyroid Carcinoma
    延泽 刘
    Advances in Clinical Medicine.2022; 12(09): 8499.     CrossRef
  • VE1 immunohistochemistry is an adjunct tool for detection of BRAFV600E mutation: Validation in thyroid cancer patients
    Faiza A. Rashid, Sobia Tabassum, Mosin S. Khan, Hifzur R. Ansari, Muhammad Asif, Ahmareen K. Sheikh, Syed Sameer Aga
    Journal of Clinical Laboratory Analysis.2021;[Epub]     CrossRef
  • BRAF testing in a South African cohort of MLH1 deficient endometrial carcinomas: lessons learnt
    Reubina Wadee, Wayne Grayson
    Southern African Journal of Gynaecological Oncology.2021; 13(1): 1.     CrossRef
  • Association between mutation profiles and clinicopathological features in Chinese patients with thyroid cancer
    Changwen Jing, Haixia Cao, Rong Ma, Jianzhong Wu, Zhuo Wang
    Precision Medical Sciences.2021; 10(3): 113.     CrossRef
  • Development of a Molecular Assay for Detection and Quantification of theBRAFVariation in Residual Tissue From Thyroid Nodule Fine-Needle Aspiration Biopsy Specimens
    Guodong Fu, Ronald S. Chazen, Christina MacMillan, Ian J. Witterick
    JAMA Network Open.2021; 4(10): e2127243.     CrossRef
  • Variations in MAP kinase gladiators and risk of differentiated thyroid carcinoma
    Faiza Rashid, Ghulam Bhat, Mosin Khan, Sobia Tabassum, Mohammad Bhat
    Molecular and Clinical Oncology.2021;[Epub]     CrossRef
  • Порівняльне імуногістохімічне дослідження BRAFV600E-позитивних і BRAFV600E-негативних радіогенних і спорадичних папілярних тиреоїдних карцином
    L. Yu. Zurnadzhy, T.I. Rogounovitch, V.O. Saenko, M.Yu. Bolgov, S.V. Masiuk, S.V. Burko, T.L. Degtyaryova, S.V. Chernyshov, S.V. Gulevatyi, N. Mitsutake, M.D. Tronko, T.I. Bogdanova
    Endokrynologia.2021; 26(2): 105.     CrossRef
  • Evaluation of the expression levels of BRAFV600E mRNA in primary tumors of thyroid cancer using an ultrasensitive mutation assay
    Tien Viet Tran, Kien Xuan Dang, Quynh Huong Pham, Ung Dinh Nguyen, Nhung Thi Trang Trinh, Luong Van Hoang, Son Anh Ho, Ba Van Nguyen, Duc Trong Nguyen, Dung Tuan Trinh, Dung Ngoc Tran, Arto Orpana, Ulf-Håkan Stenman, Jakob Stenman, Tho Huu Ho
    BMC Cancer.2020;[Epub]     CrossRef
  • VE1 Immunohistochemistry Improves the Limit of Genotyping for Detecting BRAFV600E Mutation in Papillary Thyroid Cancer
    Sonam Choden, Somboon Keelawat, Chan Kwon Jung, Andrey Bychkov
    Cancers.2020; 12(3): 596.     CrossRef
  • Comparison of Molecular Methods and BRAF Immunohistochemistry (VE1 Clone) for the Detection of BRAF V600E Mutation in Papillary Thyroid Carcinoma: A Meta-Analysis
    Kyle G. Parker, Michael G. White, Nicole A. Cipriani
    Head and Neck Pathology.2020; 14(4): 1067.     CrossRef
  • Next generation sequencing based detection of 15 target genes mutations in papillary thyroid carcinoma
    Zhuo Wang, Changwen Jing, Haixia Cao, SiWen Liu, Jianzhong Wu, Rong Ma
    Precision Medical Sciences.2020; 9(2): 90.     CrossRef
  • A Systematic Review and Meta-Analysis of the Diagnostic Performance of BRAF V600E Immunohistochemistry in Thyroid Histopathology
    Ranjit Singarayer, Ozgur Mete, Laure Perrier, Lehana Thabane, Sylvia L. Asa, Stan Van Uum, Shereen Ezzat, David P. Goldstein, Anna M. Sawka
    Endocrine Pathology.2019; 30(3): 201.     CrossRef
  • Comparison of droplet digital PCR and direct Sanger sequencing for the detection of the BRAFV600E mutation in papillary thyroid carcinoma
    Zhuo Wang, Kejing Sun, Changwen Jing, Haixia Cao, Rong Ma, Jianzhong Wu
    Journal of Clinical Laboratory Analysis.2019;[Epub]     CrossRef
  • Immunohistochemistry Innovations for Diagnosis and Tissue-Based Biomarker Detection
    Narittee Sukswai, Joseph D. Khoury
    Current Hematologic Malignancy Reports.2019; 14(5): 368.     CrossRef
  • Immunohistochemistry is a feasible method to screen BRAF V600E mutation in colorectal and papillary thyroid carcinoma
    Xiangyan Zhang, Lili Wang, Jigang Wang, Han Zhao, Jie Wu, Shuhong Liu, Lu Zhang, Yujun Li, Xiaoming Xing
    Experimental and Molecular Pathology.2018; 105(1): 153.     CrossRef
Close layer
Clinical Study
Disease-Specific Mortality of Differentiated Thyroid Cancer Patients in Korea: A Multicenter Cohort Study
Min Ji Jeon, Won Gu Kim, Tae Hyuk Kim, Hee Kyung Kim, Bo Hyun Kim, Hyon-Seung Yi, Eun Sook Kim, Hosu Kim, Young Nam Kim, Eun Heui Kim, Tae Yong Kim, Sun Wook Kim, Ho-Cheol Kang, Jae Hoon Chung, Young Kee Shong, Won Bae Kim
Endocrinol Metab. 2017;32(4):434-441.   Published online November 22, 2017
DOI: https://doi.org/10.3803/EnM.2017.32.4.434
  • 9,738 View
  • 67 Download
  • 30 Web of Science
  • 29 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   
Background

Little is known regarding disease-specific mortality of differentiated thyroid cancer (DTC) patients and its risk factors in Korea.

Methods

We retrospectively reviewed a large multi-center cohort of thyroid cancer from six Korean hospitals and included 8,058 DTC patients who underwent initial surgery between 1996 and 2005.

Results

Mean age of patients at diagnosis was 46.2±12.3 years; 87% were females. Most patients had papillary thyroid cancer (PTC; 97%) and underwent total thyroidectomy (85%). Mean size of the primary tumor was 1.6±1.0 cm. Approximately 40% of patients had cervical lymph node (LN) metastases and 1.3% had synchronous distant metastases. During 11.3 years of follow-up, 150 disease-specific mortalities (1.9%) occurred; the 10-year disease-specific survival (DSS) rate was 98%. According to the year of diagnosis, the number of disease-specific mortality was not different. However, the rate of disease-specific mortality decreased during the study period (from 7.7% to 0.7%). Older age (≥45 years) at diagnosis, male, follicular thyroid cancer (FTC) versus PTC, larger tumor size (>2 cm), presence of extrathyroidal extension (ETE), lateral cervical LN metastasis, distant metastasis and tumor node metastasis (TNM) stage were independent risk factors of disease-specific mortality of DTC patients.

Conclusion

The rate of disease-specific mortality of Korean DTC patients was 1.9%; the 10-year DSS rate was 98% during 1996 to 2005. Older age at diagnosis, male, FTC, larger tumor size, presence of ETE, lateral cervical LN metastasis, distant metastasis, and TNM stages were significant risk factors of disease-specific mortality of Korean DTC patients.

Citations

Citations to this article as recorded by  
  • Rectum, Penile, Brain and Bladder, Consecutive Rare Distant Metastasis in Two Patients With Papillary Thyroid Carcinoma: Case Reports
    Douk Kwon, Won Woong Kim, Byung-Chang Kim, Yu-mi Lee, Ki-Wook Chung, Tae-Yon Sung
    Journal of Endocrine Surgery.2025; 25(3): 109.     CrossRef
  • Laterocervical Lymph Node Metastases in Papillary Thyroid Carcinoma: Predictive Factors for Recurrence and Oncological Outcome
    Andrea Migliorelli, Marianna Manuelli, Agnese Maria Tringali, Claudio Moretti, Virginia Corazzi, Matteo Geminiani, Andrea Ciorba, Francesco Stomeo, Stefano Pelucchi, Chiara Bianchini
    Journal of Personalized Medicine.2025; 15(10): 496.     CrossRef
  • Impact of Tumor Size on Prognosis in Differentiated Thyroid Cancer with Gross Extrathyroidal Extension to Strap Muscles: Redefining T3b
    Joonseon Park, Solji An, Ja Seong Bae, Kwangsoon Kim, Jeong Soo Kim
    Cancers.2024; 16(14): 2577.     CrossRef
  • Log odds of negative lymph nodes/T stage ratio (LONT): A new prognostic tool for differentiated thyroid cancer without metastases in patients aged 55 and older
    Xuezhen Wang, Yufan Wu, Xiaoxia Li, Jinsheng Hong, Mingwei Zhang
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • The association between vitamin D supplementation and the long-term prognosis of differentiated thyroid cancer patients: a retrospective observational cohort study with propensity score matching
    Jong-hyuk Ahn, Hoonsung Choi, Su-jin Kim, Sun Wook Cho, Kyu Eun Lee, Do Joon Park, Young Joo Park
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • Linear association between radioactive iodine dose and second primary malignancy risk in thyroid cancer
    Kyeong Jin Kim, Kyoung Jin Kim, Jimi Choi, Nam Hoon Kim, Sin Gon Kim
    JNCI: Journal of the National Cancer Institute.2023; 115(6): 695.     CrossRef
  • Outcomes of Advanced Medullary Thyroid Carcinoma in the Era of Targeted Therapy
    Nicholas L. Kesby, Alexander J. Papachristos, Matti Gild, Ahmad Aniss, Mark S. Sywak, Roderick Clifton-Bligh, Stan B. Sidhu, Anthony R. Glover
    Annals of Surgical Oncology.2022; 29(1): 64.     CrossRef
  • Clinical Implication of Mutifocality for Risk of Recurrence in Patients With Papillary Thyroid Carcinoma
    Kwangsoon Kim, Ja Seong Bae, Jeong Soo Kim
    Journal of Endocrine Surgery.2022; 22(1): 10.     CrossRef
  • Clinical Factors Predictive of Lymph Node Metastasis in Thyroid Cancer Patients: A Multivariate Analysis
    Hui Zheng, Victoria Lai, Jana Lu, Jin K Kang, Jiling Chou, Kenneth D Burman, Leonard Wartofsky, Jennifer E Rosen
    Journal of the American College of Surgeons.2022; 234(4): 691.     CrossRef
  • Minimal extrathyroidal extension is associated with lymph node metastasis in single papillary thyroid microcarcinoma: a retrospective analysis of 814 patients
    Ra-Yeong Song, Hee Sung Kim, Kyung Ho Kang
    World Journal of Surgical Oncology.2022;[Epub]     CrossRef
  • Central Lymph Node Ratio Predicts Recurrence in Patients with N1b Papillary Thyroid Carcinoma
    Il Ku Kang, Kwangsoon Kim, Joonseon Park, Ja Seong Bae, Jeong Soo Kim
    Cancers.2022; 14(15): 3677.     CrossRef
  • Characterization of the CpG island methylator phenotype subclass in papillary thyroid carcinoma
    Pengfei Gu, Yu Zeng, Weike Ma, Wei Zhang, Yu Liu, Fengli Guo, Xianhui Ruan, Jiadong Chi, Xiangqian Zheng, Ming Gao
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
  • MicroRNA Profile for Diagnostic and Prognostic Biomarkers in Thyroid Cancer
    Jong-Lyul Park, Seon-Kyu Kim, Sora Jeon, Chan-Kwon Jung, Yong-Sung Kim
    Cancers.2021; 13(4): 632.     CrossRef
  • Lactate Dehydrogenase A as a Potential New Biomarker for Thyroid Cancer
    Eun Jeong Ban, Daham Kim, Jin Kyong Kim, Sang-Wook Kang, Jandee Lee, Jong Ju Jeong, Kee-Hyun Nam, Woong Youn Chung, Kunhong Kim
    Endocrinology and Metabolism.2021; 36(1): 96.     CrossRef
  • Male sex is not an independent risk factor for recurrence of differentiated thyroid cancer: a propensity score-matching study
    Joonseon Park, Kwangsoon Kim, Dong-Jun Lim, Ja Seong Bae, Jeong Soo Kim
    Scientific Reports.2021;[Epub]     CrossRef
  • A Newly Developed Pancreatic Adenocarcinoma in a Patient with Advanced Thyroid Cancer under Long-Term Sorafenib Use
    Min Ji Kim, Han-Sang Baek, Sung Hak Lee, Dong-Jun Lim
    International Journal of Thyroidology.2021; 14(2): 175.     CrossRef
  • Modified risk stratification based on cervical lymph node metastases following lobectomy for papillary thyroid carcinoma
    Eyun Song, Jonghwa Ahn, Dong Eun Song, Won Woong Kim, Min Ji Jeon, Tae‐Yon Sung, Tae Yong Kim, Ki Wook Chung, Won Bae Kim, Young Kee Shong, Suck Joon Hong, Yu‐Mi Lee, Won Gu Kim
    Clinical Endocrinology.2020; 92(4): 358.     CrossRef
  • Long-term scintigraphic and clinical follow up in patients with differentiated thyroid cancer and iodine avid bone metastases
    Omnia Mohamed Talaat, Ismail Mohamed Ali, Sherif Maher Abolyazid, Bader Abdelmaksoud, Ibrahim Mansour Nasr
    Nuclear Medicine Communications.2020; 41(4): 327.     CrossRef
  • Highly prevalent BRAF V600E and low-frequency TERT promoter mutations underlie papillary thyroid carcinoma in Koreans
    Sue Youn Kim, Taeeun Kim, Kwangsoon Kim, Ja Seong Bae, Jeong Soo Kim, Chan Kwon Jung
    Journal of Pathology and Translational Medicine.2020; 54(4): 310.     CrossRef
  • Clinical Implication of World Health Organization Classification in Patients with Follicular Thyroid Carcinoma in South Korea: A Multicenter Cohort Study
    Meihua Jin, Eun Sook Kim, Bo Hyun Kim, Hee Kyung Kim, Hyon-Seung Yi, Min Ji Jeon, Tae Yong Kim, Ho-Cheol Kang, Won Bae Kim, Young Kee Shong, Mijin Kim, Won Gu Kim
    Endocrinology and Metabolism.2020; 35(3): 618.     CrossRef
  • The age threshold of the 8th edition AJCC classification is useful for indicating patients with aggressive papillary thyroid cancer in clinical practice
    Krzysztof Kaliszewski, Dorota Diakowska, Łukasz Nowak, Beata Wojtczak, Jerzy Rudnicki
    BMC Cancer.2020;[Epub]     CrossRef
  • Lobectomy Is Feasible for 1–4 cm Papillary Thyroid Carcinomas: A 10-Year Propensity Score Matched-Pair Analysis on Recurrence
    Eyun Song, Minkyu Han, Hye-Seon Oh, Won Woong Kim, Min Ji Jeon, Yu-Mi Lee, Tae Yong Kim, Ki Wook Chung, Won Bae Kim, Young Kee Shong, Suck Joon Hong, Tae-Yon Sung, Won Gu Kim
    Thyroid.2019; 29(1): 64.     CrossRef
  • The binary presence or absence of lymph node metastasis or extrathyroidal extension is not associated with survival in papillary thyroid cancers: Implications for staging systems
    Hyun-Soo Zhang, Eun-Kyung Lee, Yuh-Seog Jung, Byung-Ho Nam, Boyoung Park
    Cancer Epidemiology.2019; 63: 101589.     CrossRef
  • Risk of Adverse Obstetric Outcomes and the Abnormal Growth of Offspring in Women with a History of Thyroid Cancer
    Geum Joon Cho, So-youn Kim, Hoi Chang Lee, Kyu-Min Lee, Sung Won Han, Min-Jeong Oh, Teresa K. Woodruff
    Thyroid.2019; 29(6): 879.     CrossRef
  • Changes in Serum Thyroglobulin Levels After Lobectomy in Patients with Low-Risk Papillary Thyroid Cancer
    Suyeon Park, Min Ji Jeon, Hye-Seon Oh, Yu-Mi Lee, Tae-Yon Sung, Minkyu Han, Ji Min Han, Tae Yong Kim, Ki-Wook Chung, Won Bae Kim, Young Kee Shong, Won Gu Kim
    Thyroid®.2018; 28(8): 997.     CrossRef
  • Clinical Outcomes of Differentiated Thyroid Cancer Patients with Local Recurrence or Distant Metastasis Detected in Old Age
    Ji Min Han, Ji Cheol Bae, Hye In Kim, Sam Kwon, Min Ji Jeon, Won Gu Kim, Tae Yong Kim, Young Kee Shong, Won Bae Kim
    Endocrinology and Metabolism.2018; 33(4): 459.     CrossRef
  • Prognosis of Differentiated Thyroid Carcinoma with Initial Distant Metastasis: A Multicenter Study in Korea
    Hosu Kim, Hye In Kim, Sun Wook Kim, Jaehoon Jung, Min Ji Jeon, Won Gu Kim, Tae Yong Kim, Hee Kyung Kim, Ho-Cheol Kang, Ji Min Han, Yoon Young Cho, Tae Hyuk Kim, Jae Hoon Chung
    Endocrinology and Metabolism.2018; 33(2): 287.     CrossRef
  • Decreasing Disease-Specific Mortality of Differentiated Thyroid Cancer in Korea: A Multicenter Cohort Study
    Min Ji Jeon, Hee Kyung Kim, Eun Heui Kim, Eun Sook Kim, Hyon-Seung Yi, Tae Yong Kim, Ho-Cheol Kang, Young Kee Shong, Won Bae Kim, Bo Hyun Kim, Won Gu Kim
    Thyroid.2018; 28(9): 1121.     CrossRef
  • Active Surveillance of Low-Risk Papillary Thyroid Microcarcinoma: A Multi-Center Cohort Study in Korea
    Hye-Seon Oh, Jeonghoon Ha, Hye In Kim, Tae Hyuk Kim, Won Gu Kim, Dong-Jun Lim, Tae Yong Kim, Sun Wook Kim, Won Bae Kim, Young Kee Shong, Jae Hoon Chung, Jung Hwan Baek
    Thyroid.2018; 28(12): 1587.     CrossRef
Close layer
Thyroid Stimulating Hormone Reference Range and Prevalence of Thyroid Dysfunction in the Korean Population: Korea National Health and Nutrition Examination Survey 2013 to 2015
Won Gu Kim, Won Bae Kim, Gyeongji Woo, Hyejin Kim, Yumi Cho, Tae Yong Kim, Sun Wook Kim, Myung-Hee Shin, Jin Woo Park, Hai-Lin Park, Kyungwon Oh, Jae Hoon Chung
Endocrinol Metab. 2017;32(1):106-114.   Published online January 23, 2017
DOI: https://doi.org/10.3803/EnM.2017.32.1.106
Correction in: Endocrinol Metab 2023;38(3):357
  • 13,528 View
  • 243 Download
  • 83 Web of Science
  • 89 Crossref
AbstractAbstract PDFPubReader   
Background

No nationwide epidemiological study evaluating the prevalence of subclinical and overt forms of hypothyroidism and hyperthyroidism has yet been conducted in Korea. This study aimed to evaluate the reference range of serum thyroid stimulating hormone (TSH) and the national prevalence of thyroid dysfunctions in Korea.

Methods

Nation-wide cross-sectional data were analyzed from a representative sample of the civilian, non-institutionalized Korean population (n=6,564) who underwent blood testing for thyroid function and anti-thyroid peroxidase antibody (TPOAb) as part of the Korea National Health and Nutrition Examination Survey VI (2013 to 2015).

Results

The reference interval of serum TSH in the Korean reference population was 0.62 to 6.68 mIU/L. Based on this reference interval, the prevalence of overt and subclinical hypothyroidism was 0.73% (males 0.40%, females 1.10%) and 3.10% (males 2.26%, females 4.04%), respectively. The prevalence of hypothyroidism increased with age until the age group between 50 to 59 years. Positive TPOAb were found in 7.30% of subjects (males 4.33%, females 10.62%). The prevalence of overt and subclinical hypothyroidism TPOAb-positive subjects was 5.16% and 10.88%, respectively. The prevalence of overt and subclinical hyperthyroidism was 0.54% (males 0.30%, females 0.81%) and 2.98% (males 2.43%, females, 3.59%), respectively.

Conclusion

The Serum TSH reference levels in the Korean population were higher than the corresponding levels in Western countries. Differences were found in the prevalence of hypothyroidism and hyperthyroidism according to age, sex, and TPOAb positivity. This study provides important baseline information for understanding patterns of thyroid dysfunction and diseases in Korea.

Citations

Citations to this article as recorded by  
  • Lifetime Atopic Dermatitis is Associated With Risk of Autoimmune Thyroid Disease: Evidence From a Nationwide Study
    Taehun Kim, Haeun Kim, Wonjin Lee, Jinhee Kim, Hyungryul Lim, Seri Hong, Young-Min Ye
    Allergy, Asthma & Immunology Research.2026; 18(1): 145.     CrossRef
  • The Impact of Physical Activity on Thyroid Health: Insights From Representative Data in Korea
    Jeongmin Lee, Han-Sang Baek, Kwanhoon Jo, Min-Hee Kim, Jung Min Lee, Sang Ah Chang, Dong-Jun Lim
    The Journal of Clinical Endocrinology & Metabolism.2025; 110(3): e717.     CrossRef
  • Metabolic and Endocrine Correlates of Subclinical Hypothyroidism in Young Adults With First-Episode and Drug-Naive Major Depressive Disorder
    ZhaoXuan Shang, ChunQing Fang, XiaoE. Lang, Xiangyang Zhang
    Journal of the Academy of Consultation-Liaison Psychiatry.2025; 66(1): 13.     CrossRef
  • The Role of the Parametric Thyroid Feedback Quantile Index in Cardiovascular Risk Evaluation Among Euthyroid Koreans
    Hun Jee Choe, Yun Mi Choi, Yeonjung Ha, Jinseob Kim, Minhyuk Kim, Ho Jin Cha, Jiwoo Lee, Mi Kyung Kwak, Eun-Gyoung Hong
    The Journal of Clinical Endocrinology & Metabolism.2025; 110(10): e3401.     CrossRef
  • Low Thyrotropin Levels Are Associated With an Increased Risk of Atherosclerotic Cardiovascular Disease in Euthyroid Individuals: The Korea National Health and Nutrition Examination Survey 2013–2015
    Jin-Woo Kim, Han-Joon Bae, Jun Sung Moon, Sung-Woo Kim
    Journal of Lipid and Atherosclerosis.2025; 14(2): 236.     CrossRef
  • Non-linear associations between exposure to a mixture of per- and polyfluoroalkyl substances and thyroid hormone levels in Korean adults
    Seung Min Chung, Ji-Hyeon Cha, Young-Heun Jung, Ju-Hyun Kim, Jun Sung Moon, Kyu Chang Won
    Environment International.2025; 201: 109585.     CrossRef
  • Prevalence of Subclinical Hypothyroidism in Information Technology Professionals With High Screen Exposure
    Subha Lakshmanan, Mohamed Nasrul Ariffin, Siiriin Shahul Hameed Sahib, Thirumeni Aravazhi, Thosit Krishnaa Arunagiri Adikesavan, Nancy Elizabeth Samuel
    Cureus.2025;[Epub]     CrossRef
  • Role of thyroid autoimmunity independent of thyroid hormone levels in pulmonary function decline: A population-based study in euthyroid adults
    Kyung-Hun Sung, Jeongeun Kwak, Mee Kyung Kim, Dong-Jun Lim, Jung-Min Lee, Sang-Ah Chang, Jeongmin Lee, Aamir Ijaz
    PLOS One.2025; 20(12): e0336920.     CrossRef
  • Iodine Intake and Risk of Mortality: Evidence from a Nationally Representative Korean Cohort
    Jung-Hwan Cho, Jun Young Kim, Nak Gyeong Ko, Hanaro Park, Byung Soo Kwan, Ji Min Han, Sunghwan Suh, Ji Cheol Bae, Tae Hyuk Kim, Sun Wook Kim, Jae Hoon Chung, Hye Rang Bak, Hye In Kim
    Nutrients.2025; 17(24): 3859.     CrossRef
  • Deciphering the roles of triiodothyronine (T3) and thyroid-stimulating hormone (TSH) on cardiac electrical remodeling in clinical and experimental hypothyroidism
    Oscar Casis, Leire Echeazarra, Beatriz Sáenz-Díez, Mónica Gallego
    Journal of Physiology and Biochemistry.2024; 80(1): 1.     CrossRef
  • Associations between short-term exposure to air pollution and thyroid function in a representative sample of the Korean population
    Kyoung-Nam Kim, SoHyun Park, Junseo Choi, Il-Ung Hwang
    Environmental Research.2024; 252: 119018.     CrossRef
  • Association between ambient temperature and thyroid-stimulating hormone and free thyroxine levels in Korean euthyroid adults
    Jisun Sung, Jong-Hun Kim
    Environmental Research.2024; 262: 119918.     CrossRef
  • Subclinical thyroid dysfunction and chronic kidney disease: a nationwide population-based study
    Hye Jeong Kim, Sang Joon Park, Hyeong Kyu Park, Dong Won Byun, Kyoil Suh, Myung Hi Yoo
    BMC Nephrology.2023;[Epub]     CrossRef
  • Association between iodine intake and metabolic syndrome in euthyroid adult in an iodine-replete area: a nationwide population-based study
    Hye Jeong Kim, Suyeon Park, Sang Joon Park, Hyeong Kyu Park, Dong Won Byun, Kyoil Suh, Myung Hi Yoo
    Endocrine Journal.2023; 70(4): 393.     CrossRef
  • 2023 Korean Thyroid Association Management Guidelines for Patients with Subclinical Hypothyroidism
    Hyun Kyung Chung, Eu Jeong Ku, Won Sang Yoo, Yea Eun Kang, Kyeong Jin Kim, Bo Hyun Kim, Tae-Yong Kim, Young Joo Park, Chang Ho Ahn, Jee Hee Yoon, Eun Kyung Lee, Jong Min Lee, Eui Dal Jung, Jae Hoon Chung, Yun Jae Chung, Won Bae Kim, Ka Hee Yi, Ho-Cheol Ka
    International Journal of Thyroidology.2023; 16(1): 32.     CrossRef
  • The Current Status of Hyperthyroidism in Korea
    Hyemi Kwon
    Endocrinology and Metabolism.2023; 38(4): 392.     CrossRef
  • Management of Subclinical Hypothyroidism: A Focus on Proven Health Effects in the 2023 Korean Thyroid Association Guidelines
    Eu Jeong Ku, Won Sang Yoo, Hyun Kyung Chung
    Endocrinology and Metabolism.2023; 38(4): 381.     CrossRef
  • Association between shift work and the risk of hypothyroidism in adult male workers in Korea: a cohort study
    Seonghyeon Kwon, Yesung Lee, Eunhye Seo, Daehoon Kim, Jaehong Lee, Youshik Jeong, Jihoon Kim, Jinsook Jeong, Woncheol Lee
    Annals of Occupational and Environmental Medicine.2023;[Epub]     CrossRef
  • Depressão e hipotireoidismo: Uma revisão sistemática
    Eduarda Silva Souza, Rosangela Soares Chriguer, Maria Cristina Mazzaia
    Revista Portuguesa de Investigação Comportamental e Social.2023;[Epub]     CrossRef
  • Comparison of Thyroid-Stimulating Hormone Results from Eight Different Reagents and Assay-Specific Korean Reference Interval for Subclinical Hypothyroidism Treatment
    Won Sang Yoo, Sollip Kim, Young Joo Park, Sang Hoon Song, Kyunghoon Lee, Eun Kyung Lee, Jehoon Lee, Ho-Young Lee, Yun Jae Chung, Hyun Kyung Chung, Jin Chul Paeng, Minje Han, Ho-Cheol Kang
    International Journal of Thyroidology.2023; 16(2): 166.     CrossRef
  • Comparison of Five Different Criteria for Diagnosis of Subclinical Hypothyroidism in a Large-Scale Chinese Population
    Yan-song Zheng, Sheng-yong Dong, Yan Gong, Jia-hong Wang, Fei Wang, Qiang Zeng
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
  • Association of thyroid autoimmunity with nonalcoholic fatty liver disease in euthyroid middle‐aged subjects: A population‐based study
    Hye Jeong Kim, Sang Joon Park, Hyeong Kyu Park, Dong Won Byun, Kyoil Suh, Myung Hi Yoo
    Journal of Gastroenterology and Hepatology.2022; 37(8): 1617.     CrossRef
  • Heart Failure and Stroke Risks in Users of Liothyronine With or Without Levothyroxine Compared with Levothyroxine Alone: A Propensity Score-Matched Analysis
    Wook Yi, Bo Hyun Kim, Mijin Kim, Jinmi Kim, Myungsoo Im, Soree Ryang, Eun Heui Kim, Yun Kyung Jeon, Sang Soo Kim, In Joo Kim
    Thyroid.2022; 32(7): 764.     CrossRef
  • Association of free thyroxine with obstructive lung pattern in euthyroid middle-aged subjects: A population-based study
    Hye Jeong Kim, Sang Joon Park, Hyeong Kyu Park, Dong Won Byun, Kyoil Suh, Myung Hi Yoo, Dong Keon Yon
    PLOS ONE.2022; 17(7): e0270126.     CrossRef
  • Long working hours and the risk of hypothyroidism in healthy Korean workers: a cohort study
    Yesung Lee, Woncheol Lee, Hyoung-Ryoul Kim
    Epidemiology and Health.2022; 44: e2022104.     CrossRef
  • Association of breastfeeding with thyroid function and autoimmunity in postmenopausal women
    Sung-Woo Kim, Ji-Hyun Lee, Ho-Sang Shon, Eonju Jeon, Tae-Yong Kim
    Endocrine.2021; 71(1): 130.     CrossRef
  • Distributions of serum thyroid-stimulating hormone in 2020 thyroid disease-free adults from areas with different iodine levels: a cross-sectional survey in China
    B. Ren, S. Wan, L. Liu, M. Qu, H. Wu, H. Shen
    Journal of Endocrinological Investigation.2021; 44(5): 1001.     CrossRef
  • Low Thyroid-stimulating Hormone Levels Are Associated With Annoying Tinnitus in Adult Women: Korea National Health and Nutrition Examination Surveys
    So Young Kim, Chanyang Min, Hyung-Jong Kim, Hyo Geun Choi
    Otology & Neurotology.2021; 42(4): e408.     CrossRef
  • Risk of All-Cause Mortality in Levothyroxine-Treated Hypothyroid Patients: A Nationwide Korean Cohort Study
    Seo Young Sohn, Gi Hyeon Seo, Jae Hoon Chung
    Frontiers in Endocrinology.2021;[Epub]     CrossRef
  • Decreased Expression of Ileal Thyroid Hormone Transporters in a Hypothyroid Patient: A Case Report
    Chae Won Chung, Eun Young Mo, Gyung Seo Jung, Yoo Hyung Kim, Sun Wook Cho, Do Joon Park, Jeong Mo Bae, Young Joo Park
    Frontiers in Endocrinology.2021;[Epub]     CrossRef
  • Korea National Health and Nutrition Examination Survey, 20th anniversary: accomplishments and future directions
    Kyungwon Oh, Yoonjung Kim, Sanghui Kweon, Soyeon Kim, Sungha Yun, Suyeon Park, Yeon-Kyeng Lee, Youngtaek Kim, Ok Park, Eun Kyeong Jeong
    Epidemiology and Health.2021; 43: e2021025.     CrossRef
  • Association between triglyceride-glucose index and thyroid function in euthyroid adults: The Korea National Health and Nutritional Examination Survey 2015
    Wonsuk Choi, Ji Yong Park, A. Ram Hong, Jee Hee Yoon, Hee Kyung Kim, Ho-Cheol Kang, Sun Young Lee
    PLOS ONE.2021; 16(7): e0254630.     CrossRef
  • Association between Subclinical Hypothyroidism and Incident Hypertension in Women: A Systematic Review and Meta-Analysis
    Jean Kim, Narut Prasitlumkum, Sandeep Randhawa, Dipanjan Banerjee
    Journal of Clinical Medicine.2021; 10(15): 3318.     CrossRef
  • Sex Difference in the Association between Sleep Duration and Thyroid Disease among South Korean Adults
    Jeong Hyun Ahn, Jin Young Nam, Soojin Park
    Journal of Health Informatics and Statistics.2021; 46(3): 337.     CrossRef
  • The Association between the Dietary Inflammatory Index and Thyroid Function in U.S. Adult Males
    Nuozhou Liu, Fang Ma, Ying Feng, Xue Ma
    Nutrients.2021; 13(10): 3330.     CrossRef
  • T4+T3 Combination Therapy: An Unsolved Problem of Increasing Magnitude and Complexity
    Wilmar M. Wiersinga
    Endocrinology and Metabolism.2021; 36(5): 938.     CrossRef
  • Association between thyroid hormones and insulin resistance indices based on the Korean National Health and Nutrition Examination Survey
    Yun Mi Choi, Min Kyung Kim, Mi Kyung Kwak, Dooman Kim, Eun-Gyoung Hong
    Scientific Reports.2021;[Epub]     CrossRef
  • Implication of thyroid function in periodontitis: a nationwide population-based study
    Eyun Song, Min Jeong Park, Jung A. Kim, Eun Roh, Ji Hee Yu, Nam Hoon Kim, Hye Jin Yoo, Ji A. Seo, Sin Gon Kim, Nan Hee Kim, Sei Hyun Baik, Kyung Mook Choi
    Scientific Reports.2021;[Epub]     CrossRef
  • Association between thyroid hormone and components of metabolic syndrome in euthyroid Korean adults
    Kyung A. Shin, Eun Jae Kim
    Medicine.2021; 100(51): e28409.     CrossRef
  • Association between Serum Free Thyroxine and Anemia in Euthyroid Adults: A Nationwide Study
    Mijin Kim, Bo Hyun Kim, Hyungi Lee, Min Hee Jang, Jeong Mi Kim, Eun Heui Kim, Yun Kyung Jeon, Sang Soo Kim, In Joo Kim
    Endocrinology and Metabolism.2020; 35(1): 106.     CrossRef
  • Unmet Clinical Needs in the Treatment of Patients with Thyroid Cancer
    Won Bae Kim, Min Ji Jeon, Won Gu Kim, Tae Yong Kim, Young Kee Shong
    Endocrinology and Metabolism.2020; 35(1): 14.     CrossRef
  • Long Work Hours Are Associated with Hypothyroidism: A Cross-Sectional Study with Population-Representative Data
    Young Ki Lee, Dong-eun Lee, Yul Hwangbo, You Jin Lee, Hyeon Chang Kim, Eun Kyung Lee
    Thyroid.2020; 30(10): 1432.     CrossRef
  • Subclinical thyroid dysfunction, bone mineral density, and osteoporosis in a middle-aged Korean population
    K. Lee, S. Lim, H. Park, H.Y. Woo, Y. Chang, E. Sung, H.S. Jung, K.E. Yun, C.W. Kim, S. Ryu, M.J. Kwon
    Osteoporosis International.2020; 31(3): 547.     CrossRef
  • Update on Thyroid Hormone Levels and Thyroid Dysfunction in the Korean Population Based on Data from the Korea National Health and Nutrition Examination Survey VI (2013 to 2015)
    Jae Hoon Chung
    Endocrinology and Metabolism.2020; 35(1): 7.     CrossRef
  • Assessment of the relationship between knee ultrasound and clinical symptoms in patients with thyroid dysfunction
    Bo Young Kim, Sung-Soo Kim, Hyeong Kyu Park, Hyun-Sook Kim
    Journal of International Medical Research.2020;[Epub]     CrossRef
  • Association between urinary sodium levels and iodine status in Korea
    Jonghwa Ahn, Jang Ho Lee, Jiwoo Lee, Ji Yeon Baek, Eyun Song, Hye-Seon Oh, Mijin Kim, Suyeon Park, Min Ji Jeon, Tae Yong Kim, Won Bae Kim, Young Kee Shong, Won Gu Kim
    The Korean Journal of Internal Medicine.2020; 35(2): 392.     CrossRef
  • Association of Thyroid Status with Health-Related Quality of Life in Korean Older Adults
    Minjung Han, Seulggie Choi, Sarang Kim, Ahryoung Ko, Joung Sik Son, Sang Min Park
    Korean Journal of Family Medicine.2020; 41(1): 38.     CrossRef
  • High neutrophil-to-lymphocyte ratio is associated with relapse in Graves’ disease after antithyroid drug therapy
    Mijin Kim, Bo Hyun Kim, Min Hee Jang, Jeong Mi Kim, Eun Heui Kim, Yun Kyung Jeon, Sang Soo Kim, In Joo Kim
    Endocrine.2020; 67(2): 406.     CrossRef
  • Sex differences in subclinical hypothyroidism and associations with metabolic risk factors: a health examination-based study in mainland China
    Li Jiang, Jinman Du, Weizhu Wu, Jianjiang Fang, Jufang Wang, Jinhua Ding
    BMC Endocrine Disorders.2020;[Epub]     CrossRef
  • Association between Serum Free Thyroxine and Anemia in Euthyroid Adults: A Nationwide Study (Endocrinol Metab 2020;35:106-14, Mijin Kim et al.)
    Mijin Kim, Bo Hyun Kim
    Endocrinology and Metabolism.2020; 35(3): 669.     CrossRef
  • Urinary Iodine Concentration and Thyroid Peroxidase Antibodies in the Korean Population Using Korea National Health and Nutrition Examination Survey VI
    Myung-Chul Chang
    International Journal of Thyroidology.2020; 13(2): 155.     CrossRef
  • Recent Issues Related to Thyroid Disease in Pregnancy
    Jae Hoon Chung
    International Journal of Thyroidology.2020; 13(2): 85.     CrossRef
  • Epidemiology of thyroid disorders in the Lifelines Cohort Study (the Netherlands)
    Hanneke J. C. M. Wouters, Sandra N. Slagter, Anneke C. Muller Kobold, Melanie M. van der Klauw, Bruce H. R. Wolffenbuttel, Silvia Naitza
    PLOS ONE.2020; 15(11): e0242795.     CrossRef
  • Hipertiroidi Hastalarında Tedavi Öncesi ve Sonrası Trombosit/Lenfosit ve Nötrofil/Lenfosit Oranlarının Değerlendirilmesi
    Çiğdem CİNDOĞLU, Mehmet GÜLER, Mehmet Ali EREN, Tevfik SABUNCU
    Harran Üniversitesi Tıp Fakültesi Dergisi.2020; 17(1): 104.     CrossRef
  • Association between Sleep Duration and Subclinical Thyroid Dysfunction Based on Nationally Representative Data
    Woojun Kim, Jeongmin Lee, Jeonghoon Ha, Kwanhoon Jo, Dong-Jun Lim, Jung-Min Lee, Sang-Ah Chang, Moo-Il Kang, Min-Hee Kim
    Journal of Clinical Medicine.2019; 8(11): 2010.     CrossRef
  • High Normal Range of Free Thyroxine is Associated with Decreased Triglycerides and with Increased High-Density Lipoprotein Cholesterol Based on Population Representative Data
    Jeongmin Lee, Jeonghoon Ha, Kwanhoon Jo, Dong-Jun Lim, Jung-Min Lee, Sang-Ah Chang, Moo-Il Kang, Min-Hee Kim
    Journal of Clinical Medicine.2019; 8(6): 758.     CrossRef
  • Association High-Iodine-Containing Seaweed Soup Consumption after Birth and Subclinical Hypothyroidism in Korean Women: Korea National Health and Nutrition Examination Survey IV (2013–2015)
    Hyunsam Kim, Ha Ni Lee, Jeonghoon Ha
    International Journal of Thyroidology.2019; 12(2): 105.     CrossRef
  • Reference Range and Sociodemographic Characteristics of TSH among Reproductive Age Women in Rural China
    Qiang Su, Shikun Zhang, Mei Hu, Qiaomei Wang, Na Liu, Haiping Shen, Yiping Zhang, Man Zhang
    Biological Trace Element Research.2019; 189(2): 336.     CrossRef
  • Prevalence of Thyroid Disease in Patients Surgically Treated for Pituitary Disease
    Daham Kim, Yongin Cho, Cheol Ryong Ku, Hyein Jung, Ju Hyung Moon, Eui Hyun Kim, Dong Yeob Shin, Sun Ho Kim, Eun Jig Lee
    Journal of Clinical Medicine.2019; 8(8): 1142.     CrossRef
  • Thyroid Dysfunction in Patients with Antineutrophil Cytoplasmic Antibody–associated Vasculitis: A Monocentric Retrospective Study
    JAE YEON KIM, YONG-BEOM PARK, SANG-WON LEE
    The Journal of Rheumatology.2019; 46(9): 1248.     CrossRef
  • Thyroid dysfunction in patients with suspected or documented supraventricular tachyarrhythmia
    Hye Bin Gwag, Ji Eun Jun, Youngjun Park, Seong Soo Lee, Seung-Jung Park, June Soo Kim, Kyoung-Min Park, Young Keun On
    International Journal of Arrhythmia.2019;[Epub]     CrossRef
  • Association between Iodine Nutrition Status and Thyroid Disease-Related Hormone in Korean Adults: Korean National Health and Nutrition Examination Survey VI (2013–2015)
    Sohye Kim, Yong Seok Kwon, Ju Young Kim, Kyung Hee Hong, Yoo Kyoung Park
    Nutrients.2019; 11(11): 2757.     CrossRef
  • Thyroid-stimulating hormone levels in the normal range and incident type 2 diabetes mellitus
    T. I. de Vries, L. J. Kappelle, Y. van der Graaf, H. W. de Valk, G. J. de Borst, H. M. Nathoe, F. L. J. Visseren, Jan Westerink
    Acta Diabetologica.2019; 56(4): 431.     CrossRef
  • The Association between Low Vitamin D Status and Autoimmune Thyroid Disease in Korean Premenopausal Women: The 6th Korea National Health and Nutrition Examination Survey, 2013–2014
    Choon-Young Kim, Yeon Ji Lee, Ji-Ho Choi, Soo Yeon Lee, Hye Young Lee, Da Hye Jeong, Yeon Jun Choi
    Korean Journal of Family Medicine.2019; 40(5): 323.     CrossRef
  • Associations between urine iodine and allergic diseases in the Korean National Health and Nutrition Examination Survey 2013–2015: A STROBE-compliant article
    Young Bok Lee, Ji hyun Lee, Min Ji Kang, Dong Soo Yu, Kyung Do Han, Yong Gyu Park
    Phytomedicine.2019; 62: 152937.     CrossRef
  • The Relationship between Thyroid Function and Different Obesity Phenotypes in Korean Euthyroid Adults
    Jeong Mi Kim, Bo Hyun Kim, Hyungi Lee, Eun Heui Kim, Mijin Kim, Jong Ho Kim, Yun Kyung Jeon, Sang Soo Kim, In Joo Kim, Yong Ki Kim
    Diabetes & Metabolism Journal.2019; 43(6): 867.     CrossRef
  • Sex-Dependent Association between Weight Change and Thyroid Dysfunction: Population-Level Analysis Using the Korean National Health and Nutrition Examination Survey
    Eyun Song, Jonghwa Ahn, Hye-Seon Oh, Min Ji Jeon, Won Gu Kim, Won Bae Kim, Young Kee Shong, Tae Yong Kim
    European Thyroid Journal.2019; 8(4): 202.     CrossRef
  • Subclinical Hypothyroidism: is it Really Subclinical with Aging?
    Robin Gourmelon, Sandrine Donadio-Andréi, Karim Chikh, Muriel Rabilloud, Elisabetta Kuczewski, Anne-Sophie Gauchez, Anne Charrié, Pierre-Yves Brard, Raphaëlle Andréani, Jean-Cyril Bourre, Christine Waterlot, Domitille Guédel, Anne Mayer, Emmanuel Disse, C
    Aging and disease.2019; 10(3): 520.     CrossRef
  • Serum thyroid‐stimulating hormone levels and smoking status: Data from the Korean National Health and Nutrition Examination Survey VI
    Suyeon Park, Won Gu Kim, Min Ji Jeon, Mijin Kim, Hye‐Seon Oh, Minkyu Han, Tae Yong Kim, Young Kee Shong, Won Bae Kim
    Clinical Endocrinology.2018; 88(6): 969.     CrossRef
  • Sex-specific genetic influence on thyroid-stimulating hormone and free thyroxine levels, and interactions between measurements: KNHANES 2013–2015
    Young Ki Lee, Dong Yeob Shin, Hyejung Shin, Eun Jig Lee, Silvia Naitza
    PLOS ONE.2018; 13(11): e0207446.     CrossRef
  • Ten Years of the Korean Thyroid Association: Achievement and Future
    Young Joo Park, Young Shin Song, Ka Hee Yi
    International Journal of Thyroidology.2018; 11(1): 1.     CrossRef
  • Association between diffuse lymphocytic infiltration and papillary thyroid cancer aggressiveness according to the presence of thyroid peroxidase antibody and BRAFV600E mutation
    Young Ki Lee, Kyeong Hye Park, Se Hee Park, Kwang Joon Kim, Dong Yeob Shin, Kee Hyun Nam, Woong Youn Chung, Eun Jig Lee
    Head & Neck.2018; 40(10): 2271.     CrossRef
  • Prevalence and Annual Incidence of Thyroid Disease in Korea from 2006 to 2015: A Nationwide Population-Based Cohort Study
    Hyemi Kwon, Jin-hyung Jung, Kyung-Do Han, Yong-Gyu Park, Jung-Hwan Cho, Da Young Lee, Ji Min Han, Se Eun Park, Eun-Jung Rhee, Won-Young Lee
    Endocrinology and Metabolism.2018; 33(2): 260.     CrossRef
  • Evaluation of Thyroid Hormone Levels and Urinary Iodine Concentrations in Koreans Based on the Data from Korea National Health and Nutrition Examination Survey VI (2013 to 2015)
    Jae Hoon Chung
    Endocrinology and Metabolism.2018; 33(2): 160.     CrossRef
  • Thyroid-Stimulating Hormone Reference Ranges in the First Trimester of Pregnancy in an Iodine-Sufficient Country
    Carmen Castillo, Nicole Lustig, Paula Margozzini, Andrea Gomez, María Paulina Rojas, Santiago Muzzo, Lorena Mosso
    Endocrinology and Metabolism.2018; 33(4): 466.     CrossRef
  • Male-specific association between subclinical hypothyroidism and the risk of non-alcoholic fatty liver disease estimated by hepatic steatosis index: Korea National Health and Nutrition Examination Survey 2013 to 2015
    Jeongmin Lee, Jeonghoon Ha, Kwanhoon Jo, Dong-Jun Lim, Jung-Min Lee, Sang-Ah Chang, Moo-Il Kang, Bong-Yun Cha, Min-Hee Kim
    Scientific Reports.2018;[Epub]     CrossRef
  • Sex differences in risk factors for subclinical hypothyroidism
    Jeonghoon Ha, Jeongmin Lee, Kwanhoon Jo, Dong-Jun Lim, Moo Il Kang, Bong Yun Cha, Min-Hee Kim
    Endocrine Connections.2018; 7(4): 511.     CrossRef
  • Associations of Urinary Cotinine-Verified Active and Passive Smoking with Thyroid Function: Analysis of Population-Based Nationally Representative Data
    Jihun Kang, Eunhee Kong, Jongsoon Choi
    Thyroid.2018; 28(5): 583.     CrossRef
  • Establishment of Korean Thyroid Association-10 Years of Development in Internal Medicine
    Jae Hoon Chung
    International Journal of Thyroidology.2018; 11(1): 7.     CrossRef
  • Association between subclinical thyroid dysfunction and depressive symptoms in the Korean adult population: The 2014 Korea National Health and Nutrition Examination Survey
    Jae Won Hong, Jung Hyun Noh, Dong-Jun Kim, Osama Ali Abulseoud
    PLOS ONE.2018; 13(8): e0202258.     CrossRef
  • Association Between Thyroid Dysfunction and Lipid Profiles Differs According to Age and Sex: Results from the Korean National Health and Nutrition Examination Survey
    Hye-Seon Oh, Hyemi Kwon, Jonghwa Ahn, Eyun Song, Suyeon Park, Mijin Kim, Minkyu Han, Min Ji Jeon, Won Gu Kim, Won Bae Kim, Young Kee Shong, Eun-Jung Rhee, Tae Yong Kim
    Thyroid.2018; 28(7): 849.     CrossRef
  • The Relationship between Subclinical Thyroid Disease and Cardiovascular Disease Risk Score in Koreans
    Hee Joong Lim, Seong Hee Ahn, Seongbin Hong, Young Ju Suh
    Journal of Korean Medical Science.2017; 32(10): 1626.     CrossRef
  • Changes in standardized mortality rates from thyroid cancer in Korea between 1985 and 2015: Analysis of Korean national data
    Yun Mi Choi, Won Gu Kim, Hyemi Kwon, Min Ji Jeon, Minkyu Han, Tae Yong Kim, Young Kee Shong, Sang Mo Hong, Eun‐Gyoung Hong, Won Bae Kim
    Cancer.2017; 123(24): 4808.     CrossRef
  • Response: Thyroid Stimulating Hormone Reference Range and Prevalence of Thyroid Dysfunction in the Korean Population: Korea National Health and Nutrition Examination Survey 2013 to 2015 (Endocrinol Metab 2017;32:106-14, Won Gu Kim et al.)
    Won Gu Kim, Jae Hoon Chung
    Endocrinology and Metabolism.2017; 32(2): 304.     CrossRef
  • Excessive Iodine Intake and Thyrotropin Reference Interval: Data from the Korean National Health and Nutrition Examination Survey
    Min Ji Jeon, Won Gu Kim, Hyemi Kwon, Mijin Kim, Suyeon Park, Hye-Seon Oh, Minkyu Han, Tae Yong Kim, Young Kee Shong, Won Bae Kim
    Thyroid.2017; 27(7): 967.     CrossRef
  • Subclinical thyroid dysfunction and risk of carotid atherosclerosis
    Hosu Kim, Tae Hyuk Kim, Hye In Kim, So Young Park, Young Nam Kim, Seonwoo Kim, Min-Ji Kim, Sang-Man Jin, Kyu Yeon Hur, Jae Hyeon Kim, Moon-Kyu Lee, Yong-Ki Min, Jae Hoon Chung, Mira Kang, Sun Wook Kim, Tatsuo Shimosawa
    PLOS ONE.2017; 12(7): e0182090.     CrossRef
  • Letter: Thyroid Stimulating Hormone Reference Range and Prevalence of Thyroid Dysfunction in the Korean Population: Korea National Health and Nutrition Examination Survey 2013 to 2015 (Endocrinol Metab 2017;32:106-14, Won Gu Kim et al.)
    Young Ki Lee, Dong Yeob Shin
    Endocrinology and Metabolism.2017; 32(2): 302.     CrossRef
  • Vitamin D deficiency affects thyroid autoimmunity and dysfunction in iodine-replete area: Korea national health and nutrition examination survey
    Mijin Kim, Eyun Song, Hye-Seon Oh, Suyeon Park, Hyemi Kwon, Min Ji Jeon, Won Gu Kim, Won Bae Kim, Young Kee Shong, Tae Yong Kim
    Endocrine.2017; 58(2): 332.     CrossRef
  • Viral Hepatitis in South Korea
    Stella C Pak, Yaseen Alastal, Zubair Khan, Umar Darr
    Euroasian Journal of Hepato-Gastroenterology.2017; 7(2): 163.     CrossRef
Close layer
Clinical Study
Molecular Diagnosis Using Residual Liquid-Based Cytology Materials for Patients with Nondiagnostic or Indeterminate Thyroid Nodules
Hyemi Kwon, Won Gu Kim, Markus Eszlinger, Ralf Paschke, Dong Eun Song, Mijin Kim, Suyeon Park, Min Ji Jeon, Tae Yong Kim, Young Kee Shong, Won Bae Kim
Endocrinol Metab. 2016;31(4):586-591.   Published online November 4, 2016
DOI: https://doi.org/10.3803/EnM.2016.31.4.586
  • 7,427 View
  • 60 Download
  • 11 Web of Science
  • 12 Crossref
AbstractAbstract PDFPubReader   
Background

Molecular analysis for common somatic mutations in thyroid cancer can improve diagnostic accuracy of fine-needle aspiration cytology (FNAC) in the nondiagnostic or indeterminate category of thyroid nodules. In this study, we evaluated the feasibility of molecular diagnosis from residual liquid-based cytology (LBC) material after cytological diagnosis.

Methods

This prospective study enrolled 53 patients with thyroid nodules diagnosed as nondiagnostic, atypia of undetermined significance (AUS), or follicular lesion of undetermined significance (FLUS) after FNAC. DNAs and RNAs were isolated from residual LBC materials. BRAFV600E and RAS point mutations, PAX8/peroxisome proliferator-activated receptor γ (PPARγ), RET/PTC1, and RET/PTC3 rearrangements were evaluated by real-time polymerase chain reaction and pyrosequencing.

Results

All DNAs from 53 residual LBC samples could be analysed and point mutations were detected in 10 samples (19%). In 17 AUS nodules, seven samples (41%) had point mutations including BRAF (n=4), NRAS (n=2), and KRAS (n=1). In 20 FLUS nodules, three samples (15%) had NRAS point mutations. RNA from only one FLUS nodule could be analysed for rearrangements and there was no abnormality.

Conclusion

Molecular analysis for BRAF and RAS mutations was feasible in residual LBC materials and might be useful for diagnosis of indeterminate thyroid nodules.

Citations

Citations to this article as recorded by  
  • Kras Gene Analysis Using Liquid-Based Cytology Specimens Predicts Therapeutic Responses and Prognosis in Patients with Pancreatic Cancer
    Masahiro Itonaga, Reiko Ashida, Shin-Ichi Murata, Yasunobu Yamashita, Keiichi Hatamaru, Takashi Tamura, Yuki Kawaji, Yuudai Kayama, Tomoya Emori, Manabu Kawai, Hiroki Yamaue, Ibu Matsuzaki, Hirokazu Nagai, Yuichi Kinoshita, Ke Wan, Toshio Shimokawa, Masay
    Cancers.2022; 14(3): 551.     CrossRef
  • From Traditional Histology to Next-Generation Pathology: A Review of The Workflow for the Characterisation and Molecular Profiling of Non-Small Cell Lung Cancer Samples

    EMJ Oncology.2020;[Epub]     CrossRef
  • Preanalytic variables in quality and quantity of nucleic acids extracted from FNA specimens of thyroid gland nodules collected in CytoLyt: Cellularity and storage time
    Jonas J. Heymann, Lorene M. Yoxtheimer, Hyeon Jin Park, Evan M. Fernandez, Kirk E. Facey, Susan A. Alperstein, Hung V. Tran, Inji Baek, Theresa Scognamiglio, Hanna Rennert, Momin T. Siddiqui, Wei Song
    Cancer Cytopathology.2020; 128(9): 656.     CrossRef
  • Diagnostic accuracy of molecular testing with three molecular markers on thyroid fine‐needle aspiration cytology with abnormal category
    Hatice Seneldir, Gozde Kir, Tuce Soylemez, Rabia B. Girgin, Nurver Ozbay, Filiz Ozen, Handan Ankarali, Gurhan Bas, Orhan Alimoglu
    Diagnostic Cytopathology.2020; 48(6): 507.     CrossRef
  • Small but powerful: the promising role of small specimens for biomarker testing
    Qiong Gan, Sinchita Roy-Chowdhuri
    Journal of the American Society of Cytopathology.2020; 9(5): 450.     CrossRef
  • Centrifuged supernatants from FNA provide a liquid biopsy option for clinical next‐generation sequencing of thyroid nodules
    Wenrui Ye, Brette Hannigan, Stephanie Zalles, Meenakshi Mehrotra, Bedia A. Barkoh, Michelle D. Williams, Maria E. Cabanillas, Beth Edeiken‐Monroe, Peter Hu, Dzifa Duose, Ignacio I. Wistuba, L. Jeffrey Medeiros, John Stewart, Rajyalakshmi Luthra, Sinchita
    Cancer Cytopathology.2019; 127(3): 146.     CrossRef
  • Molecular testing of residual cytology samples: Rethink, reclaim, repurpose
    Sinchita Roy‐Chowdhuri
    Cancer Cytopathology.2019; 127(1): 15.     CrossRef
  • K-ras mutation analysis of residual liquid-based cytology specimens from endoscopic ultrasound-guided fine needle aspiration improves cell block diagnosis of pancreatic ductal adenocarcinoma
    Yoko Sekita-Hatakeyama, Takeshi Nishikawa, Mao Takeuchi, Kouhei Morita, Maiko Takeda, Kinta Hatakeyama, Tokiko Nakai, Tomoko Uchiyama, Hiroe Itami, Tomomi Fujii, Akira Mitoro, Masayuki Sho, Chiho Ohbayashi, Giancarlo Troncone
    PLOS ONE.2018; 13(3): e0193692.     CrossRef
  • Comparison of Immunohistochemistry and Direct Sanger Sequencing for Detection of theBRAFV600EMutation in Thyroid Neoplasm
    Hye-Seon Oh, Hyemi Kwon, Suyeon Park, Mijin Kim, Min Ji Jeon, Tae Yong Kim, Young Kee Shong, Won Bae Kim, Jene Choi, Won Gu Kim, Dong Eun Song
    Endocrinology and Metabolism.2018; 33(1): 62.     CrossRef
  • Next-Generation Sequencing Identifies Gene Mutations That Are Predictive of Malignancy in Residual Needle Rinses Collected From Fine-Needle Aspirations of Thyroid Nodules
    Maren Y. Fuller, Dina Mody, April Hull, Kristi Pepper, Heather Hendrickson, Randall Olsen
    Archives of Pathology & Laboratory Medicine.2018; 142(2): 178.     CrossRef
  • Articles inEndocrinology and Metabolismin 2016
    Won-Young Lee
    Endocrinology and Metabolism.2017; 32(1): 62.     CrossRef
  • Loss of c-KIT expression in thyroid cancer cells
    Sara Franceschi, Francesca Lessi, Federica Panebianco, Elena Tantillo, Marco La Ferla, Michele Menicagli, Paolo Aretini, Alessandro Apollo, Antonio Giuseppe Naccarato, Ivo Marchetti, Chiara Maria Mazzanti, Aamir Ahmad
    PLOS ONE.2017; 12(3): e0173913.     CrossRef
Close layer
Endocrine Research
Comparison of Thyroglobulin Measurements Using Three Different Immunoassay Kits: A BRAMHS Tg-Plus RIA Kit, a BRAMHS hTg Sensitive Kryptor Kit, and a Beckman Coulter ACCESS Immunoassay Kit
Mijin Kim, Min Ji Jeon, Won Gu Kim, Jong Jin Lee, Jin-Sook Ryu, Eun-Jung Cho, Dae-Hyun Ko, Woochang Lee, Sail Chun, Won-Ki Min, Tae Yong Kim, Young Kee Shong, Won Bae Kim
Endocrinol Metab. 2016;31(3):462-468.   Published online August 2, 2016
DOI: https://doi.org/10.3803/EnM.2016.31.3.462
  • 8,021 View
  • 59 Download
  • 10 Web of Science
  • 9 Crossref
AbstractAbstract PDFPubReader   
Background

Second-generation thyroglobulin immunometric assays (Tg-IMAs) have been developed with improved sensitivity. Our aim was to compare the diagnostic value of Tg-IMA measurements using a Kryptor (BRAHMS AG) kit (Tg-K) and an ACCESS (Beckman Coulter) kit (Tg-A) with that of the first-generation Tg measurement using a Tg-plus (BRAHMS AG) kit (Tg+).

Methods

We enrolled 82 differentiated thyroid cancer patients who underwent total thyroidectomy with radioactive iodine remnant ablation and who underwent diagnostic whole body scan using recombinant human thyroid stimulating hormone (rhTSH). The Tg+, Tg-K, and Tg-A were measured before rhTSH administration during levothyroxine treatment (suppressed Tg) from the same sample. Serum Tg+ was measured after rhTSH stimulation (stimulated Tg).

Results

Suppressed Tg+ was more significantly correlated with suppressed Tg-K (R2=0.919, P<0.001) than with suppressed Tg-A (R2=0.536, P<0.001). The optimal cut-off values of suppressed Tg+, Tg-K, and Tg-A for predicting stimulated Tg+ of 1 ng/mL were 0.3, 0.2, and 0.2 ng/mL, respectively. The sensitivity, specificity, and accuracy of suppressed Tg+ were 67%, 100%, and 90%, respectively; those of suppressed Tg-K were 83%, 90%, and 88%; those of suppressed Tg-A were 96%, 82%, and 87%, respectively. The positive predictive and negative predictive values of Tg+ were 100% and 87%, respectively; those of Tg-K were 79% and 92%; and those of Tg-A were 73% and 98%.

Conclusion

We could not clearly demonstrate which kit had better diagnostic performance after comparison of first-generation Tg measurements with Tg-IMA measurements. Also, there were kit-to-kit variations between Tg-IMA kits. Suppressed Tg measured by Tg-IMA was insufficient to completely substitute for a stimulated Tg measurement.

Citations

Citations to this article as recorded by  
  • A deep dive into four thyroglobulin immunoassays from analytical perspective
    Tuba Saadet Deveci Bulut, Muhittin Abdulkadir Serdar, Mehmet Muhittin Yalçın, Meriç Coşkun, Aylar Poyraz, Seda Gökgöz Acar, Gizem Yaz Aydın, Özlem Gülbahar
    Scandinavian Journal of Clinical and Laboratory Investigation.2025; 85(2): 148.     CrossRef
  • Revisiting Thyroglobulin Measurement: Current Methods and Future Perspectives Using Dried Blood Spot Sampling for Enhanced Clinical Practice
    Nicole Monza, Claudia Fumagalli, Lisa Pagani, Natalia Shelly Porto, Felisia Di Nicoli, Clizia Chinello, Simone Serrao, Eleonora Bossi, Marta Nobile, Fabio Pagni, Fulvio Magni, Vanna Denti
    Metabolites.2025; 15(12): 769.     CrossRef
  • Comparison of the diagnostic performances of US-guided fine needle aspiration cytology and thyroglobulin measurement for lymph node metastases in patients with differentiated thyroid carcinoma: a meta-analysis
    Rong-Bin Liu, Da-Lei Zhou, Bo-Heng Xu, Xin-Hua Yang, Qing Liu, Xiao Zhang, Tao Tang, Zu-Lu Ye, Yue Li
    European Radiology.2021; 31(5): 2903.     CrossRef
  • Preoperative Serum Thyroglobulin and Its Correlation with the Burden and Extent of Differentiated Thyroid Cancer
    Hosu Kim, So Young Park, Jun-Ho Choe, Jee Soo Kim, Soo Yeon Hahn, Sun Wook Kim, Jae Hoon Chung, Jaehoon Jung, Tae Hyuk Kim
    Cancers.2020; 12(3): 625.     CrossRef
  • Estimating the Growth Rate of Lung Metastases in Differentiated Thyroid Carcinoma: Response Evaluation Criteria in Solid Tumors or Doubling Time?
    Eyun Song, Jonghwa Ahn, Min Ji Jeon, Sang Min Lee, Jeong Hyun Lee, Tae Yong Kim, Jung Hwan Baek, Won Bae Kim, Young Kee Shong, Won Gu Kim
    Thyroid.2020; 30(3): 418.     CrossRef
  • Impact of delayed radioiodine therapy in intermediate‐/high‐risk papillary thyroid carcinoma
    Mijin Kim, Minkyu Han, Min Ji Jeon, Won Gu Kim, In Joo Kim, Jin‐Sook Ryu, Won Bae Kim, Young Kee Shong, Tae Yong Kim, Bo Hyun Kim
    Clinical Endocrinology.2019; 91(3): 449.     CrossRef
  • Tertiary Care Experience of Sorafenib in the Treatment of Progressive Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Korean Multicenter Study
    Mijin Kim, Tae Hyuk Kim, Dong Yeob Shin, Dong Jun Lim, Eui Young Kim, Won Bae Kim, Jae Hoon Chung, Young Kee Shong, Bo Hyun Kim, Won Gu Kim
    Thyroid.2018; 28(3): 340.     CrossRef
  • A Follow-Up Strategy for Patients with an Excellent Response to Initial Therapy for Differentiated Thyroid Carcinoma: Less Is Better
    Min Ji Jeon, Mijin Kim, Suyeon Park, Hye-Seon Oh, Tae Yong Kim, Won Bae Kim, Young Kee Shong, Won Gu Kim
    Thyroid.2018; 28(2): 187.     CrossRef
  • Preoperative serum thyroglobulin predicts initial distant metastasis in patients with differentiated thyroid cancer
    Hosu Kim, Young Nam Kim, Hye In Kim, So Young Park, Jun-Ho Choe, Jung-Han Kim, Jee Soo Kim, Jae Hoon Chung, Tae Hyuk Kim, Sun Wook Kim
    Scientific Reports.2017;[Epub]     CrossRef
Close layer
Clinical Study
Usefulness of Measuring Thyroid Stimulating Antibody at the Time of Antithyroid Drug Withdrawal for Predicting Relapse of Graves Disease
Hyemi Kwon, Won Gu Kim, Eun Kyung Jang, Mijin Kim, Suyeon Park, Min Ji Jeon, Tae Yong Kim, Jin-Sook Ryu, Young Kee Shong, Won Bae Kim
Endocrinol Metab. 2016;31(2):300-310.   Published online April 25, 2016
DOI: https://doi.org/10.3803/EnM.2016.31.2.300
  • 9,274 View
  • 117 Download
  • 29 Web of Science
  • 30 Crossref
AbstractAbstract PDFPubReader   
Background

Hyperthyroidism relapse in Graves disease after antithyroid drug (ATD) withdrawal is common; however, measuring the thyrotropin receptor antibody (TRAb) at ATD withdrawal in order to predict outcomes is controversial. This study compared measurement of thyroid stimulatory antibody (TSAb) and thyrotropin-binding inhibitory immunoglobulin (TBII) at ATD withdrawal to predict relapse.

Methods

This retrospective study enrolled patients with Graves disease who were treated with ATDs and whose serum thyroid-stimulating hormone levels were normal after receiving low-dose ATDs. ATD therapy was stopped irrespective of TRAb positivity after an additional 6 months of receiving the minimum dose of ATD therapy. Patients were followed using thyroid function tests and TSAb (TSAb group; n=35) or TBII (TBII group; n=39) every 3 to 6 months for 2 years after ATD withdrawal.

Results

Twenty-eight patients (38%) relapsed for a median follow-up of 21 months, and there were no differences in baseline clinical characteristics between groups. In the TSAb group, relapse was more common in patients with positive TSAb at ATD withdrawal (67%) than patients with negative TSAb (17%; P=0.007). Relapse-free survival was shorter in TSAb-positive patients. In the TBII group, there were no differences in the relapse rate and relapse-free survivals according to TBII positivity. For predicting Graves disease relapse, the sensitivity and specificity of TSAb were 63% and 83%, respectively, whereas those of TBII were 28% and 65%.

Conclusion

TSAb at ATD withdrawal can predict the relapse of Graves hyperthyroidism, but TBII cannot. Measuring TSAb at ATD withdrawal can assist with clinical decisions making for patients with Graves disease.

Citations

Citations to this article as recorded by  
  • US-based, Prospective, Blinded Study of Thyrotropin Receptor Antibody in Autoimmune Thyroid Disease
    Mark A Lupo, Paul D Olivo, Maximilian Luffy, Jan Wolf, George J Kahaly
    The Journal of Clinical Endocrinology & Metabolism.2025; 110(5): e1619.     CrossRef
  • Significance of Thyroid-Stimulating Immunoglobulin and Thyrotropin Receptor Antibody in Graves Disease
    Rongguang Peng, Pu Xie, Zhou Jin, Wenzhong Zhou, Yanqiu Wang, Xinxin Chen, Qinglei Yin, Liyun Shen, Lingyang Meng, Lei Ye, Yulin Zhou, Shu Wang
    The Journal of Clinical Endocrinology & Metabolism.2025; 110(9): e3002.     CrossRef
  • Comparative efficacy and safety of rituximab, tocilizumab, and teprotumumab in Graves’ orbitopathy: a systematic review and meta-analysis
    Abdulelah G. Abumohssin, Rayan A. Alshareef, Saja Aljohani, Abdulrahman Alqutub, Abdulsalam Alqutub
    Eye.2025; 39(10): 1901.     CrossRef
  • Analysis of Influencing Factors of Radioactive Iodine Therapy for Graves’ Disease
    绍欣 李
    Journal of Clinical Personalized Medicine.2025; 04(03): 235.     CrossRef
  • Thyrotropin (TSH)-Binding Inhibiting Immunoglobulin-Negative, Thyroid-Stimulating Antibody-Positive Amiodarone-Induced Thyrotoxicosis
    Yasufumi Seki, Kei Inai, Koichiro Kaneko, Atsuhiro Ichihara
    AACE Endocrinology and Diabetes.2025; 12(3): 190.     CrossRef
  • Low-dose Methimazole in the Long-term Management of Graves' Disease: Small Doses, Big Benefits
    Danilo Villagelin, David S Cooper
    The Journal of Clinical Endocrinology & Metabolism.2025;[Epub]     CrossRef
  • Thyroid-stimulating immunoglobulin levels during low-dose antithyroid therapy predict Graves’ disease relapse
    Phong Vu Nhat Nguyen, Khue Thy Nguyen
    Frontiers in Endocrinology.2025;[Epub]     CrossRef
  • Thyroid stimulating receptor autoantibodies
    Yumeng Gao, Ling Qiu, Songlin Yu, Xinqi Cheng
    Clinica Chimica Acta.2024; 559: 119700.     CrossRef
  • Dynamic Risk Model for the Medical Treatment of Graves’ Hyperthyroidism according to Treatment Duration
    Meihua Jin, Chae A Kim, Min Ji Jeon, Won Bae Kim, Tae Yong Kim, Won Gu Kim
    Endocrinology and Metabolism.2024; 39(4): 579.     CrossRef
  • Comparison between thyroid stimulating immunoglobulin and TSH-receptor antibodies in the diagnosis and management of Graves’ disease
    Peiwei Yao, Yunliang Xie, Yunlin Wang, Chunyan Liang, Bingwen Huang
    Frontiers in Endocrinology.2024;[Epub]     CrossRef
  • Analysis of Related Factors in Refractory Graves’ Disease
    鑫 王
    Advances in Clinical Medicine.2023; 13(08): 13439.     CrossRef
  • Interpretation of Thyroid Autoantibodies in Hyperthyroidism
    Han-Sang Baek, Dong-Jun Lim
    The Korean Journal of Medicine.2023; 98(3): 132.     CrossRef
  • The Early Changes in Thyroid-Stimulating Immunoglobulin Bioassay over Anti-Thyroid Drug Treatment Could Predict Prognosis of Graves’ Disease
    Jin Yu, Han-Sang Baek, Chaiho Jeong, Kwanhoon Jo, Jeongmin Lee, Jeonghoon Ha, Min Hee Kim, Jungmin Lee, Dong-Jun Lim
    Endocrinology and Metabolism.2023; 38(3): 338.     CrossRef
  • Prediction of the recurrence risk of Graves' disease after antithyroid drug therapy
    Qiang Zhang, Ying Fu
    Environmental Disease.2023; 8(1): 7.     CrossRef
  • Thyroid-Stimulatory Antibody as a Predictive Factor for Graves’ Disease Relapse
    Tiago Da Silva Santos, José Carlos Oliveira, Cláudia Freitas, André Couto de Carvalho
    Cureus.2022;[Epub]     CrossRef
  • The Prediction Model Using Thyroid-stimulating Immunoglobulin Bioassay For Relapse of Graves’ Disease
    Han-Sang Baek, Jaejun Lee, Chai-Ho Jeong, Jeongmin Lee, Jeonghoon Ha, Kwanhoon Jo, Min-Hee Kim, Jae Hyoung Cho, Moo Il Kang, Dong-Jun Lim
    Journal of the Endocrine Society.2022;[Epub]     CrossRef
  • Identification of patients with Graves’ disease who benefit from high-dose radioactive iodine therapy
    Shiro Watanabe, Shozo Okamoto, Kazumasa Akikawa, Noriyuki Miyamoto, Miyuki Okamura-Kawasaki, Yuko Uchiyama, Junki Takenaka, Takuya Toyonaga, Kenji Hirata, Kohsuke Kudo
    Annals of Nuclear Medicine.2022; 36(11): 923.     CrossRef
  • The relationship between atherosclerotic disease and relapse during ATD treatment
    Xinxin Zhu, Yaguang Zhang, Xiaoyu Zhao, Xiaona Zhang, Zixuan Ru, Yanmeizhi Wu, Xu Yang, Boyu Hou, Hong Qiao
    Frontiers in Cardiovascular Medicine.2022;[Epub]     CrossRef
  • Antithyroid Drug Treatment in Graves’ Disease
    Jae Hoon Chung
    Endocrinology and Metabolism.2021; 36(3): 491.     CrossRef
  • The prognostic value of thyroid-stimulating immunoglobulin in the management of Graves’ disease
    Yulin Zhou, Mengxi Zhou, Yicheng Qi, Weiqing Wang, Xinxin Chen, Shu Wang
    Therapeutic Advances in Endocrinology and Metabolism.2021;[Epub]     CrossRef
  • Changes in Thyroid Peroxidase and Thyroglobulin Antibodies Might Be Associated with Graves' Disease Relapse after Antithyroid Drug Therapy
    Yun Mi Choi, Mi Kyung Kwak, Sang Mo Hong, Eun-Gyoung Hong
    Endocrinology and Metabolism.2019; 34(3): 268.     CrossRef
  • Graves' Disease: Can It Be Cured?
    Wilmar M. Wiersinga
    Endocrinology and Metabolism.2019; 34(1): 29.     CrossRef
  • Medical Treatment of Graves' Disease
    Hyun-Kyung Chung
    International Journal of Thyroidology.2019; 12(2): 79.     CrossRef
  • When should antithyroid drug therapy to reduce the relapse rate of hyperthyroidism in Graves’ disease be discontinued?
    Suyeon Park, Eyun Song, Hye-Seon Oh, Mijin Kim, Min Ji Jeon, Won Gu Kim, Tae Yong Kim, Young Kee Shong, Doo Man Kim, Won Bae Kim
    Endocrine.2019; 65(2): 348.     CrossRef
  • Elevated Serum IL-17 Expression at Cessation Associated with Graves’ Disease Relapse
    Jianhui Li, Xiaohua Sun, Danzhen Yao, Jinying Xia
    International Journal of Endocrinology.2018; 2018: 1.     CrossRef
  • Active Surveillance for Patients With Papillary Thyroid Microcarcinoma: A Single Center’s Experience in Korea
    Hyemi Kwon, Hye-Seon Oh, Mijin Kim, Suyeon Park, Min Ji Jeon, Won Gu Kim, Won Bae Kim, Young Kee Shong, Dong Eun Song, Jung Hwan Baek, Ki-Wook Chung, Tae Yong Kim
    The Journal of Clinical Endocrinology & Metabolism.2017; 102(6): 1917.     CrossRef
  • Free Thyroxine, Anti-Thyroid Stimulating Hormone Receptor Antibody Titers, and Absence of Goiter Were Associated with Responsiveness to Methimazole in Patients with New Onset Graves' Disease
    Hoon Sung Choi, Won Sang Yoo
    Endocrinology and Metabolism.2017; 32(2): 281.     CrossRef
  • The Second Antithyroid Drug Treatment Is Effective in Relapsed Graves' Disease Patients: A Median 11-Year Follow-Up Study
    Ye An Kim, Sun Wook Cho, Hoon Sung Choi, Shinje Moon, Jae Hoon Moon, Kyung Won Kim, Do Joon Park, Ka Hee Yi, Young Joo Park, Bo Youn Cho
    Thyroid.2017; 27(4): 491.     CrossRef
  • The Recurrence Rate of Graves' Disease among Patients with Subclinical Thyrotoxicosis after Initial Remission with Antithyroid Agents
    Myoung Sook Shim, Soo Min Nam, Jin Sae Yoo, Hae Kyung Kim, Sang Jun Lee, Mi Young Lee
    International Journal of Thyroidology.2017; 10(2): 77.     CrossRef
  • Articles inEndocrinology and Metabolismin 2016
    Won-Young Lee
    Endocrinology and Metabolism.2017; 32(1): 62.     CrossRef
Close layer
Clinical Study
Thyrotoxic Periodic Paralysis and Polymorphisms of the ADRB2, AR, and GABRA3 Genes in Men with Graves Disease
Suyeon Park, Tae Yong Kim, Soyoung Sim, Seonhee Lim, Mijin Kim, Hyemi Kwon, Min Ji Jeon, Won Gu Kim, Young Kee Shong, Won Bae Kim
Endocrinol Metab. 2016;31(1):142-146.   Published online March 16, 2016
DOI: https://doi.org/10.3803/EnM.2016.31.1.142
  • 5,975 View
  • 40 Download
  • 5 Web of Science
  • 5 Crossref
AbstractAbstract PDFPubReader   
Background

Thyrotoxic periodic paralysis (TPP) is a rare complication of thyrotoxicosis characterized by acute attacks of muscle weakness and hypokalemia. Recently, variation in several genes was suggested to be associated with TPP. This study evaluated the genetic predisposition to TPP in terms of the β2-adrenergic receptor (ADRB2), androgen receptor (AR), and γ-aminobutyric acid receptor α3 subunit (GABRA3) genes.

Methods

This study enrolled 48 men with Graves disease (GD) and TPP, and 48 GD patients without TPP. We compared the frequencies of candidate polymorphisms between the two groups.

Results

The frequency of the Gly16/Gly16 genotype in ADRB2 was not significantly associated with TPP (P=0.32). More CAG repeats (≥26) in the AR gene were not correlated with TPP (odds ratio [OR], 2.46; 95% confidence interval [CI], 0.81 to 8.09; P=0.08). The allele frequency of the TT genotype in the GABRA3 gene was not associated with TPP (OR, 1.83; 95% CI, 0.54 to 6.74; P=0.41).

Conclusion

The polymorphisms in the ADRB2, AR, and GABRA3 genes could not explain the genetic susceptibility to TPP in Korean men with GD.

Citations

Citations to this article as recorded by  
  • Rebound Hyperkalemia in Hypokalemic Thyrotoxic Periodic Paralysis
    Thomas J. Pisano, Brandon Merical, Zehui Wang, Joshua M. Levine
    The Neurohospitalist.2026; 16(1): 78.     CrossRef
  • RNASET2,GPR174, and PTPN22 gene polymorphisms are related to the risk of liver damage associated with the hyperthyroidism in patients with Graves’ disease
    Qing Zhang, Shaozheng Liu, Yanxing Guan, Qingjie Chen, Qing Zhang, Xiang Min
    Journal of Clinical Laboratory Analysis.2018;[Epub]     CrossRef
  • Articles inEndocrinology and Metabolismin 2016
    Won-Young Lee
    Endocrinology and Metabolism.2017; 32(1): 62.     CrossRef
  • Periodic Paralysis and Encephalopathy as Initial Manifestations of Graves’ Disease
    Theocharis Tsironis, Athanasios Tychalas, Dimitrios Kiourtidis, Jannis Kountouras, Georgia Xiromerisiou, Jobst Rudolf, Georgia Deretzi
    The Neurologist.2017; 22(4): 134.     CrossRef
  • Thyrotoxic periodic paralysis
    Zdeněk Doležel, Dana Novotná, Helena Schneiderová, Jan Papež, Martin Jouza
    Pediatrie pro praxi.2016; 17(6): 379.     CrossRef
Close layer
Clinical Study
Low Prevalence of Somatic TERT Promoter Mutations in Classic Papillary Thyroid Carcinoma
Min Ji Jeon, Won Gu Kim, Soyoung Sim, Seonhee Lim, Hyemi Kwon, Tae Yong Kim, Young Kee Shong, Won Bae Kim
Endocrinol Metab. 2016;31(1):100-104.   Published online March 16, 2016
DOI: https://doi.org/10.3803/EnM.2016.31.1.100
  • 6,969 View
  • 37 Download
  • 16 Web of Science
  • 15 Crossref
AbstractAbstract PDFPubReader   
Background

Transcriptional activating mutations of telomerase reverse transcriptase (TERT) are associated with more aggressive thyroid cancer. We evaluated the significance of TERT promoter mutations in Korean patients with classic papillary thyroid cancer (PTC).

Methods

Genomic DNA was isolated from four thyroid cancer cell lines and 35 fresh-frozen PTC tissues. TERT promoter mutations (C228T and C250T) and the BRAF V600E mutation were evaluated by polymerase chain reaction amplification and direct sequencing.

Results

The CC228229TT mutation in the TERT promoter was detected in BCPAP cells and the C250T mutation was found in 8505C cells. No TERT promoter mutation was observed in Cal-62 or ML-1 cells. The C228T mutation was found in only 1 of 35 (2.8%) PTCs and no C250T mutations were detected in any of the study subjects. The BRAF V600E mutation was found in 20 of 35 (57.1%) PTCs. One patient with the C228T TERT mutation also harbored the BRAF V600E mutation and developed a recurrence.

Conclusion

The prevalence of somatic TERT promoter mutations was low in Korean patients with classic PTC. Therefore, the prognostic role of TERT promoter mutations might be limited in this patient cohort.

Citations

Citations to this article as recorded by  
  • Risk Factors for TERT Promoter Mutations with Papillary Thyroid Carcinoma Patients: A Meta-Analysis and Systematic Review
    Jingxin Mao, Xingliang Huang, Mohammad K. Okla, Mostafa A. Abdel-Maksoud, Ayman Mubarak, Zahid Hameed, Razia Noreen, Aqsa Chaudhary, Shakira Ghazanfar, Yixuan Liao, Yasir Hameed, Chen Li, Min Tang
    Computational and Mathematical Methods in Medicine.2022; 2022: 1.     CrossRef
  • Telomerase reverse transcriptase promoter mutations in cancers derived from multiple organ sites among middle eastern population
    Abdul K. Siraj, Rong Bu, Kaleem Iqbal, Sandeep Kumar Parvathareddy, Nabil Siraj, Sarah Siraj, Mark Ranier F. Diaz, Dionne Rae Rala, Allianah D. Benito, Maria Angelita Sabido, Maha Al-Rasheed, Khadija A.S. Al-Obaisi, Wael Al-Haqawi, Ingrid G. Victoria, Waf
    Genomics.2020; 112(2): 1746.     CrossRef
  • Association between TERT promoter mutations and clinical behaviors in differentiated thyroid carcinoma: a systematic review and meta-analysis
    Jing Yang, Yanping Gong, Shuping Yan, Hui Chen, Siqin Qin, Rixiang Gong
    Endocrine.2020; 67(1): 44.     CrossRef
  • The Combination of RET, BRAF and Demographic Data Identifies Subsets of Patients with Aggressive Papillary Thyroid Cancer
    Jose R. W. Martínez, Sergio Vargas-Salas, Soledad Urra Gamboa, Estefanía Muñoz, José Miguel Domínguez, Augusto León, Nicolás Droppelmann, Antonieta Solar, Mark Zafereo, F. Christopher Holsinger, Hernán E. González
    Hormones and Cancer.2019; 10(2-3): 97.     CrossRef
  • Correlation between TERT C228T and clinic-pathological features in pediatric papillary thyroid carcinoma
    Jiangqiao Geng, Yuanhu Liu, Yongli Guo, Huanmin Wang, Jun Tai, Yaqiong Jin, Jie Zhang, Yongbo Yu, Shengcai Wang, Yingluan Song, Xin Ni
    Science China Life Sciences.2019; 62(12): 1563.     CrossRef
  • Human telomerase reverse transcriptase in papillary thyroid cancer: gene expression, effects of silencing and regulation by BET inhibitors in thyroid cancer cells
    Valentina Maggisano, Marilena Celano, Saverio Massimo Lepore, Marialuisa Sponziello, Francesca Rosignolo, Valeria Pecce, Antonella Verrienti, Federica Baldan, Catia Mio, Lorenzo Allegri, Marianna Maranghi, Rosa Falcone, Giuseppe Damante, Diego Russo, Stef
    Endocrine.2019; 63(3): 545.     CrossRef
  • BRAF and RAS Mutational Status in Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features and Invasive Subtype of Encapsulated Follicular Variant of Papillary Thyroid Carcinoma in Korea
    Mijin Kim, Min Ji Jeon, Hye-Seon Oh, Suyeon Park, Tae Yong Kim, Young Kee Shong, Won Bae Kim, Kyunggon Kim, Won Gu Kim, Dong Eun Song
    Thyroid.2018; 28(4): 504.     CrossRef
  • The role of TERT promoter mutations in postoperative and preoperative diagnosis and prognosis in thyroid cancer
    Anqi Jin, Jianhao Xu, Yan Wang
    Medicine.2018; 97(29): e11548.     CrossRef
  • Telomere Maintenance Mechanisms in Cancer
    Tiago Bordeira Gaspar, Ana Sá, José Manuel Lopes, Manuel Sobrinho-Simões, Paula Soares, João Vinagre
    Genes.2018; 9(5): 241.     CrossRef
  • Anti-hTERT siRNA-Loaded Nanoparticles Block the Growth of Anaplastic Thyroid Cancer Xenograft
    Giovanni E. Lombardo, Valentina Maggisano, Marilena Celano, Donato Cosco, Chiara Mignogna, Federica Baldan, Saverio M. Lepore, Lorenzo Allegri, Sonia Moretti, Cosimo Durante, Giuseppe Damante, Massimo Fresta, Diego Russo, Stefania Bulotta, Efisio Puxeddu
    Molecular Cancer Therapeutics.2018; 17(6): 1187.     CrossRef
  • Silencing of hTERT blocks growth and migration of anaplastic thyroid cancer cells
    Valentina Maggisano, Marilena Celano, Giovanni Enrico Lombardo, Saverio Massimo Lepore, Marialuisa Sponziello, Francesca Rosignolo, Antonella Verrienti, Federica Baldan, Efisio Puxeddu, Cosimo Durante, Sebastiano Filetti, Giuseppe Damante, Diego Russo, St
    Molecular and Cellular Endocrinology.2017; 448: 34.     CrossRef
  • Articles inEndocrinology and Metabolismin 2016
    Won-Young Lee
    Endocrinology and Metabolism.2017; 32(1): 62.     CrossRef
  • Telomerase: The Devil Inside
    Mukesh Kumar, Andre Lechel, Çagatay Güneş
    Genes.2016; 7(8): 43.     CrossRef
  • Cancer-Specific Telomerase Reverse Transcriptase (TERT) Promoter Mutations: Biological and Clinical Implications
    Tiantian Liu, Xiaotian Yuan, Dawei Xu
    Genes.2016; 7(7): 38.     CrossRef
  • Transcription Regulation of the Human Telomerase Reverse Transcriptase (hTERT) Gene
    Muhammad Ramlee, Jing Wang, Wei Toh, Shang Li
    Genes.2016; 7(8): 50.     CrossRef
Close layer
Erratum
Thyroid
Erratum: Figure Correction: Standardized Thyroid Cancer Mortality in Korea between 1985 and 2010
Yun Mi Choi, Tae Yong Kim, Eun Kyung Jang, Hyemi Kwon, Min Ji Jeon, Won Gu Kim, Young Kee Shong, Won Bae Kim
Endocrinol Metab. 2015;30(1):116.   Published online March 27, 2015
DOI: https://doi.org/10.3803/EnM.2015.30.1.116
  • 3,924 View
  • 32 Download
PDFPubReader   
Close layer
Namgok Lecture 2014
Thyroid
A Closer Look at Papillary Thyroid Carcinoma
Won Bae Kim
Endocrinol Metab. 2015;30(1):1-6.   Published online March 27, 2015
DOI: https://doi.org/10.3803/EnM.2015.30.1.1
  • 7,700 View
  • 46 Download
  • 31 Web of Science
  • 32 Crossref
AbstractAbstract PDFPubReader   

Recent surge of thyroid cancer, especially papillary thyroid carcinoma (PTC), ignited a debate on over-diagnosis of cancer. Such increase in incidence is a worldwide phenomenon, but it has been the most prominent in Korea. Although increased detection might have played a major role, some evidences suggest that true increase in incidence have also contributed to such phenomenon. PTC is a very common disease being the most common cancer in human. As the mortality due to PTC is relatively low, understanding pathophysiology of the disease and risk prediction in individual patient have particular importance for optimal management, but little has been known. I suggest a reason for such a commonality of PTC, and would like to describe my view on some aspects of PTC including unresolved issue on management based on our recent observations.

Citations

Citations to this article as recorded by  
  • Comparative Prognostic Analysis of the Tall Cell Subtype of Papillary Thyroid Carcinoma With the Conventional Subtype Following the WHO 2022 Revision: An Indian Cohort Study
    Jameera Nazer, Smitha NV, Usha Menon, Krishnakumar Thankappan
    Cureus.2025;[Epub]     CrossRef
  • Predictors of lateral lymph node metastasis and skip metastasis in patients with papillary thyroid microcarcinoma
    Jee Hee Yoon, Ji Yong Park, A Ram Hong, Hee Kyung Kim, Ho-Cheol Kang
    Frontiers in Endocrinology.2024;[Epub]     CrossRef
  • Incidence of thyroid cancer in Abu Dhabi, UAE: A registry-based study
    Eiman Alseddeeqi, Ajda Altinoz, Abderrahim Oulhaj, Abubaker Suliman, Luai A. Ahmed
    Journal of Cancer Research and Therapeutics.2023; 19(2): 321.     CrossRef
  • Organochlorine pesticides induce thyroid tumors through oxidative stress; an in vivo and in silico study
    Fouzieh Salimi, Gholamreza Asadikaram, Moslem Abolhassani, Yasin Pourfarjam, Hamid Zeynali Nejad, Mojtaba Abbasi-Jorjandi, Mojgan Sanjari
    Environmental Science and Pollution Research.2023; 30(15): 45046.     CrossRef
  • Appraisal of cytohistomorphology of papillary carcinoma thyroid and its variants with evaluation of discrepant cases
    Supreetha Megalamane, Hemalatha Anatharamiah, C. S. B. R. Prasad
    Medical Journal of Dr. D.Y. Patil Vidyapeeth.2022; 15(6): 877.     CrossRef
  • Microwave Ablation versus Surgery for Papillary Thyroid Carcinoma: More Therapeutic Options, More Controversies
    Eric vanSonnenberg, Joseph F. Simeone
    Radiology.2022; 304(3): 714.     CrossRef
  • PSHG-TISS: A collection of polarization-resolved second harmonic generation microscopy images of fixed tissues
    Radu Hristu, Stefan G. Stanciu, Adrian Dumitru, Lucian G. Eftimie, Bogdan Paun, Denis E. Tranca, Pavel Gheorghita, Mariana Costache, George A. Stanciu
    Scientific Data.2022;[Epub]     CrossRef
  • Clinical implications of age and excellent response to therapy in patients with high‐risk differentiated thyroid carcinoma
    Meihua Jin, Jonghwa Ahn, Yu‐Mi Lee, Tae‐Yon Sung, Dong Eun Song, Tae Yong Kim, Ki‐Wook Chung, Jin‐Sook Ryu, Won Bae Kim, Young Kee Shong, Min Ji Jeon, Won Gu Kim
    Clinical Endocrinology.2021; 95(6): 882.     CrossRef
  • Level V Lateral Neck Dissection in FNA-proven Papillary Thyroid Carcinoma
    Mohamad S Farahat, Mohamed K Kamel, Doaa A Saad, Hosam M Hamza
    World Journal of Endocrine Surgery.2021; 13(1): 4.     CrossRef
  • SREBP1 as a potential biomarker predicts levothyroxine efficacy of differentiated thyroid cancer
    Cuilin Li, Xiaowei Peng, Jing Lv, Hecun Zou, Jianqiu Liu, Ke Zhang, Zhi Li
    Biomedicine & Pharmacotherapy.2020; 123: 109791.     CrossRef
  • A‐kinase interacting protein 1 as a potential biomarker of advanced tumor features and increased recurrence risk in papillary thyroid carcinoma patients
    Luqing Zhang, Haiying Tao, Kongliang Ke, Cui Ma
    Journal of Clinical Laboratory Analysis.2020;[Epub]     CrossRef
  • A miRNA-clinicopathological nomogram for the prediction of central lymph node metastasis in papillary thyroid carcinoma-analysis from TCGA database
    Mingjun Wang, Rongjing Li, Xiuhe Zou, Tao Wei, Rixiang Gong, Jingqiang Zhu, Zhihui Li
    Medicine.2020; 99(35): e21996.     CrossRef
  • Clinical Outcomes of N1b Papillary Thyroid Cancer Patients Treated with Two Different Doses of Radioiodine Ablation Therapy
    Meihua Jin, Jonghwa Ahn, Yu-Mi Lee, Tae-Yon Sung, Won Gu Kim, Tae Yong Kim, Jin-Sook Ryu, Won Bae Kim, Young Kee Shong, Min Ji Jeon
    Endocrinology and Metabolism.2020; 35(3): 602.     CrossRef
  • Ultrasound-Guided Percutaneous Ethanol Ablation for the Management of Recurrent Thyroid Cancer: Evaluation of Efficacy and Impact on Disease Course
    Santiago Tofé, Iñaki Argüelles, Guillermo Serra, Honorato García, Antonia Barcelo, Vicente Pereg
    International Journal of Thyroidology.2020; 13(2): 128.     CrossRef
  • Synergistic repression of thyroid hyperplasia by cyclin C and Pten
    Jan Jezek, Kun Wang, Ruilan Yan, Antonio Di Cristofano, Katrina F. Cooper, Randy Strich
    Journal of Cell Science.2019;[Epub]     CrossRef
  • Relationship between ultrasonographic and pathologic calcification patterns in papillary thyroid cancer
    Bu Kyung Kim, Eun Mi Lee, Jeong Hoon Kim, So Young Oak, Su Kyoung Kwon, Young Sik Choi, Young Ok Kim
    Medicine.2018; 97(41): e12675.     CrossRef
  • Tiam1 promotes thyroid carcinoma metastasis by modulating EMT via Wnt/β-catenin signaling
    Lin Liu, Bo Wu, Haidong Cai, Dan Li, Yushui Ma, Xuchao Zhu, Zhongwei Lv, Youben Fan, Xiaoping Zhang
    Experimental Cell Research.2018; 362(2): 532.     CrossRef
  • Young Age and Male Sex Are Predictors of Large-Volume Central Neck Lymph Node Metastasis in Clinical N0 Papillary Thyroid Microcarcinomas
    Hye-Seon Oh, Suyeon Park, Mijin Kim, Hyemi Kwon, Eyun Song, Tae-Yon Sung, Yu-Mi Lee, Won Gu Kim, Tae Yong Kim, Young Kee Shong, Won Bae Kim, Min Ji Jeon
    Thyroid.2017; 27(10): 1285.     CrossRef
  • Lack of Efficacy of Radioiodine Remnant Ablation for Papillary Thyroid Microcarcinoma: Verification Using Inverse Probability of Treatment Weighting
    Hyemi Kwon, Min Ji Jeon, Won Gu Kim, Suyeon Park, Mijin Kim, Tae Yong Kim, Minkyu Han, Dong Eun Song, Tae-Yon Sung, Jong Ho Yoon, Suck Joon Hong, Jin-Sook Ryu, Young Kee Shong, Won Bae Kim
    Annals of Surgical Oncology.2017; 24(9): 2596.     CrossRef
  • Genetic Alterations and Their Clinical Implications in High-Recurrence Risk Papillary Thyroid Cancer
    Min-Young Lee, Bo Mi Ku, Hae Su Kim, Ji Yun Lee, Sung Hee Lim, Jong-Mu Sun, Se-Hoon Lee, Keunchil Park, Young Lyun Oh, Mineui Hong, Han-Sin Jeong, Young-Ik Son, Chung-Hwan Baek, Myung-Ju Ahn
    Cancer Research and Treatment.2017; 49(4): 906.     CrossRef
  • Long-term outcomes of ethanol injection therapy for locally recurrent papillary thyroid cancer
    Soo Young Kim, Seok-Mo Kim, Hojin Chang, Bup-Woo Kim, Chi Young Lim, Yong Sang Lee, Hang-Seok Chang, Cheong Soo Park
    European Archives of Oto-Rhino-Laryngology.2017; 274(9): 3497.     CrossRef
  • Active Surveillance for Patients With Papillary Thyroid Microcarcinoma: A Single Center’s Experience in Korea
    Hyemi Kwon, Hye-Seon Oh, Mijin Kim, Suyeon Park, Min Ji Jeon, Won Gu Kim, Won Bae Kim, Young Kee Shong, Dong Eun Song, Jung Hwan Baek, Ki-Wook Chung, Tae Yong Kim
    The Journal of Clinical Endocrinology & Metabolism.2017; 102(6): 1917.     CrossRef
  • Preoperative clinicopathological characteristics of patients with solitary encapsulated follicular variants of papillary thyroid carcinomas
    Hyemi Kwon, Min Ji Jeon, Jong Ho Yoon, Suck Joon Hong, Jeong Hyun Lee, Tae Yong Kim, Young Kee Shong, Won Bae Kim, Won Gu Kim, Dong Eun Song
    Journal of Surgical Oncology.2017; 116(6): 746.     CrossRef
  • Does the Risk of Metabolic Syndrome Increase in Thyroid Cancer Survivors?
    Min-Hee Kim, Jin-young Huh, Dong-jun Lim, Moo-Il Kang
    Thyroid.2017; 27(7): 936.     CrossRef
  • Features of papillary thyroid microcarcinoma associated with lateral cervical lymph node metastasis
    Min Ji Jeon, Mi Sun Chung, Hyemi Kwon, Mijin Kim, Suyeon Park, Jung Hwan Baek, Dong Eun Song, Tae‐Yon Sung, Suck Joon Hong, Tae Yong Kim, Won Bae Kim, Young Kee Shong, Jeong Hyun Lee, Won Gu Kim
    Clinical Endocrinology.2017; 86(6): 845.     CrossRef
  • Clinical Analysis of Elderly Thyroid Cancer Patients Following Thyroidect
    Keun Hee Lee, Hak Hoon Jun, Jong Woo Kim, Seung Ki Kim, Jin Hyung Heo
    Korean Journal of Endocrine Surgery.2016; 16(4): 89.     CrossRef
  • Changing trends in the clinicopathological features and clinical outcomes of medullary thyroid carcinoma
    Hyemi Kwon, Won Gu Kim, Tae‐Yon Sung, Min Ji Jeon, Dong Eun Song, Yu‐Mi Lee, Jong Ho Yoon, Ki‐Wook Chung, Suck Joon Hong, Jung Hwan Baek, Jeong Hyun Lee, Tae Yong Kim, Young Kee Shong, Won Bae Kim
    Journal of Surgical Oncology.2016; 113(2): 152.     CrossRef
  • Coexistence of papillary thyroid microcarcinoma and mucosa-associated lymphoid tissue lymphoma in a context of Hashimoto's thyroiditis
    Saul Levy-Blitchtein, Stefany Plasencia-Rebata, Domingo Morales Luna, Juana del Valle Mendoza
    Asian Pacific Journal of Tropical Medicine.2016; 9(8): 812.     CrossRef
  • Clinical Analysis of Elderly Thyroid Cancer Patients Following Thyroidect
    Keun Hee Lee, Hak Hoon Jun, Jong Woo Kim, Seung Ki Kim, Jin Hyung Heo
    Korean Journal of Endocrine Surgery.2016; 16(4): 89.     CrossRef
  • Aberrant Activation of Notch Signaling Inhibits PROX1 Activity to Enhance the Malignant Behavior of Thyroid Cancer Cells
    Dongwon Choi, Swapnika Ramu, Eunkyung Park, Eunson Jung, Sara Yang, Wonhyeuk Jung, Inho Choi, Sunju Lee, Kyu Eui Kim, Young Jin Seong, Mingu Hong, George Daghlian, Daniel Kim, Eugene Shin, Jung In Seo, Vicken Khatchadourian, Mengchen Zou, Wei Li, Roger De
    Cancer Research.2016; 76(3): 582.     CrossRef
  • Metformin-Associated Lactic Acidosis
    Sunghwan Suh
    Endocrinology and Metabolism.2015; 30(1): 45.     CrossRef
  • Administration of Radioactive Iodine Therapy Within 1 Year After Total Thyroidectomy Does Not Affect Vocal Function
    Chang Hwan Ryu, Junsun Ryu, Youn Mi Ryu, You Jin Lee, Eun-Kyung Lee, Seok-Ki Kim, Tae-Sung Kim, Tae Hyun Kim, Chang Yoon Lee, Seog Yun Park, Ki Wook Chung, Yuh-S. Jung
    Journal of Nuclear Medicine.2015; 56(10): 1480.     CrossRef
Close layer
Case Report
Thyroid
Solitary Skin Metastasis of Papillary Thyroid Carcinoma
Hyemi Kwon, Hyojung Kim, Sojung Park, Dong Eun Song, Won Gu Kim, Tae Yong Kim, Young Kee Shong, Won Bae Kim
Endocrinol Metab. 2014;29(4):579-583.   Published online December 29, 2014
DOI: https://doi.org/10.3803/EnM.2014.29.4.579
  • 7,389 View
  • 61 Download
  • 8 Web of Science
  • 12 Crossref
AbstractAbstract PDFPubReader   

A solitary skin metastasis is a rare manifestation of papillary thyroid carcinoma (PTC). A 55-year-old woman presented with a movable subcutaneous nodule in her anterior neck for several months. Three years ago, she underwent total thyroidectomy and remnant ablation for classical PTC (pT3N0M0) and was under thyroxine suppression therapy without any evidence of recurrent disease. The subcutaneous nodule was 0.4 cm in size, firm, and movable without any change in the overlying skin. Recurrent PTC was confirmed after excision biopsy. Eight months after, she got a new nodule along the previous excision site. After punch biopsy, metastatic PTC was confirmed in the deep dermis and was re-excised with a clear resection margin. This is the first report of a case of solitary skin metastasis of PTC in Korea. Although solitary skin metastasis of PTC is rare, it should be considered in patients with a skin nodule.

Citations

Citations to this article as recorded by  
  • An atypical metastatic pattern of papillary thyroid carcinoma presenting with concurrent neck skin and lung involvement in the absence of cervical lymph node spread, a rare case report and literature review
    Ehsanollah Rahimi-Movaghar, Amir Ehtemami, Setareh Mostaghni, Tahmineh Tahouri
    International Journal of Surgery Case Reports.2026;[Epub]     CrossRef
  • Isolated Skin Metastasis From Papillary Thyroid Carcinoma: A Rare Presentation
    Naseem Eisa
    JCEM Case Reports.2025;[Epub]     CrossRef
  • Cutaneous Manifestation of Metastatic Papillary Thyroid Carcinoma
    Joseph H. Kelly, Elise V. H. Meide, Brian J. Tjarks
    The American Journal of Dermatopathology.2025;[Epub]     CrossRef
  • Skin metastasis of papillary thyroid carcinoma: A case report and literature review
    Haidi Chu, Dong Wang, Yanqing Qu
    Oncology Letters.2024;[Epub]     CrossRef
  • Skin Metastasis Occurring 30 Years After Thyroidectomy for Papillary Thyroid Carcinoma
    Mohammed S Alwhaid, Olaa Mhish, Mutahir A Tunio, Salman AlMalki, Mushabbab Al Asiri, Khalid Al-Qahtani
    Cureus.2022;[Epub]     CrossRef
  • Solitary Nasopharyngeal Metastasis From Papillary Thyroid Carcinoma Shown on FDG PET/CT
    Anqi Xu, Xiao Jie, Yan Xiu, Hongcheng Shi
    Clinical Nuclear Medicine.2022; 47(5): e425.     CrossRef
  • PD-L1-positive Anaplastic Transformation in a BRAF V600E Expressing Papillary Thyroid Carcinoma with Cutaneous Metastasis: An Unusual Case Report
    Pooja Ramakant, Anand Mishra, Chanchal Rana, Kulranjan Singh
    Indian Journal of Endocrine Surgery and Research.2022; 17(1): 21.     CrossRef
  • Unusual Thyroid Carcinoma Metastases: a Case Series and Literature Review
    Eleonora Farina, Fabio Monari, Giovanni Tallini, Andrea Repaci, Renzo Mazzarotto, Francesca Giunchi, Riccardo Panzacchi, Silvia Cammelli, Gilbert D. A. Padula, Francesco Deodato, Renato Pasquali, Stefano Fanti, Michelangelo Fiorentino, Alessio G. Morganti
    Endocrine Pathology.2016; 27(1): 55.     CrossRef
  • Skin manifestations of endocrine and neuroendocrine tumors
    Jonathan S. Leventhal, Irwin M. Braverman
    Seminars in Oncology.2016; 43(3): 335.     CrossRef
  • Isolated Metastasis in Male Breast from Differentiated Thyroid Carcinoma – Oncological Curiosity. A Case Report and Review of Literature
    Lakshminarasimman Parasuraman, Shubhada V. Kane, Prathamesh S. Pai, Kintan Shanghvi
    Indian Journal of Surgical Oncology.2016; 7(1): 91.     CrossRef
  • A Closer Look at Papillary Thyroid Carcinoma
    Won Bae Kim
    Endocrinology and Metabolism.2015; 30(1): 1.     CrossRef
  • Articles in 'Endocrinology and Metabolism' in 2014
    Won-Young Lee
    Endocrinology and Metabolism.2015; 30(1): 47.     CrossRef
Close layer
Original Articles
Thyroid
Standardized Thyroid Cancer Mortality in Korea between 1985 and 2010
Yun Mi Choi, Tae Yong Kim, Eun Kyung Jang, Hyemi Kwon, Min Ji Jeon, Won Gu Kim, Young Kee Shong, Won Bae Kim
Endocrinol Metab. 2014;29(4):530-535.   Published online December 29, 2014
DOI: https://doi.org/10.3803/EnM.2014.29.4.530
  • 7,339 View
  • 41 Download
  • 23 Web of Science
  • 36 Crossref
AbstractAbstract PDFPubReader   
Background

The prevalence of thyroid cancer has increased very rapidly in Korea. However, there is no published report focusing on thyroid cancer mortality in Korea. In this study, we aimed to evaluate standardized thyroid cancer mortality using data from Statistics Korea (the Statistical Office of Korea).

Methods

Population and mortality data from 1985 to 2010 were obtained from Statistics Korea. Age-standardized rates of thyroid cancer mortality were calculated according to the standard population of Korea, as well as World Health Organization (WHO) standard population and International Cancer Survival Standard (ICSS) population weights.

Results

The crude thyroid cancer mortality rate increased from 0.1 to 0.7 per 100,000 between 1985 and 2010. The pattern was the same for both sexes. The age-standardized mortality rate (ASMR) for thyroid cancer for Korean resident registration population increased from 0.19 to 0.67 between 1985 and 2000. However, it decreased slightly, from 0.67 to 0.55, between 2000 and 2010. When mortality was adjusted using the WHO standard population and ICSS population weights, the ASMR similarly increased until 2000, and then decreased between 2000 and 2010.

Conclusion

Thyroid cancer mortality increased until 2000 in Korea. It started to decrease from 2000.

Citations

Citations to this article as recorded by  
  • Trends in incidence and overdiagnosis of thyroid cancer in China, Japan, and South Korea
    Yongtian Lin, Yu Wu
    Cancer Science.2023; 114(10): 4052.     CrossRef
  • Risk of Adverse Pregnancy Outcomes in Young Women with Thyroid Cancer: A Systematic Review and Meta-Analysis
    Shinje Moon, Ka Hee Yi, Young Joo Park
    Cancers.2022; 14(10): 2382.     CrossRef
  • Asymptomatic Patients and Rising Incidence of Thyroid Cancer—Reply
    Mirabelle Sajisevi, Louise Davies
    JAMA Otolaryngology–Head & Neck Surgery.2022; 148(12): 1186.     CrossRef
  • Asymptomatic Patients and Rising Incidence of Thyroid Cancer
    Shijie Yang, Xiequn Xu
    JAMA Otolaryngology–Head & Neck Surgery.2022; 148(12): 1185.     CrossRef
  • Does the radioactive iodine dose affect smell, taste sensation and nose function?
    B Tutar, T Özülker, G Berkiten, S Karaketir, M E Ekincioğlu, Z Saltürk, Ö Onaran, B Gürpınar, Ş Karaketir, T L Kumral, Y Uyar
    The Journal of Laryngology & Otology.2021; 135(1): 50.     CrossRef
  • Disparities in Cancer-Related Avoidable Mortality by the Level of Area Deprivation in South Korea
    Woorim Kim, Seongkyeong Jang, Gangeun Lee, Yoon Jung Chang
    International Journal of Environmental Research and Public Health.2021; 18(15): 7856.     CrossRef
  • Thyroid cancer: incidence and mortality trends in China, 2005–2015
    Junyi Wang, Fangfang Yu, Yanna Shang, Zhiguang Ping, Li Liu
    Endocrine.2020; 68(1): 163.     CrossRef
  • A miRNA-clinicopathological nomogram for the prediction of central lymph node metastasis in papillary thyroid carcinoma-analysis from TCGA database
    Mingjun Wang, Rongjing Li, Xiuhe Zou, Tao Wei, Rixiang Gong, Jingqiang Zhu, Zhihui Li
    Medicine.2020; 99(35): e21996.     CrossRef
  • Trends in the Diagnosis and Treatment of Patients with Medullary Thyroid Carcinoma in Korea
    Hwa Young Ahn, Jae Eun Chae, Hyemi Moon, Junghyun Noh, Young Joo Park, Sin Gon Kim
    Endocrinology and Metabolism.2020; 35(4): 811.     CrossRef
  • Optimal Thyrotropin Suppression Therapy in Low-Risk Thyroid Cancer Patients after Lobectomy
    Yu-Mi Lee, Min Ji Jeon, Won Woong Kim, Tae-Yon Sung, Ki-Wook Chung, Young Kee Shong, Suck Joon Hong
    Journal of Clinical Medicine.2019; 8(9): 1279.     CrossRef
  • Improved survival after early detection of asymptomatic distant metastasis in patients with thyroid cancer
    Hosu Kim, So Young Park, Jaehoon Jung, Jung-Han Kim, Soo Yeon Hahn, Jung Hee Shin, Young Lyun Oh, Man Ki Chung, Hye In Kim, Sun Wook Kim, Jae Hoon Chung, Tae Hyuk Kim
    Scientific Reports.2019;[Epub]     CrossRef
  • Do aggressive variants of papillary thyroid carcinoma have worse clinical outcome than classic papillary thyroid carcinoma?
    Eyun Song, Min Ji Jeon, Hye-Seon Oh, Minkyu Han, Yu-Mi Lee, Tae Yong Kim, Ki-Wook Chung, Won Bae Kim, Young Kee Shong, Dong Eun Song, Won Gu Kim
    European Journal of Endocrinology.2018; 179(3): 135.     CrossRef
  • Study Protocol of Multicenter Prospective Cohort Study of Active Surveillance on Papillary Thyroid Microcarcinoma (MAeSTro)
    Jae Hoon Moon, Ji-hoon Kim, Eun Kyung Lee, Kyu Eun Lee, Sung Hye Kong, Yeo Koon Kim, Woo-jin Jung, Chang Yoon Lee, Roh-Eul Yoo, Yul Hwangbo, Young Shin Song, Min Joo Kim, Sun Wook Cho, Su-jin Kim, Eun Jae Jung, June Young Choi, Chang Hwan Ryu, You Jin Lee
    Endocrinology and Metabolism.2018; 33(2): 278.     CrossRef
  • Surgeon volume and prognosis of patients with advanced papillary thyroid cancer and lateral nodal metastasis
    H I Kim, T H Kim, J-H Choe, J-H Kim, J S Kim, Y N Kim, H Kim, S W Kim, J H Chung
    British Journal of Surgery.2018; 105(3): 270.     CrossRef
  • Ultrasound requested by general practitioners or for symptoms unrelated to the thyroid gland may explain higher prevalence of thyroid nodules in females
    Ana Germano, Willian Schmitt, Pedro Almeida, Rui Mateus-Marques, Valeriano Leite
    Clinical Imaging.2018; 50: 289.     CrossRef
  • Associations between Hashimoto Thyroiditis and Clinical Outcomes of Papillary Thyroid Cancer: A Meta-Analysis of Observational Studies
    Shinje Moon, Hye Soo Chung, Jae Myung Yu, Hyung Joon Yoo, Jung Hwan Park, Dong Sun Kim, Young Joo Park
    Endocrinology and Metabolism.2018; 33(4): 473.     CrossRef
  • Refining the eighth edition AJCC TNM classification and prognostic groups for papillary thyroid cancer with lateral nodal metastasis
    Hye In Kim, Kyunga Kim, So Young Park, Jun-Ho Choe, Jung-Han Kim, Jee Soo Kim, Young Lyun Oh, Soo Yeon Hahn, Jung Hee Shin, Hyeon Seon Ahn, Sun Wook Kim, Tae Hyuk Kim, Jae Hoon Chung
    Oral Oncology.2018; 78: 80.     CrossRef
  • Decreasing Disease-Specific Mortality of Differentiated Thyroid Cancer in Korea: A Multicenter Cohort Study
    Min Ji Jeon, Hee Kyung Kim, Eun Heui Kim, Eun Sook Kim, Hyon-Seung Yi, Tae Yong Kim, Ho-Cheol Kang, Young Kee Shong, Won Bae Kim, Bo Hyun Kim, Won Gu Kim
    Thyroid.2018; 28(9): 1121.     CrossRef
  • Are pregnancy, parity, menstruation and breastfeeding risk factors for thyroid cancer? Results from the Korea National Health and Nutrition Examination Survey, 2010‐2015
    Hosu Kim, Kyong Young Kim, Jong Ha Baek, Jaehoon Jung
    Clinical Endocrinology.2018; 89(2): 233.     CrossRef
  • Case–Control Study of Papillary Thyroid Carcinoma on Urinary and Dietary Iodine Status in South Korea
    Joon‐Hyop Lee, Ra‐Yeong Song, Jin Wook Yi, Hyeong Won Yu, Hyungju Kwon, Su‐jin Kim, Young Jun Chai, June Young Choi, Jae Hoon Moon, Kyu Eun Lee, Young Joo Park, Sue K. Park
    World Journal of Surgery.2018; 42(5): 1424.     CrossRef
  • Patterns of Initial Recurrence in Completely Resected Papillary Thyroid Carcinoma
    Hosu Kim, Tae Hyuk Kim, Jun-Ho Choe, Jung-Han Kim, Jee Soo Kim, Young Lyun Oh, Soo Yeon Hahn, Jung Hee Shin, Sang ah Chi, Sin-Ho Jung, Young Nam Kim, Hye In Kim, Sun Wook Kim, Jae Hoon Chung
    Thyroid.2017; 27(7): 908.     CrossRef
  • Changes in standardized mortality rates from thyroid cancer in Korea between 1985 and 2015: Analysis of Korean national data
    Yun Mi Choi, Won Gu Kim, Hyemi Kwon, Min Ji Jeon, Minkyu Han, Tae Yong Kim, Young Kee Shong, Sang Mo Hong, Eun‐Gyoung Hong, Won Bae Kim
    Cancer.2017; 123(24): 4808.     CrossRef
  • Thyrotropin Suppressive Therapy for Low-Risk Small Thyroid Cancer: A Propensity Score–Matched Cohort Study
    Suyeon Park, Won Gu Kim, Minkyu Han, Min Ji Jeon, Hyemi Kwon, Mijin Kim, Tae-Yon Sung, Tae Yong Kim, Won Bae Kim, Suck Joon Hong, Young Kee Shong
    Thyroid.2017; 27(9): 1164.     CrossRef
  • Preoperative serum thyroglobulin predicts initial distant metastasis in patients with differentiated thyroid cancer
    Hosu Kim, Young Nam Kim, Hye In Kim, So Young Park, Jun-Ho Choe, Jung-Han Kim, Jee Soo Kim, Jae Hoon Chung, Tae Hyuk Kim, Sun Wook Kim
    Scientific Reports.2017;[Epub]     CrossRef
  • Young Age and Male Sex Are Predictors of Large-Volume Central Neck Lymph Node Metastasis in Clinical N0 Papillary Thyroid Microcarcinomas
    Hye-Seon Oh, Suyeon Park, Mijin Kim, Hyemi Kwon, Eyun Song, Tae-Yon Sung, Yu-Mi Lee, Won Gu Kim, Tae Yong Kim, Young Kee Shong, Won Bae Kim, Min Ji Jeon
    Thyroid.2017; 27(10): 1285.     CrossRef
  • Restratification of survival prognosis of N1b papillary thyroid cancer by lateral lymph node ratio and largest lymph node size
    Hye In Kim, Tae Hyuk Kim, Jun‐Ho Choe, Jung‐Han Kim, Jee Soo Kim, Young Lyun Oh, Soo Yeon Hahn, Jung Hee Shin, Hye Won Jang, Young Nam Kim, Hosu Kim, Hyeon Seon Ahn, Kyunga Kim, Sun Wook Kim, Jae Hoon Chung
    Cancer Medicine.2017; 6(10): 2244.     CrossRef
  • Risk factors associated with high thyroglobulin level following radioactive iodine ablation, measured 12 months after treatment for papillary thyroid carcinoma
    Eun Young Kim, Kee Hoon Hyun, Yong Lai Park, Chan Heun Park, Ji-Sup Yun
    Annals of Surgical Treatment and Research.2017; 92(1): 1.     CrossRef
  • Disease-Specific Mortality of Differentiated Thyroid Cancer Patients in Korea: A Multicenter Cohort Study
    Min Ji Jeon, Won Gu Kim, Tae Hyuk Kim, Hee Kyung Kim, Bo Hyun Kim, Hyon-Seung Yi, Eun Sook Kim, Hosu Kim, Young Nam Kim, Eun Heui Kim, Tae Yong Kim, Sun Wook Kim, Ho-Cheol Kang, Jae Hoon Chung, Young Kee Shong, Won Bae Kim
    Endocrinology and Metabolism.2017; 32(4): 434.     CrossRef
  • Features of papillary thyroid microcarcinoma associated with lateral cervical lymph node metastasis
    Min Ji Jeon, Mi Sun Chung, Hyemi Kwon, Mijin Kim, Suyeon Park, Jung Hwan Baek, Dong Eun Song, Tae‐Yon Sung, Suck Joon Hong, Tae Yong Kim, Won Bae Kim, Young Kee Shong, Jeong Hyun Lee, Won Gu Kim
    Clinical Endocrinology.2017; 86(6): 845.     CrossRef
  • Dynamic Risk Stratification for Predicting Recurrence in Patients with Differentiated Thyroid Cancer Treated Without Radioactive Iodine Remnant Ablation Therapy
    Suyeon Park, Won Gu Kim, Eyun Song, Hye-Seon Oh, Mijin Kim, Hyemi Kwon, Min Ji Jeon, Tae Yong Kim, Young Kee Shong, Won Bae Kim
    Thyroid.2017; 27(4): 524.     CrossRef
  • Clinical outcomes of low-dose and high-dose postoperative radioiodine therapy in patients with intermediate-risk differentiated thyroid cancer
    Ju Hye Jeong, Eun Jung Kong, Shin Young Jeong, Sang-Woo Lee, Ihn Ho Cho, Kyung Ah Chun, Jaetae Lee, Byeong-Cheol Ahn
    Nuclear Medicine Communications.2017; 38(3): 228.     CrossRef
  • Single-Incision, Gasless, Endoscopic Trans-Axillary Total Thyroidectomy: A Feasible and Oncologic Safe Surgery in Patients with Papillary Thyroid Carcinoma
    Eun Young Kim, Kwan Ho Lee, Yong Lai Park, Chan Heun Park, Cho Rok Lee, Jong Ju Jeong, Kee-Hyun Nam, Woong Youn Chung, Ji-Sup Yun
    Journal of Laparoendoscopic & Advanced Surgical Techniques.2017; 27(11): 1158.     CrossRef
  • Prognostic value of the eighth edition AJCC TNM classification for differentiated thyroid carcinoma
    Tae Hyuk Kim, Young Nam Kim, Hye In Kim, So Young Park, Jun-Ho Choe, Jung-Han Kim, Jee Soo Kim, Young Lyun Oh, Soo Yeon Hahn, Jung Hee Shin, Kyunga Kim, Jong Gill Jeong, Sun Wook Kim, Jae Hoon Chung
    Oral Oncology.2017; 71: 81.     CrossRef
  • Changing trends in the clinicopathological features and clinical outcomes of medullary thyroid carcinoma
    Hyemi Kwon, Won Gu Kim, Tae‐Yon Sung, Min Ji Jeon, Dong Eun Song, Yu‐Mi Lee, Jong Ho Yoon, Ki‐Wook Chung, Suck Joon Hong, Jung Hwan Baek, Jeong Hyun Lee, Tae Yong Kim, Young Kee Shong, Won Bae Kim
    Journal of Surgical Oncology.2016; 113(2): 152.     CrossRef
  • Thyroid lobectomy with minimal incision approach
    Tsuyoshi Kojima, Kazuhiko Shoji, Ryusuke Hori, Yusuke Okanoue, Shintaro Fujimura, Hideaki Okuyama, Masayuki Kitano
    JOURNAL OF JAPAN SOCIETY FOR HEAD AND NECK SURGERY.2016; 26(2): 283.     CrossRef
  • Articles in 'Endocrinology and Metabolism' in 2014
    Won-Young Lee
    Endocrinology and Metabolism.2015; 30(1): 47.     CrossRef
Close layer
Thyroid
Lack of Associations between Body Mass Index and Clinical Outcomes in Patients with Papillary Thyroid Carcinoma
Hyemi Kwon, Mijin Kim, Yun Mi Choi, Eun Kyung Jang, Min Ji Jeon, Won Gu Kim, Tae Yong Kim, Young Kee Shong, Dong Eun Song, Jung Hwan Baek, Suck Joon Hong, Won Bae Kim
Endocrinol Metab. 2015;30(3):305-311.   Published online November 26, 2014
DOI: https://doi.org/10.3803/EnM.2015.30.3.305
  • 7,142 View
  • 44 Download
  • 15 Web of Science
  • 16 Crossref
AbstractAbstract PDFPubReader   
Background

Obesity is associated with aggressive pathological features and poor clinical outcomes in breast and prostate cancers. In papillary thyroid carcinoma (PTC), these relationships remain still controversial. This study aimed to evaluate the associations between body mass index (BMI) and the clinical outcomes of patients with PTC.

Methods

This retrospective study included 1,189 patients who underwent total thyroidectomy for PTCs equal to or larger than 1 cm in size. Clinical outcomes were evaluated and compared based on the BMI quartiles.

Results

There were no significant associations between BMI quartiles and primary tumor size, extrathyroidal invasion, cervical lymph node metastasis, or distant metastasis. However, an increase in mean age was associated with an increased BMI (P for trend <0.001). Multifocality and advanced tumor-node-metastasis (TNM) stage (stage III or IV) were significantly associated with increases of BMI (P for trend 0.02 and <0.001, respectively). However, these associations of multifocality and advanced TNM stage with BMI were not significant in multivariate analyses adjusted for age and gender. Moreover, there were no differences in recurrence-free survivals according to BMI quartiles (P=0.26).

Conclusion

In the present study, BMI was not associated with the aggressive clinicopathological features or recurrence-free survivals in patients with PTC.

Citations

Citations to this article as recorded by  
  • Body Mass Index and Sporadic Medullary Thyroid Cancer: Insights from a Large Series
    Alessandro Prete, Carla Gambale, Valeria Bottici, Virginia Cappagli, Giacomo Aringhieri, Marco Puccini, Stefano Landi, Liborio Torregrossa, Ferruccio Santini, Antonio Matrone, Rossella Elisei
    Cancers.2025; 17(6): 950.     CrossRef
  • The Role of Body Mass Index (BMI) in Differentiated Thyroid Cancer: A Potential Prognostic Factor?
    Chiara Mele, Lucrezia De Marchi, Giulia Marsan, Marco Zavattaro, Maria Grazia Mauri, Paolo Aluffi Valletti, Gianluca Aimaretti, Paolo Marzullo
    Biomedicines.2024; 12(9): 1962.     CrossRef
  • A Data-Driven Approach to Refine Predictions of Differentiated Thyroid Cancer Outcomes: A Prospective Multicenter Study
    Giorgio Grani, Michele Gentili, Federico Siciliano, Domenico Albano, Valentina Zilioli, Silvia Morelli, Efisio Puxeddu, Maria Chiara Zatelli, Irene Gagliardi, Alessandro Piovesan, Alice Nervo, Umberto Crocetti, Michela Massa, Maria Teresa Samà, Chiara Mel
    The Journal of Clinical Endocrinology & Metabolism.2023; 108(8): 1921.     CrossRef
  • Potential impact of obesity on the aggressiveness of low- to intermediate-risk papillary thyroid carcinoma: results from a MASTER cohort study
    Mijin Kim, Yae Eun Kang, Young Joo Park, Bon Seok Koo, Eu Jeong Ku, June Young Choi, Eun Kyung Lee, Bo Hyun Kim
    Endocrine.2023; 82(1): 134.     CrossRef
  • Potential Impact of Body Mass Index on the Clinical Outcome of Papillary Thyroid Cancer After High-Dose Radioactive Iodine Therapy
    Jingjia Cao, Xiaolu Zhu, Yaru Sun, Xiao Li, Canhua Yun, Wei Zhang
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
  • Nutritional status and follicular-derived thyroid cancer: An update
    Luigi Barrea, Marco Gallo, Rosaria Maddalena Ruggeri, Paola Di Giacinto, Franz Sesti, Natalie Prinzi, Valerio Adinolfi, Viola Barucca, Valerio Renzelli, Giovanna Muscogiuri, Annamaria Colao, Roberto Baldelli
    Critical Reviews in Food Science and Nutrition.2021; 61(1): 25.     CrossRef
  • Effects of concomitant obesity and diabetes on the aggressiveness and outcomes of differentiated thyroid cancer patients
    Onur Elbasan, Dilek Gogas Yavuz
    Archives of Endocrinology and Metabolism.2021;[Epub]     CrossRef
  • Association of BMI with Clinicopathological Features of Papillary Thyroid Cancer: A Systematic Review and Meta‐Analysis
    R. J. O'Neill, S. Abd Elwahab, M. J. Kerin, A. J. Lowery
    World Journal of Surgery.2021; 45(9): 2805.     CrossRef
  • Association Between Aggressive Clinicopathologic Features of Papillary Thyroid Carcinoma and Body Mass Index: A Systematic Review and Meta-Analysis
    Aliki Economides, Konstantinos Giannakou, Ioannis Mamais, Panayiotis A. Economides, Panagiotis Papageorgis
    Frontiers in Endocrinology.2021;[Epub]     CrossRef
  • Potential Impact of BMI on the Aggressiveness of Presentation and Clinical Outcome of Differentiated Thyroid Cancer
    Antonio Matrone, Giovanni Ceccarini, Marianna Beghini, Federica Ferrari, Carla Gambale, Mariaida D’Aqui, Paolo Piaggi, Liborio Torregrossa, Eleonora Molinaro, Fulvio Basolo, Paolo Vitti, Ferruccio Santini, Rossella Elisei
    The Journal of Clinical Endocrinology & Metabolism.2020; 105(4): e1124.     CrossRef
  • Correlation between obesity and clinicopathological characteristics in patients with papillary thyroid cancer: a study of 1579 cases: a retrospective study
    Huijuan Wang, Pingping Wang, Yu Wu, Xiukun Hou, Zechun Peng, Weiwei Yang, Lizhao Guan, Linfei Hu, Jingtai Zhi, Ming Gao, Xiangqian Zheng
    PeerJ.2020; 8: e9675.     CrossRef
  • Lack of association between obesity and aggressiveness of differentiated thyroid cancer
    G. Grani, L. Lamartina, T. Montesano, G. Ronga, V. Maggisano, R. Falcone, V. Ramundo, L. Giacomelli, C. Durante, D. Russo, M. Maranghi
    Journal of Endocrinological Investigation.2019; 42(1): 85.     CrossRef
  • Mitochondrial DNA haplogroup K as a contributor to protection against thyroid cancer in a population from southeast Europe
    Relu Cocoş, Sorina Schipor, Corin Badiu, Florina Raicu
    Mitochondrion.2018; 39: 43.     CrossRef
  • The impact of BMI on clinical progress, response to treatment, and disease course in patients with differentiated thyroid cancer
    Danuta Gąsior-Perczak, Iwona Pałyga, Monika Szymonek, Artur Kowalik, Agnieszka Walczyk, Janusz Kopczyński, Katarzyna Lizis-Kolus, Tomasz Trybek, Estera Mikina, Dorota Szyska-Skrobot, Klaudia Gadawska-Juszczyk, Stefan Hurej, Artur Szczodry, Anna Słuszniak,
    PLOS ONE.2018; 13(10): e0204668.     CrossRef
  • Pretreatment BMI Is Associated with Aggressive Clinicopathological Features of Papillary Thyroid Carcinoma: A Multicenter Study
    Shi-tong Yu, Wanzhi Chen, Qian Cai, Faya Liang, Debin Xu, Ping Han, Jichun Yu, Xiaoming Huang
    International Journal of Endocrinology.2017; 2017: 1.     CrossRef
  • Associations between body mass index and lymph node metastases of patients with papillary thyroid cancer
    Changhua Wu, Liang Wang, Wanjun Chen, Shujuan Zou, Aiju Yang
    Medicine.2017; 96(9): e6202.     CrossRef
Close layer
Review Article
Thyroid
Current Status and Future Perspectives in Differentiated Thyroid Cancer
Tae Yong Kim, Won Gu Kim, Won Bae Kim, Young Kee Shong
Endocrinol Metab. 2014;29(3):217-225.   Published online September 25, 2014
DOI: https://doi.org/10.3803/EnM.2014.29.3.217
  • 8,444 View
  • 45 Download
  • 79 Web of Science
  • 67 Crossref
AbstractAbstract PDFPubReader   

Thyroid cancer is increasing all over the world. The exact cause of this increase is still debated and there are conflicting reports. Sophisticated molecular studies suggest that environmental chemicals may have effects of thyroid carcinogenesis. The development of powerful molecular biology techniques has enabled targeted next-generation sequencing for detection of mutations in thyroid cancer, and this technique can make a specific diagnosis of thyroid cancer in cytologically indeterminate cases. The initial treatment of well-differentiated thyroid cancer (DTC) is surgery followed by radioiodine remnant ablation. However, further studies are needed to determine the optimal dosage of radioactive iodine for DTC patients with lateral neck metastasis. DTC is an indolent tumor and may cause death even decades later. Thus, long-term follow-up is mandatory. Recently, dynamic risk stratification (DRS) has begun to use stimulated thyroglobulin level at 1 year after the initial treatment and restratified the risk in accordance with the response to the initial treatment. This DRS strategy accurately predicts disease free survival and can be widely used in daily clinical settings. For the iodine refractory metastatic disease, redifferentiation therapy and targeted therapy are two promising alternative treatments. Sorafenib is the first approved agent for the treatment of progressive iodine refractory advanced thyroid cancer in Korea and may be very helpful for radioactive-refractory locally advanced or metastatic DTC. Selumetinib may be an effective redifferentiating agent and could be used within several years.

Citations

Citations to this article as recorded by  
  • Locoregional Recurrence after Biochemical Incomplete Response in Differentiated Thyroid Cancer Patients: Insights into Influencing Clinicopathological Factors and the Potential Role of 18F-FDG PET/CT
    Mai Amr Elahmadawy, Ismail Mohamed Ali, Ibrahim Mansour Nasr, Omnia Talaat
    World Journal of Nuclear Medicine.2025; 24(04): 293.     CrossRef
  • Association between metabolic dysfunction-associated steatotic liver disease and the risk of thyroid cancer: a nationwide cohort study
    Jeongmin Lee, Jeongeun Kwak, Min-Hee Kim, Seung-Hwan Lee, Jae-Hyoung Cho, Dong-Jun Lim, Jung Min Lee, Sang-Ah Chang, Hun-Sung Kim
    The Korean Journal of Internal Medicine.2025; 40(5): 813.     CrossRef
  • The Association of Number of Retrieved Lymph Nodes with Oncologic Outcomes in Patients with Papillary Thyroid Cancer with Lateral Cervical Nodal Metastasis
    Hye In Kim, Jung Hee Shin, Boram Kim, Mihyeon Jin, Nak Gyeong Ko, Jung Hwan Cho, Ji Min Han, Sunghwan Suh, Ji Cheol Bae, Jung-Han Kim, Sun Wook Kim, Jae Hoon Chung, Tae Hyuk Kim, Ji Soo Kim
    Thyroid®.2025; 35(11): 1311.     CrossRef
  • Nonalcoholic Fatty Liver Disease and the Risk of Thyroid Cancer Among Young Adults in South Korea
    Hyemi Kwon, Kyung-Do Han, Sun Joon Moon, Se Eun Park, Eun-Jung Rhee, Won-Young Lee
    The Journal of Clinical Endocrinology & Metabolism.2024; 109(3): e1095.     CrossRef
  • Dual targeting of MAPK and PI3K pathways unlocks redifferentiation of Braf-mutated thyroid cancer organoids
    Hélène Lasolle, Andrea Schiavo, Adrien Tourneur, Pierre Gillotay, Bárbara de Faria da Fonseca, Lucieli Ceolin, Olivier Monestier, Benilda Aganahi, Laura Chomette, Marina Malta Letro Kizys, Lieven Haenebalcke, Tim Pieters, Steven Goossens, Jody Haigh, Vinc
    Oncogene.2024; 43(3): 155.     CrossRef
  • Leveraging molecular targeted drugs and immune checkpoint inhibitors treat advanced thyroid carcinoma to achieve thyroid carcinoma redifferentiation
    Jing-Yang Su
    American Journal of Cancer Research.2024; 14(2): 407.     CrossRef
  • F-18 FDG PET/CT Versus RAI-WBS and Neck USG in Early Diagnosis of Recurrent Differentiated Thyroid Cancer
    Jaimanti Bakshi, Naresh K. Panda, Atul Kumar Goyal, Jyoti Saini, Sovit Jung Baral, Bhagwant Rai Mittal, Anupam Lal
    Journal of Pharmaceutical and BioSciences.2024; 12(3): 9.     CrossRef
  • Study on Impact of Interpolation Methods on Performance of Super-Resolution ResNet Model in Nuclear Medicine Thyroid Phantom Imaging
    Minha Kim, Chanrok Park
    Journal of Radiological Science and Technology.2024; 47(6): 433.     CrossRef
  • Clinical significance and diagnostic value of QPCT, SCEL and TNFRSF12A in papillary thyroid cancer
    Tairong Liang, Xiuqian Wu, Lan Wang, Zhengzhong Ni, Ying Fan, Peishan Wu, Hongzhi Wang, Yongdong Niu, Haihua Huang
    Pathology - Research and Practice.2023; 245: 154431.     CrossRef
  • Thyroidkeeper: a healthcare management system for patients with thyroid diseases
    Jing Zhang, Jianhua Li, Yi Zhu, Yu Fu, Lixia Chen
    Health Information Science and Systems.2023;[Epub]     CrossRef
  • Repeated Low High-Density Lipoprotein Cholesterol and the Risk of Thyroid Cancer: A Nationwide Population- Based Study in Korea
    Jinyoung Kim, Mee Kyoung Kim, Ki-Hyun Baek, Ki-Ho Song, Kyungdo Han, Hyuk-Sang Kwon
    Endocrinology and Metabolism.2022; 37(2): 303.     CrossRef
  • Comparison of the prognostic value of AJCC cancer staging system 7th and 8th editions for differentiated thyroid cancer
    Y. J. Morosán Allo, L. Bosio, A. Morejón, C. Parisi, M. C. Faingold, V. Ilera, A. Gauna, G. Brenta
    BMC Endocrine Disorders.2022;[Epub]     CrossRef
  • Immune Profiling of Advanced Thyroid Cancers Using Fluorescent Multiplex Immunohistochemistry
    Jonghwa Ahn, Meihua Jin, Eyun Song, Yeon-mi Ryu, Dong Eun Song, Sang-Yeob Kim, Tae Yong Kim, Won Bae Kim, Young Kee Shong, Min Ji Jeon, Won Gu Kim
    Thyroid.2021; 31(1): 61.     CrossRef
  • A double mutation of BRAF L597Q and V600E in situ and solitary brain metastasis of occult papillary thyroid carcinoma
    Ling Chen, Yue Wu, Huili Bai, Huandong Liu, Xiaosong Li
    Medicine.2021; 100(6): e24458.     CrossRef
  • Mutation in Genes Encoding Key Functional Groups Additively Increase Mortality in Patients with BRAFV600E-Mutant Advanced Papillary Thyroid Carcinoma
    Eyun Song, Meihua Jin, Ahreum Jang, Min Ji Jeon, Dong Eun Song, Hye Jin Yoo, Won Bae Kim, Young Kee Shong, Won Gu Kim
    Cancers.2021; 13(22): 5846.     CrossRef
  • Current Status and Future Perspective of the Treatment for Radioiodine Refractory Differentiated Thyroid Cancer
    Young Kee Shong
    International Journal of Thyroidology.2021; 14(2): 98.     CrossRef
  • Comprehensive evaluation of risk factors for lymph node metastasis in patients with papillary thyroid carcinoma
    Yan Dong, Dan Wang, Yisheng Luo, Ling Chen, Huili Bai, Yifan Shen, Yangli Zhang, Xueping Chen, Xinliang Su, Jinqiu Zhao, Huandong Liu, Jungao Lu, Zuoyi Yao, Yajing Zhao, Changlong He, Xiaosong Li
    Oncology Letters.2021;[Epub]     CrossRef
  • Lenvatinib for Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma and Candidate Biomarkers Associated with Survival: A Multicenter Study in Korea
    Eyun Song, Mijin Kim, Eui Young Kim, Bo Hyun Kim, Dong Yeob Shin, Ho-Cheol Kang, Byeong-Cheol Ahn, Won Bae Kim, Young Kee Shong, Min Ji Jeon, Dong Jun Lim
    Thyroid.2020; 30(5): 732.     CrossRef
  • Radioiodine ablation in thyroid cancer patients: renal function and external radiation dose rate at discharge according to patient preparation
    Yeon-Hee Han, Hwan-Jeong Jeong, Myung-Hee Sohn, Sun Y. Lee, Seok T. Lim
    The Quarterly Journal of Nuclear Medicine and Molecular Imaging.2020;[Epub]     CrossRef
  • Metabolic Syndrome and the Risk of Thyroid Cancer: A Nationwide Population-Based Cohort Study
    Joo-Hyun Park, Moonyoung Choi, Jung-Hun Kim, Jaemin Kim, Kyungdo Han, Bongsung Kim, Do-Hoon Kim, Yong-Gyu Park
    Thyroid.2020; 30(10): 1496.     CrossRef
  • Serum Adiponectin and Progranulin Level in Patients with Benign Thyroid Nodule or Papillary Thyroid Cancer
    Hyemi Kwon, Se Eun Park, Ji-Sup Yun, Cheol-Young Park
    Endocrinology and Metabolism.2020; 35(2): 396.     CrossRef
  • The role of Slit2 as a tumor suppressor in thyroid cancer
    Min Ji Jeon, Seonhee Lim, Mi-hyeon You, Yangsoon Park, Dong Eun Song, Soyoung Sim, Tae Yong Kim, Young Kee Shong, Won Bae Kim, Won Gu Kim
    Molecular and Cellular Endocrinology.2019; 483: 87.     CrossRef
  • Metabolic Obesity Phenotypes and Thyroid Cancer Risk: A Cohort Study
    Hyemi Kwon, Yoosoo Chang, Ara Cho, Jiin Ahn, Se Eun Park, Cheol-Young Park, Won-Young Lee, Ki-Won Oh, Sung-Woo Park, Hocheol Shin, Seungho Ryu, Eun-Jung Rhee
    Thyroid.2019; 29(3): 349.     CrossRef
  • Impact of delayed radioiodine therapy in intermediate‐/high‐risk papillary thyroid carcinoma
    Mijin Kim, Minkyu Han, Min Ji Jeon, Won Gu Kim, In Joo Kim, Jin‐Sook Ryu, Won Bae Kim, Young Kee Shong, Tae Yong Kim, Bo Hyun Kim
    Clinical Endocrinology.2019; 91(3): 449.     CrossRef
  • Myxedema coma precipitated by diabetic ketoacidosis after total thyroidectomy: a case report
    Jin Joo Kim, Eun Young Kim
    Journal of Medical Case Reports.2019;[Epub]     CrossRef
  • Comprehensive analysis for diagnosis of preoperative non-invasive follicular thyroid neoplasm with papillary-like nuclear features
    Hye Seung Lee, Jae-Wook Lee, Ji Hyun Park, Wan-Seop Kim, Hye Seung Han, Seung Eun Lee, Paula Soares
    PLOS ONE.2019; 14(7): e0218046.     CrossRef
  • Rutin Scavenges Reactive Oxygen Species, Inactivates 5′-Adenosine Monophosphate-Activated Protein Kinase, and Increases Sodium–Iodide Symporter Expression in Thyroid PCCL3 Cells
    Carlos Frederico Lima Gonçalves, Mariana Lopes de Freitas, Rodrigo Soares Fortunato, Leandro Miranda-Alves, Denise P. Carvalho, Andrea Claudia Freitas Ferreira
    Thyroid.2018; 28(2): 265.     CrossRef
  • Prevalence ofBRAFV600EMutation in Follicular Variant of Papillary Thyroid Carcinoma and Non-Invasive Follicular Tumor with Papillary-Like Nuclear Features (NIFTP) in aBRAFV600EPrevalent Area
    Hyereen Kim, Bo Hyun Kim, Young Keum Kim, Jeong Mi Kim, Seo Young Oh, Eun Heui Kim, Min Jin Lee, Jong Ho Kim, Yun Kyung Jeon, Sang Soo Kim, Byung Joo Lee, Yong Ki Kim, In Joo Kim
    Journal of Korean Medical Science.2018;[Epub]     CrossRef
  • Whole-Exome Sequencing Identifies Two Discrete Druggable Signaling Pathways in Follicular Thyroid Cancer
    Neeta J. Erinjeri, Norman G. Nicolson, Christine Deyholos, Reju Korah, Tobias Carling
    Journal of the American College of Surgeons.2018; 226(6): 950.     CrossRef
  • Efficacy and Affecting Factors of 131I Thyroid Remnant Ablation After Surgical Treatment of Differentiated Thyroid Carcinoma
    Chen Wang, Hongcui Diao, Ping Ren, Xufu Wang, Yangang Wang, Wenjuan Zhao
    Frontiers in Oncology.2018;[Epub]     CrossRef
  • Do aggressive variants of papillary thyroid carcinoma have worse clinical outcome than classic papillary thyroid carcinoma?
    Eyun Song, Min Ji Jeon, Hye-Seon Oh, Minkyu Han, Yu-Mi Lee, Tae Yong Kim, Ki-Wook Chung, Won Bae Kim, Young Kee Shong, Dong Eun Song, Won Gu Kim
    European Journal of Endocrinology.2018; 179(3): 135.     CrossRef
  • SPC24 is critical for anaplastic thyroid cancer progression
    Huabin Yin, Tong Meng, Lei Zhou, Haiyan Chen, Dianwen Song
    Oncotarget.2017; 8(13): 21884.     CrossRef
  • Analysis of radioiodine therapy and prognostic factors of differentiated thyroid cancer patients with pulmonary metastasis
    Renfei Wang, Yueqian Zhang, Jian Tan, Guizhi Zhang, Ruiguo Zhang, Wei Zheng, Yajing He
    Medicine.2017; 96(19): e6809.     CrossRef
  • Effect of Rifampin on Thyroid Function Test in Patients on Levothyroxine Medication
    Hye In Kim, Tae Hyuk Kim, Hosu Kim, Young Nam Kim, Hye Won Jang, Jae Hoon Chung, Seong Mi Moon, Byung Woo Jhun, Hyun Lee, Won-Jung Koh, Sun Wook Kim, Dongmei Li
    PLOS ONE.2017; 12(1): e0169775.     CrossRef
  • DelayedTSHrecovery after dose adjustment duringTSH‐suppressive levothyroxine therapy of thyroid cancer
    Hye In Kim, Tae Hyuk Kim, Hosu Kim, Young Nam Kim, Hye Won Jang, Jung‐Han Kim, Kyu Yeon Hur, Jae Hoon Chung, Sun Wook Kim
    Clinical Endocrinology.2017; 87(3): 286.     CrossRef
  • Serum vitamin D3 levels are not associated with thyroid cancer prevalence in euthyroid subjects without autoimmune thyroid disease
    Yun Mi Choi, Won Gu Kim, Tae Yong Kim, Sung Jin Bae, Hong-Kyu Kim, Eun Kyung Jang, Min Ji Jeon, Ji Min Han, Young Kee Shong, Won Bae Kim
    The Korean Journal of Internal Medicine.2017; 32(1): 102.     CrossRef
  • Optimal cut-off age in the TNM Staging system of differentiated thyroid cancer: is 55 years better than 45 years?
    Mijin Kim, Young Nam Kim, Won Gu Kim, Suyeon Park, Hyemi Kwon, Min Ji Jeon, Hyeon Seon Ahn, Sin-Ho Jung, Sun Wook Kim, Won Bae Kim, Jae Hoon Chung, Young Kee Shong, Tae Hyuk Kim, Tae Yong Kim
    Clinical Endocrinology.2017; 86(3): 438.     CrossRef
  • Initial Size of Metastatic Lesions Is Best Prognostic Factor in Patients with Metastatic Differentiated Thyroid Carcinoma Confined to the Lung
    Mijin Kim, Won Gu Kim, Suyeon Park, Hyemi Kwon, Min Ji Jeon, Jong Jin Lee, Jin-Sook Ryu, Tae Yong Kim, Young Kee Shong, Won Bae Kim
    Thyroid.2017; 27(1): 49.     CrossRef
  • Refining Dynamic Risk Stratification and Prognostic Groups for Differentiated Thyroid Cancer With TERT Promoter Mutations
    Tae Hyuk Kim, Chang-Seok Ki, Hye Seung Kim, Kyunga Kim, Jun-Ho Choe, Jung-Han Kim, Jee Soo Kim, Young Lyun Oh, Soo Yeon Hahn, Jung Hee Shin, Hye Won Jang, Sun Wook Kim, Jae Hoon Chung
    The Journal of Clinical Endocrinology & Metabolism.2017; 102(5): 1757.     CrossRef
  • Comparison of the Seventh and Eighth Editions of the American Joint Committee on Cancer/Union for International Cancer Control Tumor-Node-Metastasis Staging System for Differentiated Thyroid Cancer
    Mijin Kim, Won Gu Kim, Hye-Seon Oh, Suyeon Park, Hyemi Kwon, Dong Eun Song, Tae Yong Kim, Young Kee Shong, Won Bae Kim, Tae-Yon Sung, Min Ji Jeon
    Thyroid.2017; 27(9): 1149.     CrossRef
  • Growth Kinetics of Macronodular Lung Metastases and Survival in Differentiated Thyroid Carcinoma
    Mijin Kim, Won Gu Kim, Suyeon Park, Hyemi Kwon, Min Ji Jeon, Sang Min Lee, Jeong Hyun Lee, Tae Yong Kim, Young Kee Shong, Won Bae Kim
    Thyroid.2017; 27(7): 915.     CrossRef
  • Preoperative clinicopathological characteristics of patients with solitary encapsulated follicular variants of papillary thyroid carcinomas
    Hyemi Kwon, Min Ji Jeon, Jong Ho Yoon, Suck Joon Hong, Jeong Hyun Lee, Tae Yong Kim, Young Kee Shong, Won Bae Kim, Won Gu Kim, Dong Eun Song
    Journal of Surgical Oncology.2017; 116(6): 746.     CrossRef
  • Prescribed Activity of 131I Therapy in Differentiated Thyroid Cancer
    Douglas Van Nostrand
    Journal of Nuclear Medicine.2017; 58(5): 697.     CrossRef
  • Metabolomics of papillary thyroid carcinoma tissues: potential biomarkers for diagnosis and promising targets for therapy
    Xingchen Shang, Xia Zhong, Xingsong Tian
    Tumor Biology.2016; 37(8): 11163.     CrossRef
  • Recent Updates on the Management of Medullary Thyroid Carcinoma
    Bo Hyun Kim, In Joo Kim
    Endocrinology and Metabolism.2016; 31(3): 392.     CrossRef
  • Intraoperative Near‐infrared Imaging for Parathyroid Gland Identification by Auto‐fluorescence: A Feasibility Study
    Frederic De Leeuw, Ingrid Breuskin, Muriel Abbaci, Odile Casiraghi, Haïtham Mirghani, Aïcha Ben Lakhdar, Corinne Laplace‐Builhé, Dana Hartl
    World Journal of Surgery.2016; 40(9): 2131.     CrossRef
  • Papillary thyroid carcinoma: different clinical behavior among pT3 tumors
    Maria Joana Santos, Maria João Bugalho
    Endocrine.2016; 53(3): 754.     CrossRef
  • Changing trends in the clinicopathological features and clinical outcomes of medullary thyroid carcinoma
    Hyemi Kwon, Won Gu Kim, Tae‐Yon Sung, Min Ji Jeon, Dong Eun Song, Yu‐Mi Lee, Jong Ho Yoon, Ki‐Wook Chung, Suck Joon Hong, Jung Hwan Baek, Jeong Hyun Lee, Tae Yong Kim, Young Kee Shong, Won Bae Kim
    Journal of Surgical Oncology.2016; 113(2): 152.     CrossRef
  • Assessment of radioiodine therapy efficacy for treatment of differentiated thyroid cancer patients with pulmonary metastasis undetected by chest computed tomography
    BIN LONG, MENGDI YANG, ZHIWEN YANG, HEQING YI, LINFA LI
    Oncology Letters.2016; 11(2): 965.     CrossRef
  • Usefulness of PET/CT in the diagnosis of recurrent or metastasized differentiated thyroid carcinoma
    CUN-ZHI LU, SU-SHENG CAO, WEI WANG, JUN LIU, NING FU, FENG LU
    Oncology Letters.2016; 11(4): 2420.     CrossRef
  • Coexistence of papillary thyroid microcarcinoma and mucosa-associated lymphoid tissue lymphoma in a context of Hashimoto's thyroiditis
    Saul Levy-Blitchtein, Stefany Plasencia-Rebata, Domingo Morales Luna, Juana del Valle Mendoza
    Asian Pacific Journal of Tropical Medicine.2016; 9(8): 812.     CrossRef
  • Iodine-131 Therapy and Nasolacrimal Duct Obstructions: What We Know and What We Need to Know
    Mohammad Javed Ali
    Ophthalmic Plastic & Reconstructive Surgery.2016; 32(4): 243.     CrossRef
  • Low Prevalence of Somatic TERT Promoter Mutations in Classic Papillary Thyroid Carcinoma
    Min Ji Jeon, Won Gu Kim, Soyoung Sim, Seonhee Lim, Hyemi Kwon, Tae Yong Kim, Young Kee Shong, Won Bae Kim
    Endocrinology and Metabolism.2016; 31(1): 100.     CrossRef
  • Dietary evaluation of a low-iodine diet in Korean thyroid cancer patients preparing for radioactive iodine therapy in an iodine-rich region
    Dal Lae Ju, Young Joo Park, Hee-Young Paik, Min-Ji Kim, Seonyeong Park, Kyong Yeun Jung, Tae Hyuk Kim, Hun Sung Choi, Yoon Ju Song
    Nutrition Research and Practice.2016; 10(2): 167.     CrossRef
  • Features Predictive of Distant Metastasis in Papillary Thyroid Microcarcinomas
    Min Ji Jeon, Won Gu Kim, Yun Mi Choi, Hyemi Kwon, Yu-Mi Lee, Tae-Yon Sung, Jong Ho Yoon, Ki-Wook Chung, Suck Joon Hong, Tae Yong Kim, Young Kee Shong, Dong Eun Song, Won Bae Kim
    Thyroid.2016; 26(1): 161.     CrossRef
  • Alpha lipoic acid inhibits proliferation and epithelial mesenchymal transition of thyroid cancer cells
    Min Ji Jeon, Won Gu Kim, Seonhee Lim, Hyun-Jeung Choi, Soyoung Sim, Tae Yong Kim, Young Kee Shong, Won Bae Kim
    Molecular and Cellular Endocrinology.2016; 419: 113.     CrossRef
  • Differentiated Thyroid Cancer in Asians
    Bo Hyun Kim
    Endocrinology and Metabolism.2016; 31(1): 62.     CrossRef
  • Sub-Classification of Lateral Cervical Lymph Node Metastasis in Papillary Thyroid Carcinoma by Pathologic Criteria
    Min Ji Jeon, Won Gu Kim, Eun Kyung Jang, Yun Mi Choi, Dong Eun Song, Tae-Yon Sung, Jong Ho Yoon, Ki-Wook Chung, Suck Joon Hong, Jin-Sook Ryu, Ji Min Han, Tae Yong Kim, Young Kee Shong, Won Bae Kim, Konradin Metze
    PLOS ONE.2015; 10(7): e0133625.     CrossRef
  • The Impact of Low Adherence to the Low-iodine Diet on the Efficacy of the Radioactive Iodine Ablation Therapy
    Dal Lae Ju, Young Joo Park, Hee-Young Paik, YoonJu Song
    Clinical Nutrition Research.2015; 4(4): 267.     CrossRef
  • High metabolic tumor volume and total lesion glycolysis are associated with lateral lymph node metastasis in patients with incidentally detected thyroid carcinoma
    Bo Hyun Kim, Seong-Jang Kim, Keunyoung Kim, Heeyoung Kim, So Jung Kim, Won Jin Kim, Yun Kyung Jeon, Sang Soo Kim, Yong Ki Kim, In Joo Kim
    Annals of Nuclear Medicine.2015; 29(8): 721.     CrossRef
  • Articles in 'Endocrinology and Metabolism' in 2014
    Won-Young Lee
    Endocrinology and Metabolism.2015; 30(1): 47.     CrossRef
  • Changes in the Pulmonary Function Test after Radioactive Iodine Treatment in Patients with Pulmonary Metastases of Differentiated Thyroid Cancer
    Eun Kyung Jang, Won Gu Kim, Ho-Cheol Kim, Jin-Won Huh, Hyemi Kwon, Yun Mi Choi, Min Ji Jeon, Tae Yong Kim, Young Kee Shong, Jin-Sook Ryu, Won Bae Kim, Karen M. Tordjman
    PLOS ONE.2015; 10(4): e0125114.     CrossRef
  • Negative Expression of CPSF2 Predicts a Poorer Clinical Outcome in Patients with Papillary Thyroid Carcinoma
    Tae Yon Sung, Mijin Kim, Tae Yong Kim, Won Gu Kim, Yangsoon Park, Dong Eun Song, Su-Yeon Park, Hyemi Kwon, Yun Mi Choi, Eun Kyung Jang, Min Ji Jeon, Young Kee Shong, Suck Joon Hong, Won Bae Kim
    Thyroid.2015; 25(9): 1020.     CrossRef
  • Thyroglobulin Level in Fine-Needle Aspirates for Preoperative Diagnosis of Cervical Lymph Node Metastasis in Patients with Papillary Thyroid Carcinoma: Two Different Cutoff Values According to Serum Thyroglobulin Level
    Min Ji Jeon, Won Gu Kim, Eun Kyung Jang, Yun Mi Choi, Yu-Mi Lee, Tae-Yon Sung, Jong Ho Yoon, Ki-Wook Chung, Suck Joon Hong, Jung Hwan Baek, Jeong Hyun Lee, Tae Yong Kim, Young Kee Shong, Won Bae Kim
    Thyroid.2015; 25(4): 410.     CrossRef
  • A Closer Look at Papillary Thyroid Carcinoma
    Won Bae Kim
    Endocrinology and Metabolism.2015; 30(1): 1.     CrossRef
  • Protecting the normal in order to better kill the cancer
    Bingya Liu, Lewis Ezeogu, Lucas Zellmer, Baofa Yu, Ningzhi Xu, Dezhong Joshua Liao
    Cancer Medicine.2015; 4(9): 1394.     CrossRef
  • Recent Changes in the Clinical Outcome of Papillary Thyroid Carcinoma With Cervical Lymph Node Metastasis
    Min Ji Jeon, Won Gu Kim, Yun Mi Choi, Hyemi Kwon, Dong Eun Song, Yu-Mi Lee, Tae-Yon Sung, Jong Ho Yoon, Suck Joon Hong, Jung Hwan Baek, Jeong Hyun Lee, Jin-Sook Ryu, Tae Yong Kim, Young Kee Shong, Ki-Wook Chung, Won Bae Kim
    The Journal of Clinical Endocrinology & Metabolism.2015; 100(9): 3470.     CrossRef
Close layer
Case Reports
Long-Term Survival of a Patient with Pulmonary Artery Intimal Sarcoma after Sequential Metastasectomies of the Thyroid and Adrenal Glands
Yun Mi Choi, Eun Kyung Jang, Seong Hee Ahn, Min Ji Jeon, Ji Min Han, Seong Chul Kim, Duck Jong Han, Gyungyup Gong, Tae Yong Kim, Young Kee Shong, Won Bae Kim
Endocrinol Metab. 2013;28(1):46-49.   Published online March 25, 2013
DOI: https://doi.org/10.3803/EnM.2013.28.1.46
  • 6,185 View
  • 29 Download
  • 9 Crossref
AbstractAbstract PDFPubReader   

Cancer metastases to the thyroid or adrenal gland are uncommon. Furthermore, cases showing long-term survival after surgical resection of those metastatic tumors are rare. We report a case of pulmonary artery intimal sarcoma with metastases to the thyroid and adrenal glands sequentially that was successfully treated with sequential metastasectomies. A 62-year-old woman presented with a 4-week history of dyspnea on exertion and facial edema in November 1999. Echocardiography and chest computed tomography (CT) revealed an embolism-like mass in the pulmonary trunk. Pulmonary artery endarterectomy with pulmonary valve replacement was performed, and histopathology revealed pulmonary artery intimal sarcoma. A thyroid nodule was found by chest CT in November 2001 (2 years after initial surgery). During follow-up, this lesion showed no change, but we decided to obtain fine needle aspiration cytology (FNAC) in August 2004 (4.7 years after initial surgery). FNAC revealed atypical spindle cells suggestive of metastatic intimal sarcoma. She underwent total thyroidectomy. During follow-up, a right adrenal gland mass was detected by chest CT in March 2006 (6.3 years after initial surgery), and adrenalectomy was done, which also revealed metastatic sarcoma. She has been followed up without any evidence of recurrent disease until May 2012 (12.5 years after initial surgery).

Citations

Citations to this article as recorded by  
  • Reoperation of Pulmonary Artery Intimal Sarcoma for Recurrence After Pulmonary Artery Replacement
    Kentaro Miyazaki, Isao Matsumoto, Satoshi Nishikawa, Takashi Wada, Tetsuya Takayama, Daisuke Saito, Shuhei Yoshida, Kenji Iino, Hirofumi Takemura
    Annals of Thoracic Surgery Short Reports.2024; 2(3): 484.     CrossRef
  • Pulmonary artery sarcoma: An important mimic of pulmonary embolism—Case reports and literature review
    Colin Tuft, Krishan Maheepala, Ajantha Raguparan, Anas Naeem, Suhrid Lodh, Steven Lindstrom
    Respirology Case Reports.2022;[Epub]     CrossRef
  • Rare case of metastatic liposarcoma to the thyroid gland and a review of the literature of metastatic sarcomas to the thyroid
    Monica H. Xing, Neil Mundi, Aparna Govindan, Azita Khorsandi, Margaret Brandwein‐Weber, Ammar Matloob, Bobby Liaw, Mark L. Urken
    Head & Neck.2021;[Epub]     CrossRef
  • Left pneumonectomy with pulmonary arterioplasty under cardiopulmonary bypass for pulmonary artery intimal sarcoma
    Akihiko Kitahara, Yuki Shimizu, Tatsuya Goto, Seijiro Sato, Terumoto Koike, Masanori Tsuchida
    The Journal of the Japanese Association for Chest Surgery.2018; 32(4): 492.     CrossRef
  • Intimal sarcoma of the pulmonary artery with multiple lung metastases: Long-term survival case
    Sonia García-Cabezas, Macarena Centeno-Haro, Simona Espejo-Pérez, Elvira Carmona-Asenjo, Alberto L Moreno-Vega, Rosa Ortega-Salas, Amalia Palacios-Eito
    World Journal of Clinical Oncology.2017; 8(4): 366.     CrossRef
  • Clinical Characteristics and Treatment Outcomes of Primary Pulmonary Artery Sarcoma in Korea
    Yunkyoung Lee, Hyun Jung Kim, Heeyoung Yoon, Chang-Min Choi, Yeon-Mok Oh, Sang-Do Lee, Chae-Man Lim, Woo-Sung Kim, Younsuck Koh, Jae Seung Lee
    Journal of Korean Medical Science.2016; 31(11): 1755.     CrossRef
  • An Extraordinary Case of Mesenchymal Chondrosarcoma Metastasis in the Thyroid
    Santiago Ortiz, Francisco Tortosa, Manuel Sobrinho Simões
    Endocrine Pathology.2015; 26(1): 33.     CrossRef
  • Presentation and management of pulmonary artery sarcoma
    Han Hsi Wong, Ioannis Gounaris, Ann McCormack, Marius Berman, Dochka Davidson, Gail Horan, Joanna Pepke-Zaba, David Jenkins, Helena M Earl, Helen M Hatcher
    Clinical Sarcoma Research.2015;[Epub]     CrossRef
  • Brief Review of Articles in 'Endocrinology and Metabolism' in 2013
    Won-Young Lee
    Endocrinology and Metabolism.2014; 29(3): 251.     CrossRef
Close layer
Four Cases of Malignant Pleural Effusion in Patients with Papillary Thyroid Carcinoma.
Min Ji Jeon, Ji Hye Yim, Eui Young Kim, Won Gu Kim, Tae Yong Kim, Won Bae Kim, Young Kee Shong
Endocrinol Metab. 2011;26(4):330-334.   Published online December 1, 2011
DOI: https://doi.org/10.3803/EnM.2011.26.4.330
  • 41,732 View
  • 38 Download
  • 3 Crossref
AbstractAbstract PDF
Papillary thyroid carcinoma could be a rare cause of malignant pleural effusion. The development of malignant pleural effusion in patients with papillary thyroid cancer is an extremely adverse prognostic indicator. Here, we report four cases that showed development of malignant pleural effusion during the clinical course of the papillary thyroid carcinoma and consider the prognosis. In four patients, the median survival time after the development of malignant pleural effusion was only 17 months.

Citations

Citations to this article as recorded by  
  • Pleural fluid due to papillary thyroid cancer
    Tomohiro Tamura, Toshihiro Shiozawa, Hiroaki Satoh, Koichi Kurishima, Katsunori Kagohashi, Norio Takayashiki, Nobuyuki Hizawa
    Oncology Letters.2019;[Epub]     CrossRef
  • Outcome and characteristics of patients with malignant pleural effusion from differentiated thyroid carcinoma
    Chisato Tomoda, Yuna Ogimi, Fumi Saito, Chie Masaki, Junko Akaishi, Kenichi Matsuzu, Akifumi Suzuki, Takashi Uruno, Keiko Ohkuwa, Hiroshi Shibuya, Wataru Kitagawa, Mitsuji Nagahama, Kiminori Sugino, Koichi Ito
    Endocrine Journal.2016; 63(3): 257.     CrossRef
  • A distinctive colour associated with high iodine content in malignant pleural effusion from metastatic papillary thyroid cancer: a case report
    Andrew Rosenstengel, Ee Mun Lim, Michael Millward, YC Gary Lee
    Journal of Medical Case Reports.2013;[Epub]     CrossRef
Close layer
Comment
Response: Postoperative Findings of the Cytological Diagnosis of Follicular Neoplasm or Hurthle Cell Neoplasm and the Risk of Malignancy.
Ji Hye Yim, Won Bae Kim
Endocrinol Metab. 2011;26(3):277-278.   Published online September 1, 2011
DOI: https://doi.org/10.3803/EnM.2011.26.3.277
  • 21,519 View
  • 24 Download
AbstractAbstract PDF
No abstract available.
Close layer
Original Articles
Comparison of Different Staging Systems for Predicting Recurrence of Papillary Thyroid Carcinoma.
Won Gu Kim, Eui Young Kim, Ji Hye Yim, Ji Min Han, Min Ji Jeon, Tae Yong Kim, Jin Sook Ryu, Gyungyub Gong, Suck Joon Hong, Won Bae Kim, Young Kee Shong
Endocrinol Metab. 2011;26(1):53-61.   Published online March 1, 2011
DOI: https://doi.org/10.3803/EnM.2011.26.1.53
  • 4,054 View
  • 26 Download
  • 10 Crossref
AbstractAbstract PDF
BACKGROUND
Various staging systems for thyroid cancer that focus on cancer specific death have been suggested, but this approach had a limitation due to the relatively long clinical course and very low rate of cancer death. This study was performed to evaluate the staging systems and to determine the most predictive staging system for predicting recurrence. METHODS: The patients who underwent first total or near total thyroidectomy due to papillary thyroid cancer (PTC) at Asan Medical Center between January 1995 and December 2001 were the subjects of this study. The commonly used 8 staging systems were applied to these subjects. Disease free survival (DFS) and the relative importance of each staging system were determined by the Kaplan-Meier method, the Cox-proportional hazards model and the proportion of variation in the survival time explained (PVE). RESULTS: A total of 952 patients (M = 117, F = 835) were enrolled and their mean age was 45 years. During a median of 10 years of follow-up, 146 (15.3%) of 952 patients had recurred tumor. The independent prognostic factors were male gender, tumor size, extrathyroidal invasion and cervical lymph node metastasis. Risk stratification according to the American thyroid association (ATA) guideline was the most predictive staging system for recurrence of PTC (PVE 88.6%). The staging systems from EORTC (PVE 79.5%), and MACIS (PVE 68.4%) had significant values for predicting recurrence of PTC. The stage of NTCTCS could not predict recurrence (PVE 4.5%, P = 0.11). CONCLUSION: Risk stratification according to the ATA was most predictive staging system for predicting recurrence of PTC. The MACIS and EORTC staging systems have good value for predicting recurrence of PTC.

Citations

Citations to this article as recorded by  
  • Unmet Clinical Needs in the Treatment of Patients with Thyroid Cancer
    Won Bae Kim, Min Ji Jeon, Won Gu Kim, Tae Yong Kim, Young Kee Shong
    Endocrinology and Metabolism.2020; 35(1): 14.     CrossRef
  • Impact of delayed radioiodine therapy in intermediate‐/high‐risk papillary thyroid carcinoma
    Mijin Kim, Minkyu Han, Min Ji Jeon, Won Gu Kim, In Joo Kim, Jin‐Sook Ryu, Won Bae Kim, Young Kee Shong, Tae Yong Kim, Bo Hyun Kim
    Clinical Endocrinology.2019; 91(3): 449.     CrossRef
  • Clinical Value of Lymph Node Ratio Integration with the 8th Edition of the UICC TNM Classification and 2015 ATA Risk Stratification Systems for Recurrence Prediction in Papillary Thyroid Cancer
    Jandee Lee, Seul Gi Lee, Kwangsoon Kim, Seung Hyuk Yim, Haengrang Ryu, Cho Rok Lee, Sang Wook Kang, Jong Ju Jeong, Kee-Hyun Nam, Woong Youn Chung, Young Suk Jo
    Scientific Reports.2019;[Epub]     CrossRef
  • Clinical prognostic significance of cancer stem cell markers in patients with papillary thyroid carcinoma
    Yoon‑Jong Ryu, Ji‑Young Choe, Kyoungyul Lee, Soon‑Hyun Ahn
    Oncology Letters.2019;[Epub]     CrossRef
  • Dynamic Risk Stratification for Predicting Recurrence in Patients with Differentiated Thyroid Cancer Treated Without Radioactive Iodine Remnant Ablation Therapy
    Suyeon Park, Won Gu Kim, Eyun Song, Hye-Seon Oh, Mijin Kim, Hyemi Kwon, Min Ji Jeon, Tae Yong Kim, Young Kee Shong, Won Bae Kim
    Thyroid.2017; 27(4): 524.     CrossRef
  • Optimal cut-off age in the TNM Staging system of differentiated thyroid cancer: is 55 years better than 45 years?
    Mijin Kim, Young Nam Kim, Won Gu Kim, Suyeon Park, Hyemi Kwon, Min Ji Jeon, Hyeon Seon Ahn, Sin-Ho Jung, Sun Wook Kim, Won Bae Kim, Jae Hoon Chung, Young Kee Shong, Tae Hyuk Kim, Tae Yong Kim
    Clinical Endocrinology.2017; 86(3): 438.     CrossRef
  • Sub-Classification of Lateral Cervical Lymph Node Metastasis in Papillary Thyroid Carcinoma by Pathologic Criteria
    Min Ji Jeon, Won Gu Kim, Eun Kyung Jang, Yun Mi Choi, Dong Eun Song, Tae-Yon Sung, Jong Ho Yoon, Ki-Wook Chung, Suck Joon Hong, Jin-Sook Ryu, Ji Min Han, Tae Yong Kim, Young Kee Shong, Won Bae Kim, Konradin Metze
    PLOS ONE.2015; 10(7): e0133625.     CrossRef
  • Recent Changes in the Clinical Outcome of Papillary Thyroid Carcinoma With Cervical Lymph Node Metastasis
    Min Ji Jeon, Won Gu Kim, Yun Mi Choi, Hyemi Kwon, Dong Eun Song, Yu-Mi Lee, Tae-Yon Sung, Jong Ho Yoon, Suck Joon Hong, Jung Hwan Baek, Jeong Hyun Lee, Jin-Sook Ryu, Tae Yong Kim, Young Kee Shong, Ki-Wook Chung, Won Bae Kim
    The Journal of Clinical Endocrinology & Metabolism.2015; 100(9): 3470.     CrossRef
  • Differentiating the location of cervical lymph node metastasis is very useful for estimating the risk of distant metastases in papillary thyroid carcinoma
    Min Ji Jeon, Tae Yong Kim, Won Gu Kim, Ji Min Han, Eun Kyung Jang, Yun Mi Choi, Dong Eun Song, Jong Ho Yoon, Ki‐Wook Chung, Suck Joon Hong, Young Kee Shong, Won Bae Kim
    Clinical Endocrinology.2014; 81(4): 593.     CrossRef
  • Influences of Hashimoto's Thyroiditis as Prognostic Factor of Papillary Thyroid Carcinoma
    Hyun Ju Park, Dong Kun Lee, Ji Won Seo, Myung Koo Kang, Heon Soo Park, Rock Bum Kim, Sung Hwan Suh, Mi Kyoung Park, Duk Kyu Kim, Jong Chul Hong
    Korean Journal of Otorhinolaryngology-Head and Neck Surgery.2014; 57(5): 320.     CrossRef
Close layer
Postoperative Findings of the Cytological Diagnosis of Follicular Neoplasm or Hurthle Cell Neoplasm and the Risk of Malignancy.
Ji Hye Yim, Eui Young Kim, Won Gu Kim, Tae Yong Kim, Gyungyup Gong, Suck Joon Hong, Won Bae Kim, Young Kee Shong
Endocrinol Metab. 2010;25(4):316-320.   Published online December 1, 2010
DOI: https://doi.org/10.3803/EnM.2010.25.4.316
  • 3,384 View
  • 32 Download
  • 5 Crossref
AbstractAbstract PDF
BACKGROUND
Follicular neoplasm (FN) or Hurthle cell neoplasm (HN) is a less well understood pitfall when evaluating thyroid nodule with fine-needle aspiration (FNA). This study aimed to determine the rates of malignancy and the predictive factors for malignancy in thyroid nodules with a cytological diagnosis of FN or HN. METHODS: The patients who were cytologically diagnosed as having FN or HN after FNA between 1995 and 2004 at Asan Medical Center were included in this study. We collected the pathology data until 2009 and we analyzed the clinical characteristics associated with malignancy. RESULTS: A total 478 patients were cytologically diagnosed as having FN or HN during the study period and 327 (68%) among them underwent thyroid surgery. Thyroid malignancy was confirmed in 157 (48%) of 327 patients. Malignancy was confirmed in 124 patients with FN (124/253, 49%). They were 48 papillary, 65 follicular, 7 Hurthle cell and 3 medullary carcinomas and 1 anaplastic carcinoma. The malignancy in the cases of HN (33/71, 44.6%) was 9 papillary, 4 follicular and 20 Hurthle cell carcinomas. The risk of malignancy was not associated with male gender, a larger tumor size (> 4 cm) or the diagnosis of HN. However, an age below 20 years (RR 3.6, P = 0.03) and above 60 years (RR 2.3, P = 0.04) was associated with an increased risk of malignancy. CONCLUSION: About half of the patients with FN or HN on FNA cytology were diagnosed as having thyroid cancer after surgery. The malignancy rate for the cytologic diagnosis of HN was similar to that for FN. Thyroid surgery should be recommended for this situation, and especially for patients younger than 20 years or older than 60 years.

Citations

Citations to this article as recorded by  
  • Predictive Factors Increasing the Risk of Malignancy in Thyroid Follicular Neoplasia
    Fatma Özarslan, Hüseyin Özgür Aytaç, İlker Murat Arer, M. Eda Ertörer, Emrah Koçer, Murathan Erkent, Hakan Yabanoğlu
    Cukurova Anestezi ve Cerrahi Bilimler Dergisi.2025; 8(1): 85.     CrossRef
  • Diagnostic Value of Preoperative Serum Thyroglobulin Measurement for the Diagnosis of Malignancy in Follicular or Hürthle Cell Neoplasms of the Thyroid Gland
    Nam Kyu Kim, Seong Joo Kang, Weon Hyoung Lee, Go Eun Yeo, You Jin Han, Bu Kyung Kim, Su Kyoung Kwon, Yo-Han Park, Young Sik Choi
    Kosin Medical Journal.2014; 29(1): 17.     CrossRef
  • Fine Needle Aspiration Cytology of Thyroid Follicular Neoplasm: Cytohistologic Correlation and Accuracy
    Changyoung Yoo, Hyun Joo Choi, Soyoung Im, Ji Han Jung, Kiouk Min, Chang Suk Kang, Young-Jin Suh
    Korean Journal of Pathology.2013; 47(1): 61.     CrossRef
  • Predictive Factors of Malignancy in Thyroid Nodules with a Cytological Diagnosis of Follicular Neoplasm
    Seong Hyeon Lee, Jeong Su Baek, Joo Young Lee, Jung Ah Lim, Soo Youn Cho, Tae Hyun Lee, Yun Hyi Ku, Hong Il Kim, Min Joo Kim
    Endocrine Pathology.2013; 24(4): 177.     CrossRef
  • Postoperative Findings of the Cytological Diagnosis of Follicular Neoplasm or Hürthle Cell Neoplasm and Risk of Malignancy
    Jung Uee Lee, Minho Shong
    Endocrinology and Metabolism.2010; 25(4): 298.     CrossRef
Close layer

Endocrinol Metab : Endocrinology and Metabolism
TOP